Methods for treating T cell exhaustion by inhibiting or modulating T cell receptor signaling
By transiently inhibiting T cell receptor signaling and regulating CAR surface expression, the problem of T cell depletion is solved, T cell function is restored, the response to tumors and infections is improved, and the risk of treatment side effects is reduced.
Patent Information
- Application Number
- CN201880029045.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2017-03-31
- Filing Date
- 2018-03-30
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2038-03-30
AI Technical Summary
T cell depletion leads to loss of function, especially in chronic infections or cancers. The prior art is difficult to effectively prevent or reverse T cell depletion, affecting the persistence and efficiency of the immune response.
By transiently inhibiting T cell receptor (TCR) signaling, fusing with CAR T cells using a modulated destabilizing domain (RDD) is used to regulate CAR surface expression, prevent or reverse T cell depletion, and restore its function.
Effectively restore T cell function, prolong its activity, improve the response to tumors and infections, reduce the risk of cytokine release syndrome, and prolong the therapeutic effect.
Smart Images

Figure HDA0002256572630000011 
Figure HDA0002256572630000021 
Figure HDA0002256572630000031
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Application Serial No. 62 / 479,930, filed March 31, 2017, which is incorporated herein by reference in its entirety. Field of the Invention
[0003] The present invention relates to methods for treating T cell exhaustion. Specifically, the present invention relates to methods for preventing or reversing T cell exhaustion by transiently inhibiting T cell receptor (TCR) signal transduction to restore T cell function. Background Art
[0004] T cells are immune cells that are activated by T cell receptor (TCR) signal transduction and co-stimulation after binding to antigens. Physiological activation of T cell receptors enables T cells to mediate effective anti-tumor and / or anti-infection effects. During the period of resolution of the acute inflammatory response, a subset of activated effector T cells differentiates into long-term memory cells. In contrast, in patients with chronic infections or cancer, T cells may undergo pathological differentiation in response to a state of dysfunction, which is referred to as T cell exhaustion. T cell exhaustion is characterized by significant changes in metabolic function, transcriptional programming, loss of effector function (such as cytokine secretion, killing ability), and co-expression of multiple surface inhibitory receptors. The root cause of T cell exhaustion is continuous antigen exposure, which results in continuous TCR signal transduction. For a long time, preventing or reversing T cell exhaustion has been regarded as a means of improving T cell efficacy (for example, in patients with cancer or chronic infection). Summary of the Invention
[0005] The present invention relates to a method for treating T cell exhaustion by transiently inhibiting T cell receptor (TCR) signal transduction. On the one hand, the present invention provides compositions and methods for preventing chimeric antigen receptor (CAR) T cell exhaustion. Specifically, the present invention provides CAR T cells modified to maintain function under conditions where unmodified CAR T cells become dysfunctional (e.g., display exhaustion). CAR T cells modified according to the present invention (e.g., via regulating CAR surface expression), compositions containing the same, and methods for using the same, enhance T cell function, including, for example, activity against cancer or infectious diseases.
[0006] In some embodiments, CAR T cell exhaustion is suppressed or reversed via regulating CAR surface expression. In some embodiments, CAR surface expression may be regulated via the fusion of an adjustable destabilizing domain (RDD) and CAR T cells. In some embodiments, the RDD is a ligand-adjustable destabilizing domain. For example, in some embodiments, the regulation of CAR expression is achieved by the fusion of CAR and RDD, and the fusion causes the generated modified CAR protein to be unstable and prone to proteasome degradation. By adding ligands such as small molecules or drugs (e.g., Shield-1 or trimethoprim (TMP)), the modified CAR protein is protected from degradation, and the CAR construct comprising RDD is stably expressed (see Banaszynski et al., (2006) Cell 126:995–1004; Banaszynski et al., (2008) Nat Med 14:1123–1127; Iwamoto et al., (2010). Chem Biol 17:981–988).
[0007] In some embodiments, the RDD comprises a binding domain derived from dihydrofolate reductase (DHFR) RDD. In some embodiments, the RDD derived from DHFR comprises a binding domain from bacterial DHFR. In some embodiments, bacterial DHFR is Escherichia coli DHFR. In some embodiments, the RDD derived from DHFR comprises a binding domain from human DHFR. In some embodiments, the RDD comprises a binding domain derived from FK506 binding protein (FKBP). In some embodiments, FKBP is FKBP12. In some embodiments, the nucleic acid sequence of FKBP DD comprises the sequence listed in SEQ ID NO: 1. In one embodiment, the FKBP DD comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 2. In another embodiment, the FKBP DD portion of the CAR of the present invention comprises the amino acid sequence listed in SEQ ID NO.2.
[0008] In some embodiments, an ecDHFR destabilizing domain is used. In some embodiments, the nucleic acid sequence of the ecDHFR DD comprises the sequence set forth in SEQ ID NO: 3. In one embodiment, the ecDHFR DD comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 4. In another embodiment, the ecDHFR DD portion of the CAR of the present invention comprises the amino acid sequence set forth in SEQ ID NO. 4. In other embodiments, the nucleic acid sequence of the ecDHFR DD comprises the sequence set forth in SEQ ID NO: 5. In one embodiment, the ecDHFR DD comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 6. In another embodiment, the ecDHFR DD portion of the CAR of the present invention comprises the amino acid sequence set forth in SEQ ID NO. 6.
[0009] The present invention is not limited by the type of ligand. In some embodiments, Shield-1 or trimethoprim (TMP) is used to stabilize the surface expression of a fusion protein containing DHFR RDD or FKBP RDD and promote the stable surface expression.
[0010] In some embodiments, a T cell is provided, which is genetically engineered to express a CAR comprising an RDD (e.g., fused to a CAR), wherein the degradation (e.g., ubiquitin-mediated and / or proteasomal degradation) of the RDD-labeled CAR is prevented by the addition or presence of a stable small molecule drug that directly interacts with the RDD (e.g., binding) to prevent CAR degradation, and the removal (e.g., by metabolic clearance) or absence of a stable small molecule drug that directly interacts with the RDD allows CAR to degrade. Although the practice of the present invention does not require an understanding of the mechanism, and although the present invention is not limited to any particular mechanism, in some embodiments, nourishing CAR signal transduction (tonic CAR signaling) is prevented by allowing degradation or destruction of CAR, and the degradation or destruction of CAR causes the surface expression level of any CAR protein to be lower than the concentration required to allow nourishing CAR signal transduction. In some embodiments, the exhausted T cells are rejuvenated by regulating (e.g., reducing) the CAR protein level and CAR surface expression achieved by using this “drug on” RDD for CAR, and a marker for T cell exhaustion due to nourishing CAR signal transduction has been developed. For example, CAR T cells exposed to a stabilizing small molecule exhibited all the phenotypic and functional hallmarks of T cell exhaustion. However, when the stabilizing small molecule was removed by proteolysis and CAR protein levels were reduced, the phenotypic and functional indicators of T cell exhaustion were reversed and effector T cell function was restored.
[0011] On the other hand, the present invention provides a genetically modified T cell comprising an isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the isolated nucleic acid sequence comprises a nucleic acid sequence (e.g., a human, mouse or humanized mouse nucleic acid sequence) of a tumor antigen binding domain (e.g., a single-chain variable fragment or scFv), a nucleic acid sequence of a transmembrane domain, a nucleic acid sequence of an intracellular domain of one or more costimulatory molecules, a nucleic acid sequence of a CD3ζ signaling domain, and a nucleic acid sequence of an RDD domain.
[0012] The present invention further includes a vector comprising an isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the isolated nucleic acid sequence comprises a nucleic acid sequence (e.g., a human, mouse or humanized mouse nucleic acid sequence) of a tumor antigen binding domain (e.g., a single-chain variable fragment or scFv), a nucleic acid sequence of a transmembrane domain, a nucleic acid sequence of an intracellular domain of one or more costimulatory molecules, a nucleic acid sequence of a CD3ζ signaling domain, and a nucleic acid sequence of an RDD domain.
[0013] In addition, the present invention includes methods for providing anti-tumor immunity in a subject with cancer. The method includes administering an effective amount of genetically modified T cells to the subject, and the genetically modified T cells include the nucleic acid sequence encoding the separation of a chimeric antigen receptor (CAR), wherein the nucleic acid sequence of the separation includes a tumor antigen binding domain (e.g., single-chain variable fragment or scFv) nucleic acid sequence (e.g., people, mice or humanized mouse nucleic acid sequence), a nucleic acid sequence of a membrane-spanning domain, the nucleic acid sequence of the intracellular domain of one or more costimulatory molecules, the nucleic acid sequence of CD3 ζ signal transduction domains and the nucleic acid sequence of RDD domains, thereby providing anti-tumor immunity in the subject. In some embodiments, the subject is a person.
[0014] The present invention also includes a method for stimulating the beneficial and / or therapeutic T cell-mediated immune response for the cell mass, tumor or tissue in a subject.The method includes administering an effective amount of genetically modified T cells to the subject, and the genetically modified T cells include the nucleic acid sequence encoding the separation of chimeric antigen receptor (CAR), wherein the nucleic acid sequence of the separation includes tumor antigen binding domains (for example, single-chain variable fragment or scFv) nucleic acid sequence (for example, people, mice or humanized mouse nucleic acid sequence), the nucleic acid sequence of the intracellular domain of the membrane-spanning domain, one or more costimulatory molecules, the nucleic acid sequence of CD3 ζ signal transduction domains and the nucleic acid sequence of RDD domains, thus stimulating T cell-mediated immune response in the subject.
[0015] Also provided herein is a method for treating the cancer of a subject.Methods described includes administering a therapeutically effective amount of genetically modified T cells to a subject suffering from cancer, the genetically modified T cells include the nucleic acid sequence encoding the separation of a chimeric antigen receptor (CAR), wherein the nucleic acid sequence of the separation includes a tumor antigen binding domain (for example, single-chain variable fragment or scFv) nucleic acid sequence (for example, people, mice or humanized mouse nucleic acid sequence), a membrane-spanning domain nucleic acid sequence, one or more costimulatory molecules intracellular domain nucleic acid sequence, CD3 ζ signal transduction domain nucleic acid sequence and RDD domain nucleic acid sequence, thus treating the cancer of the subject.
[0016] The present invention also includes a method for producing a persistent population of genetically engineered T cells (e.g., memory T cells) in a subject diagnosed with cancer, the method comprising: administering to the subject an effective amount of genetically modified T cells, the genetically modified T cells comprising an isolated nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the isolated nucleic acid sequence comprises a nucleic acid sequence (e.g., a human, mouse, or humanized mouse nucleic acid sequence) of a tumor antigen binding domain (e.g., a single-chain variable fragment or scFv), a nucleic acid sequence of a transmembrane domain, a nucleic acid sequence of an intracellular domain of one or more costimulatory molecules, a nucleic acid sequence of a CD3ζ signaling domain, and a nucleic acid sequence of an RDD domain, wherein the persistent population of genetically engineered T cells persists in the subject after administration (e.g., several weeks, one month, several months, etc.). In some embodiments, the persistent population of genetically engineered T cells persists in humans for at least three months after administration.
[0017] The present invention is not limited by the mode of expressing CAR containing RDD. In some embodiments, constitutively express CAR. In other embodiments, CAR is expressed in a regulated manner (for example, using a system for regulating expression via small molecules or using an endogenous regulatory system). In another embodiment, retrovirus, slow virus or other viral vectors or CAR gene integration into cell DNA is performed using a system based on CRISPR / Cas9 CAR. In another embodiment, CAR is expressed via RNA or oncolytic virus or other transient expression systems known in the art. CAR can be delivered in vitro to T cells for adoptive transfer, or delivered via in vivo gene transfer.
[0018] The present invention is not limited to the type of T cells genetically modified to express and / or contain the CAR of the present invention. In some embodiments, T cells are CD3+ T cells (e.g., CD4+ and / or CD8+ T cells). In certain embodiments, T cells are CD8+ T cells. In other embodiments, T cells are CD4+ T cells. In some embodiments, T cells are natural killer (NK) T cells. In some embodiments, T cells are αβ T cells. In some embodiments, T cells are γδ T cells. In some embodiments, T cells are a combination of CD4+ and CD8 T+ cells (e.g., CD3+). In certain embodiments, T cells are memory T cells. In certain embodiments, memory T cells are central memory T cells. In other embodiments, memory T cells are effector memory T cells. In some embodiments, T cells are tumor infiltrating lymphocytes (TIL). In certain embodiments, T cells are a combination of CD8+ T cells, CD4+ T cells, NK T cells, memory T cells, and / or γδ T cells. In some embodiments, T cells are cytokine-induced killer cells.
[0019] In some embodiments, CAR T cells include peripheral blood-derived T cells modified by CAR genes, and the CAR recognizes and responds to tumor antigens. This receptor is generally composed of the following: an extracellular domain, a transmembrane domain, and an intracellular signal transduction domain comprising a single-chain antibody (scFv) specific for a tumor antigen (see, for example, Westwood, JA et al., 2005, Proc. Natl. Acad. Sci., USA, 102 (52): 19051-19056). In other embodiments, T cells are engineered to express human or mouse-derived CARs that recognize tumor antigens. The present invention is not limited by the type of tumor antigen recognized. In fact, any CAR that recognizes tumor antigens is applied to the compositions and methods of the present invention. Examples include, but are not limited to, CARs that recognize antigens selected from the group consisting of HER2, CD19, CD20, CD22, CD30, CD33 / IL3Rα, CD123, CD38, receptor tyrosine kinase-like orphan receptor 1 (ROR1), ErbB3 / 4, glycolipid F77, epidermal growth factor receptor (EGFR), EGFR variant III (EGFRvIII), melanoma antigen recognized by T cells 1 (MART-1), EphA2, FA P, human carcinoembryonic antigen (CEA), EGP2, EGP40, mesothelin, TAG72, prostate-specific membrane antigen (PSMA), NKG2D ligand, B7-H6, IL-13 receptor α2, IL-11 receptor α, MUC1, MUC16, CA9, disialoganglioside 2 (GD2), GD3, tyrosine protein kinase Met (c-Met) or hepatocyte growth factor receptor (HGFR), HMW-MAA, CD171, Lewis Y, G250 / CAIX, melanoma antigen gene (MAGE) family member A3 (MAGE-A3), HLA-AI, MAGE A1, NY-ESO-1, PSC1, folate receptor-α, CD44v7 / 8, 8H9, NCAM, VEGF receptor, fetal AchR, NKG2D ligand, CD44v6, TEM1, TEM8, GP1000, p53, Epstein-Barr virus (EBV) proteins or antigens, or other virus-associated antigens expressed by the tumor.
[0020] The present invention is not limited by CAR types. In fact, any CAR that specifically binds to a desired antigen (for example, tumor antigen or other antigen types) can be modified as disclosed herein or described to regulate the surface expression of CAR. In certain embodiments, CAR includes antigen binding domains. In certain embodiments, the antigen binding domain is a single-chain variable fragment (scFv), which contains a heavy chain and light chain variable region that specifically binds to a desired antigen. In some embodiments, the CAR includes a transmembrane domain and a signal transduction domain, which includes one or more activation motifs (ITAMs) based on immunoreceptor tyrosine. In some embodiments, the transmembrane domain includes a transmembrane domain of a protein selected from the group consisting of: T cell receptor (TCR) α chain, TCR β chain, CD3 ζ, CD28, CD3 ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154. In some embodiments, the intracellular signal transduction domain includes the functional signal transduction domain of 4-1BB polypeptides, the functional signal transduction domain of CD3 ζ polypeptides or both.In some embodiments, the CAR includes one or more costimulatory domains (for example, providing a second signal to stimulate the domain of T cell activation). The present invention is not limited by the costimulatory domain type. In fact, any costimulatory domain as known in the art can be used, including but not limited to CD28, OX40 / CD134, 4-1BB / CD137 / TNFRSF9, high-affinity immunoglobulin E receptor-γ subunit (FcεRIγ), ICOS / CD278, interleukin 2 subunit β (ILRβ) or CD122, cytokine receptor common subunit γ (IL-2Rγ) or CD132 and CD40. In one embodiment, the costimulatory domain is 4-1BB.
[0021] The present invention is not limited to any specific RDD or domain within the CAR to which the RDD is fused. In some embodiments, the RDD is fused to the CAR antigen binding domain. In other embodiments, the RDD is fused to a hinge or transmembrane CAR domain. In yet other embodiments, the RDD is fused to a cytoplasmic CAR stimulatory domain, such as, but not limited to, CD28, 4-1BB, OX-40. In still other embodiments, the RDD is fused to a CAR CD3ζ domain. In fact, according to the present methods and compositions, cells comprising a CAR containing an RDD may have an RDD attached to any portion of the CAR, as long as the CAR retains antigen-specific activity.
[0022] On the other hand, the present invention provides a method for treating a disease or condition in a subject, the method comprising administering an effective amount of CAR T cells to a subject (e.g., a patient) suffering from a disease or condition, the CAR T cells comprising a CAR containing or fused to an RDD. The present invention is not limited by the type of disease or condition being treated. In fact, any disease or condition that can be treated by administering CAR T cells (e.g., after treatment, the signs or symptoms of the disease are alleviated) can be treated in an improved and more effective manner using the compositions and methods of the present invention. In one embodiment, the disease or condition is cancer. In another embodiment, the disease or condition is an infectious disease. The present invention is not limited by the type of cancer or infectious disease. In fact, any cancer or disease that is used for treatment with CAR T cell therapy known in the art can be treated with the compositions and methods of the present invention. For example, the compositions and methods of the present invention can be modified by introducing the RDD gene into the CAR of therapeutic CART cells to modify any CAR T cell therapy known in the art. In some embodiments, administering an effective amount of CAR T cells of the present invention to a subject (e.g., a patient) suffering from a disease or condition inhibits or reverses T cell exhaustion in the patient (e.g., compared to a subject receiving the same amount of CAR T cells lacking DD).
[0023] On the other hand, the present invention provides a method for maintaining, recovering or improving CAR T cells (for example, otherwise the CAR T cells will be subjected to antigen-induced nourishing signal transduction and exhaustion in the case of a disease or condition) function via selective regulation (for example, reduction) CAR cell surface expression. In some embodiments, RDD is incorporated into CAR to allow regulation (for example, reduction) CAR expression during in vitro or ex vivo culture and amplification of T cells, which in turn improves the function (for example, effector function) of CAR T cells in the case of a disease or condition for treating a subject. The present invention is not limited by the functional type that is maintained, recovered or improved. In some embodiments, the function is antigen-induced cytokine production. In other embodiments, the function is the cytotoxicity (for example, improvement of tumor target identification) of CAR T cells. In some embodiments, the function is an increase in the formation of memory cells in response to antigens and / or an increase in proliferation. In some embodiments, the regulation (for example, reduction) of CAR cell surface expression causes a measurable reduction in the marker indicating exhaustion in CAR T cells, including but not limited to PD-1, TIM-3 and LAG-3. In other embodiments, the regulation (e.g., reduction) of CAR cell surface expression causes a reduction in CAR T cell programmed cell death levels. In other embodiments, the regulation (e.g., reduction) of CAR cell surface expression on CAR T cells significantly enhances the clinical effects of CAR T cell therapy.
[0024] On the other hand, the present invention provides a method for treating a patient's cancer or delaying its progress, the method comprising administering to the patient a therapeutically effective amount of a composition comprising CAR T cells, the CAR T cells being modified (e.g., genetically) to express a CAR containing or fused to an RDD. In certain embodiments, a therapeutically effective amount of a composition comprising modified CAR T cells reduces the number of cancer cells in the patient after such treatment. In certain embodiments, a therapeutically effective amount of a composition comprising modified CAR T cells reduces and / or eliminates the tumor load in the patient after such treatment. In certain embodiments, the method further comprises administering radiotherapy to the patient. In certain embodiments, radiotherapy is administered before, simultaneously, and / or after the patient receives a therapeutically effective amount of a composition comprising modified CAR T cells. In certain embodiments, the method further comprises administering to the patient one or more anticancer agents and / or one or more chemotherapeutics. In certain embodiments, one or more anticancer agents and / or one or more chemotherapeutics are administered before, simultaneously, and / or after the patient receives a therapeutically effective amount of a composition comprising modified CAR T cells. In certain embodiments, treatment of patients with a therapeutically effective amount of modified CAR T cells and an anticancer agent results in a greater tumor response and clinical benefit in such patients compared to treatment with modified CAR T cells or anticancer drugs / radiation alone. Since the dosages of all approved anticancer drugs and radiation therapy are known, the present invention includes various combinations of them with modified CAR T cells.
[0025] In certain embodiments, the present invention provides a therapeutically effective amount of a composition comprising a CAR T cell modified according to the present disclosure (e.g., for treating a subject's cancer or delaying its progression). As described herein, the composition can be administered before, during, or after other types of cancer treatment (e.g., chemotherapy, surgical resection of cancer, or radiotherapy). The present invention also provides the use of a composition to induce cell cycle inhibition and / or apoptosis. The present invention further relates to compositions for sensitizing cells to additional agents such as inducers of apoptosis and / or cell cycle inhibition and for chemically protecting normal cells by inducing cell cycle inhibition. The present composition is suitable for treating, improving, or preventing conditions such as any type of cancer or infectious disease and any cells that are otherwise responsive to induction of apoptotic cell death (e.g., conditions characterized by apoptosis dysregulation, including hyperproliferative diseases, such as cancer). In certain embodiments, the composition can be used to treat, alleviate, or prevent cancers that are otherwise characterized as being resistant to cancer therapy (e.g., those cancer cells with chemotherapy resistance, radiation resistance, hormone resistance, etc.). The present invention also provides pharmaceutical compositions including compositions (e.g., immunotherapeutic compositions) comprising the modified CAR T cells of the present invention in a pharmaceutically acceptable carrier.
[0026] In another embodiment, the present invention provides a method for treating a patient's cancer or delaying its progression, the method comprising administering to the patient a therapeutically effective amount of a composition comprising a CAR T cell modified according to the present disclosure (e.g., a gene) in combination with a therapeutically effective amount of a TCR signal transduction inhibitor (e.g., for preventing T cell exhaustion). Multiple treatment cycles may be administered to the subject. In certain embodiments, the TCR signal transduction inhibitor is administered according to a standard dosing regimen (e.g., daily or intermittently). In another embodiment, the TCR signal transduction inhibitor is administered for a period of time sufficient to restore at least some T cell function and then stopped.
[0027] These and other embodiments of the present invention will readily occur to those skilled in the art in view of the disclosure herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 Figure 3: Characterization of the GD2.28z.FKBP CAR. T cells were transduced with lentivirus encoding the GD2.28z.FKBP CAR on day 1 after activation and subsequently cultured in growth medium with various concentrations of shield-1. On day 7, CAR expression was quantified by FACS.
[0029] Figure 2 : Removal of S1 from the culture medium results in reversal of surface expression of T cell exhaustion markers.
[0030] Figure 3 : Removal of S1 from the culture medium maintained CD62L expression and prevented cell apoptosis.
[0031] Figure 4 : Removal of S1 from the culture medium results in reversal of functional T cell depletion.
[0032] Figure 5 : Removal of surface CAR resulted in more effective prevention of T cell exhaustion than PD-1 / PDL-1 blockade.
[0033] Figure 6 : Removal of surface CAR rescues exhaustion in PD-1 / TIM-3 / LAG-3 triple-positive CAR T cells only after 4 days.
[0034] Figure 7 : Dasatinib inhibits cytokine secretion by CAR T cells in response to tumor antigens.
[0035] Figure 8 : Dasatinib reverses exhaustion marker expression and co-expression.
[0036] Figure 9: Dasatinib treatment results in maintenance of CD62L expression.
[0037] Figure 10 : Dasatinib treatment results in enhanced IL-2 and IFNγ secretion in response to tumor antigens.
[0038] Figure 11 Depicts a schematic diagram of a chimeric antigen receptor (CAR) in one embodiment of the present invention. For example, CAR may contain an extracellular antigen binding domain (e.g., a single-chain variable fragment (scFv)) and an extracellular hinge region, a transmembrane domain, an intracellular costimulatory domain (e.g., containing CD28 or 4-1BB domains), an intracellular CD3 ζ domain, and an adjustable destabilizing domain (RDD).
[0039] Figure 12 Shown are dose-dependent regulation of several different CARs of various sizes containing an RDD fused at the C-terminal position. A) CAR fused to an FKBP12 DD regulated by the rapalog shield-1. B) CAR fused to an E. coli-derived DHFR DD regulated by trimethoprim.
[0040] Figure 13 Rapid CAR protein stabilization or destabilization in the presence or absence of stabilizing drugs / small molecules is shown. In general, the IC50, the time it takes for 50% of the surface CAR to be degraded, is less than 2 hours.
[0041] Figure 14 The results show that the stable drug modulates the anti-tumor activity of RDD-CAR. The absence of the stable drug resulted in low in vitro CAR surface expression compared to CAR T cells cultured in the presence of the stable drug and high CAR surface expression, accompanied by impaired cytokine secretion and reduced cytotoxicity in response to tumors.
[0042] Figure 15 It is shown that trimethoprim regulates CAR surface expression and activity of DHFR DD-CAR in vivo. Figure 15 A shows that CAR expression is regulatable in vivo, and the dynamic range of CAR surface expression achieved in vitro is similar to that observed in vivo. Figure 15 B shows that mice receiving stable injections of the drug trimethoprim (TMP) not only exhibited CAR expression, but the higher expressing CAR T cells in this group also exhibited higher CD69 surface expression, indicating that they became activated in vivo in response to tumors. Figure 15 C shows the difference in tumor burden in mice receiving daily injections of vehicle versus mice receiving TMP. Mice receiving TMP and thereby expressing CAR on their surface exhibited a greater ability to control tumor growth than mock and vehicle controls.
[0043] Figure 16 It is shown that the nourishing signal transduction in HA-GD2.28z is blocked or reversed via the RDD of fusion. When (wherein CAR CD3 ζ domains are phosphorylated at baseline) CAR is expressed on T cell surfaces by Western blotting, HA-GD2.28z.FKBP CAR carries out nourishing signal transduction in the absence of tumor antigen. Nourishing signal transduction causes T cell exhaustion, which causes these CAR T cells to be less effective. Nourishing signal transduction is blocked in RDD-CAR T cells by amplifying the cells in the absence of stable drugs. When CAR expression is reduced or suppressed and is not expressed on T cell surfaces (in the absence of shield-1, CAR is always closed), or if CAR is expressed at a certain point, but then removed from the surface and continued for 72 hours (CAR closes D7), it is observed that CD3 ζ phosphorylation is weakened.
[0044] Figure 17 The co-expression of typical exhaustion markers on HA-GD2.28z.FKBP is shown to be rapidly down-regulated after shield-1 is removed from the culture medium and the prevention or reversal of nourishing signal transduction improves the exhaustion phenotype of CAR T cells. The co-expression of PD-1 / TIM-3 / LAG-3 is associated with reduced effector function. When CAR is always expressed (cultivated with shield-1, "CAR is always on"), these markers are co-expressed in most cells. However, when CAR is not expressed on the surface (without shield-1, "CAR is always off") or is cultured in shield-1 for 7 days and then removed, only a small portion of cells co-expressing exhaustion markers are observed. Figure 17 B shows a similar trend of cells co-expressing Tbet and Blimp-1, transcription factors associated with T cell exhaustion.
[0045] Figure 18 Shown is the suppression of nourishing signal transduction or removal and rescue memory phenotype.T cell exhaustion suppresses the ability of T cell to form memory.Exhausted (CAR is always on) cells have a high percentage of effector T cells (Teff) and a low percentage of stem cell memory (Tscm).On the contrary, non-exhausted cells (CAR is always off) or those cells (CAR off D7 or CAR off D10) wherein depleted by removing stable drugs from culture show an increase in stem cell memory compartments.
[0046] Figure 19The time-dependent regulation of CAR surface expression via fused FKBP or E. coli-derived DHFR destabilizing domain (DD) is shown. Exhausted CAR T cells fail to secrete effector cytokines IL-2 and IFNγ in response to tumors. However, CAR T cells in which exhaustion is prevented or reversed exhibit enhanced secretion of IL-2 and IFNγ.
[0047] Figure 20 It was shown that exhausted CAR T cells had significantly reduced cytotoxicity. However, CAR T cells in which exhaustion was prevented or reversed exhibited improved cytotoxicity.
[0048] Figure 21 Mice exposed to repeated dosing with stable drug were shown. Four days of T cell "rest" were provided, during which vehicle was injected instead of TMP. TMP injections were then resumed for another three days. The data demonstrate profound functional rescue after the "rest" period, when tumor burden dropped below that before the "rest" period.
[0049] Figure 22 Dose-response curves and EC values for various tunable DD-CARs are shown. 50 CAR median fluorescence intensity (MFI) was calculated by first gating CAR+ and CAR- cells and then subtracting the MFI of the CAR- population from the CAR+ population. Values were normalized to the maximum CAR MFI in the drug titration study, and nonlinear regression and least squares fit curves were generated. The EC of each curve was plotted in the bar graph. 50 For GD2.28z.FKBP, HA-GD2.28z.FKBP, GD2.28z.ecDHFR, n=3 donors. For CD19.28z.FKBP, CD19.28z.ecDHFR, and HA-GD2.28z.ecDHFR, n=2 donors.
[0050] Figure 23It is shown that certain destabilizing domains are better for drug-dependent regulation of CAR expression. (A) T cells were transduced with lentivirus to express GD2.28z.ecDHFR, wherein the ecDHFR domain contained the following mutations: R12H, N18T, V19A, and G67S. T cells were removed from the culture and stained with a fluorescently conjugated anti-idiotypic antibody, and CAR surface expression was subsequently assessed via FACS. Due to high background expression in the absence of stabilizing drugs, slight drug-dependent CAR regulation was observed. (B) T cells were transduced with lentivirus to express GD2.28z.ecDHFR, wherein the ecDHFR domain contained the following mutations: R12Y, G67S, Y100I. T cells were removed from the culture again, stained with an anti-idiotypic antibody, and CAR expression was assessed via FACS. In this DD-CAR repeat incorporating different ecDHFR domains, drug-dependent regulation of CAR surface expression was observed. Dashed lines are drawn in both sub-graphs to highlight the difference in CAR expression levels between 0 uM TMP and 10 uM TMP.
[0051] Figure 24 Shown is the drug-dependent regulation of Her.28z CAR via fused FKBP DD. The FKBP12 DD domain was fused to the distal c-terminus of Her2.28z CAR. T cells were transduced with lentivirus to express Her2.28z.FKBP. On day 7 after activation, CAR T cells were cultured in the presence or absence of shield-1. 24 hours after drug addition, CAR T cells were stained with protein L and CAR expression was assessed via FACS. After cultivation with 0.1uM or 1uM Shield-1 (S1), the percentage of CAR+ cells (quantified by histogram) and CAR MFI increased.
[0052] Figure 25 Tables of nucleic acid and amino acid sequences suitable for use in the embodiments of the invention described herein are provided.
[0053] definition
[0054] For purposes of this specification, the following definitions will apply and, where appropriate, terms used in the singular will also include the plural and vice versa. In the event of a conflict between any definition set forth below and any document incorporated herein by reference, the definition set forth below will control.
[0055] It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.
[0056] As used herein, the articles "a" and "an" refer to one or to more than one (ie, to at least one) of the grammatical object of the article. For example, "an element" means one element or more than one element.
[0057] As used herein, the term "about" when referring to a measurable value (e.g., an amount, a duration, etc.) is intended to include variations of + / - 20% or + / - 10%, more preferably + / - 5%, even more preferably + / - 1%, and still more preferably + / - 0.1% of the specified value, so long as such variations are appropriate for practicing the disclosed methods.
[0058] "T cell exhaustion" refers to a decrease in T cell function, which can occur as a result of infection (e.g., chronic infection) or disease. T cell exhaustion is associated with increased expression of PD-1, TIM-3, and LAG-3 and reduced cytokine secretion. Therefore, the terms "reducing T cell exhaustion," "inhibiting T cell exhaustion," "reducing T cell exhaustion," and the like refer to a situation in which T cell function is restored, characterized by one or more of the following: reducing the expression and / or level of one or more of PD-1, TIM-3, and LAG-3; increasing memory cell formation and / or maintaining memory markers (e.g., CD62L); preventing apoptosis; increasing antigen-induced cytokine (e.g., IL-2) production and / or secretion; improving cytotoxicity / killing ability; improving recognition of tumor targets with low surface antigens; and enhancing proliferation in response to antigens.
[0059] As used herein, the term "antigen binding domain" as in "GD2 binding domain" may refer to any antigen-specific binding domain known to those skilled in the art (e.g., a GD2-specific binding domain). In one embodiment, the GD2 binding domain comprises a single-chain variable fragment (scFv), which comprises a heavy chain (V) of an antibody that specifically binds to GD2. H ) and light chain (V L ) variable region. Anti-GD2 antibodies, antibody fragments, and variants thereof are well known in the art and include, for example, 14G2a, ch14.18, hu14.18K322A, m3F8, hu3F8-IgG1, hu3F8-IgG4, HM3F8, UNITUXIN, DMAb-20, or any other antibody that specifically binds to GD2. In one embodiment, the GD2 binding domain is a homolog, variant, isomer, or functional fragment of an anti-GD2 antibody. Each possibility represents a separate embodiment of the present invention.
[0060] As used herein, "activated" refers to a state in which T cells have been sufficiently stimulated to induce detectable cell proliferation. Activation can also be associated with induced cytokine production and detectable effector function. The term "activated T cell" particularly refers to a T cell that is undergoing cell division.
[0061] As used herein, the term "antibody" refers to an immunoglobulin molecule that specifically binds to an antigen. An antibody can be a complete immunoglobulin derived from a natural or recombinant source and can be an immunoreactive portion of a complete immunoglobulin. An antibody can be a polymer of a single immunoglobulin molecule. The antibodies of the present invention can exist in various forms, including, for example, polyclonal antibodies, monoclonal antibodies, Fv, Fab and F(ab)2, as well as single-chain antibodies, human antibodies and humanized antibodies (see Harlow et al., 1999, In:Using Antibodies:A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989, In:Antibodies:A Laboratory Manual, Cold Spring Harbor, NY; Houston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science 242:423-426).
[0062] The term "antibody fragment" refers to a portion of an intact antibody and preferably refers to the antigen-determining variable region of an intact antibody. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments, linear antibodies, scFv antibodies, and multispecific antibodies formed from antibody fragments.
[0063] As used herein, an "antibody heavy chain" refers to the larger of the two types of polypeptide chains found in all antibody molecules in their naturally occurring conformation. As used herein, an "antibody light chain" refers to the smaller of the two types of polypeptide chains found in all antibody molecules in their naturally occurring conformation. Kappa and lambda light chains refer to the two major antibody light chain isotypes.
[0064] As used herein, the term "synthetic antibody" refers to an antibody produced using recombinant DNA technology, for example, an antibody expressed by a bacteriophage as described herein. The term should also be interpreted as meaning an antibody produced by synthesizing a DNA molecule encoding the antibody that expresses an antibody protein or an amino acid sequence specifying the antibody, wherein the DNA or amino acid sequence has been obtained using techniques for synthesizing DNA or amino acid sequences available or known in the art.
[0065] As used herein, the term "antigen" or "Ag" is defined as a molecule that causes an immune response. This immune response may involve antibody production, or the activation of specific immunocompetent cells, or both. It will be understood by those skilled in the art that any macromolecule (including virtually all proteins or peptides) can serve as an antigen. In addition, antigens can be derived from recombinant or genomic DNA. It will be understood by those skilled in the art that any DNA comprising a nucleotide sequence or partial nucleotide sequence encoding a protein that causes an immune response is therefore encoded as the term "antigen" as used herein. In addition, it will be understood by those skilled in the art that antigens are not necessarily encoded only by the full-length nucleotide sequence of a gene. In addition, it will be understood by those skilled in the art that antigens do not need to be encoded by a "gene" at all. Obviously, antigens can be produced, synthesized or obtained from biological samples. Such biological samples may include, but are not limited to, tissue samples, tumor samples, cells or biological fluids.
[0066] As used herein, the term "anti-tumor effect" refers to a biological effect that can be manifested as: a reduction in tumor volume, a reduction in the number of tumor cells, a reduction in the number of metastases, an increase in life expectancy, or an improvement in various physiological symptoms associated with cancer. An "anti-tumor effect" can also be manifested by the ability of the peptides, polynucleotides, antibodies (or antigen-binding portions thereof) and CAR T cells of the present invention to prevent tumors from appearing in the first place.
[0067] As used herein, the term "autoimmune disease" is defined as a condition caused by an autoimmune reaction. An autoimmune disease is the result of an inappropriate and excessive reaction to a self-antigen. Examples of autoimmune diseases include, but are not limited to, Addison's disease, alopecia areata, ankylosing spondylitis, autoimmune hepatitis, autoimmune mumps, Crohn's disease, diabetes (type I), dystrophic epidermolysis bullosa, epididymitis, glomerulonephritis, Graves' disease, Guillain-Barré syndrome, lymphocytic goiter, hemolytic anemia, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, psoriasis, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjögren's syndrome, spondyloarthropathies, thyroiditis, vasculitis, vitiligo, myxedema, pernicious anemia, ulcerative colitis, etc.
[0068] As used herein, the term "autologous" means any material derived from an individual that is later reintroduced into the same individual. "Allogeneic" refers to a transplant derived from a different animal of the same species. "Xenogeneic" refers to a transplant derived from an animal of a different species.
[0069] As used herein, the term "cancer" is defined as a disease characterized by the rapid and uncontrolled growth of abnormal cells. Cancer cells can spread locally or to other parts of the body through the bloodstream and lymphatic system. Examples of various cancers include, but are not limited to, breast cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colorectal cancer, kidney cancer, liver cancer, brain cancer, lymphoma, leukemia, lung cancer, etc.
[0070] As used herein, "costimulatory ligands" include molecules on antigen presenting cells (APCs) (e.g., dendritic cells, B cells, etc.) that specifically bind to cognate costimulatory molecules on T cells, thereby providing a signal that, in addition to the primary signal provided by, for example, binding of the TCR / CD3 complex to the peptide-loaded MHC molecule, mediates T cell responses, including but not limited to proliferation, activation, differentiation, etc. Costimulatory ligands may include, but are not limited to, CD7, B7-1 (CD80), B7-2 (CD86), PD-L1, PD-L2, 4-1BBL, OX40L, inducible co-stimulatory ligand (ICOS-L), intercellular adhesion molecule (ICAM), CD30L, CD40, CD70, CD83, HLA-G, MICA, MICB, HVEM, lymphotoxin beta receptor, 3 / TR6, ILT3, ILT4, HVEM, agonists or antibodies that bind to Toll ligand receptors, and ligands that specifically bind to B7-H3. Co-stimulatory ligands particularly also encompass antibodies that specifically bind to co-stimulatory molecules present on T cells, such as, but not limited to, CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and ligands that specifically bind to CD83.
[0071] "Costimulatory molecule" refers to a cognate binding partner that specifically binds to a costimulatory ligand on a T cell, thereby mediating a costimulatory response by the T cell, such as, but not limited to, proliferation. Costimulatory molecules include, but are not limited to, MHC class I molecules, BTLA, and Toll ligand receptors.
[0072] As used herein, a "co-stimulatory signal" refers to a signal that, in combination with a primary signal, such as TCR / CD3 engagement, results in T cell proliferation and / or upregulation or downregulation of key molecules.
[0073] As used herein, an "effective amount" means an amount that provides a therapeutic or prophylactic benefit.
[0074] As used herein, the term "therapeutic" means treatment and / or prevention. A therapeutic effect is achieved by suppressing, alleviating, or eradicating a disease state.
[0075] The term "therapeutically effective amount" refers to the amount of a compound of the present invention that will elicit the biological or medical response of a tissue, system, or subject that is being sought by the researcher, veterinarian, medical doctor, or other clinician. The term "therapeutically effective amount" includes an amount of a compound that, when administered, is sufficient to prevent the progression of, or alleviate to some extent, one or more signs or symptoms of the condition or disease being treated. The therapeutically effective amount will vary depending on the compound, the disease and its severity, and the age, weight, etc., of the subject being treated.
[0076] As used herein, the term "treating" a disease means reducing the incidence or severity of at least one sign or symptom of the disease or condition experienced by a subject.
[0077] "Encoding" refers to the inherent property and resulting biological properties of a particular nucleotide sequence in a polynucleotide, such as a gene, cDNA, or mRNA, that serves as a template for the synthesis of other polymers and macromolecules having a defined nucleotide sequence (e.g., rRNA, tRNA, and mRNA) or a defined amino acid sequence in biological processes. Thus, if transcription and translation of the mRNA corresponding to a gene produces a protein in a cell or other biological system, the gene encodes the protein. Both the coding strand (whose nucleotide sequence is identical to the mRNA sequence and is typically provided in a sequence listing) and the non-coding strand (which serves as a template for transcription of the gene or cDNA) can be said to encode a protein or other product of the gene or cDNA.
[0078] As used herein, "endogenous" refers to any substance from or produced within an organism, cell, tissue, or system. As used herein, the term "exogenous" refers to any substance introduced from or produced outside an organism, cell, tissue, or system.
[0079] As used herein, the term "expression" refers to the transcription and / or translation of a specific nucleotide sequence driven by its promoter. "Expression" also refers to the presence of a protein on the surface of a cell (e.g., CAR expression on the surface of a T cell).
[0080] As used herein, the term "transfection" or "transformation" or "transduction" refers to the process by which exogenous nucleic acid is transferred or introduced into a host cell. A "transfected" or "transformed" or "transduced" cell is one that has been transfected, transformed, or transduced with an exogenous nucleic acid. Cells include primary subject cells and their progeny.
[0081] A "vector" is a composition of matter that contains an isolated nucleic acid and can be used to deliver the isolated nucleic acid into a cell. Many vectors are known in the art, including but not limited to linear polynucleotides, polynucleotides associated with ions or amphiphilic compounds, plasmids, and viruses. Thus, the term "vector" includes autonomously replicating plasmids or viruses. The term should also be interpreted to include non-plasmid and non-viral compounds that facilitate the transfer of nucleic acids into cells, such as, for example, polylysine compounds, liposomes, and the like. Examples of viral vectors include, but are not limited to, adenoviral vectors, adeno-associated viral vectors, retroviral vectors, and the like.
[0082] "Expression vector" refers to a vector comprising a recombinant polynucleotide comprising expression control sequences operably linked to a nucleotide sequence to be expressed. An expression vector comprises sufficient cis-acting elements for expression; other elements for expression may be provided by the host cell or in an in vitro expression system. Expression vectors include all expression vectors known in the art, such as cosmids, plasmids (e.g., naked or contained in liposomes), and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses), which incorporate a recombinant polynucleotide.
[0083] As used herein, "lentivirus" refers to a genus of the Retroviridae family. Lentiviruses are unique among retroviruses in that they are able to infect non-dividing cells. Lentivirus-derived vectors can transfer significant amounts of genetic information into the host cell's DNA, making them one of the most effective methods of gene delivery vectors. HIV, SIV, and FIV are all examples of lentiviruses.
[0084] "Homologous" refers to the sequence similarity or sequence identity between two polypeptides or two nucleic acid molecules. When a position in both compared sequences is occupied by the same base or amino acid monomer subunit, for example, if a position in each of two DNA molecules is occupied by adenine, then the molecules are homologous at that position. The percentage homology between two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of positions compared × 100. For example, if 6 out of 10 positions in two sequences are matched or homologous, then the two sequences have 60% homology. For example, the DNA sequences ATTGCC and TATGGC share 50% homology. Typically, when aligning two sequences, the comparison is performed to maximize homology.
[0085] As used herein, the term "immunoglobulin" or "Ig" is defined as a class of proteins that act as antibodies. Antibodies expressed by B cells are sometimes referred to as B cell receptors (BCRs) or antigen receptors. The five members included in this class of proteins are IgA, IgG, IgM, IgD, and IgE. IgA is the primary antibody found in body secretions such as saliva, tears, breast milk, gastrointestinal secretions, and mucous secretions of the respiratory and urogenital tracts. IgG is the most common circulating antibody. IgM is the main immunoglobulin produced in the primary immune response of most subjects. It is the most effective immunoglobulin in agglutination, complement fixation, and other antibody responses and is important for defending against bacteria and viruses. IgD is an immunoglobulin that has no known antibody function but can act as an antigen receptor. IgE is an immunoglobulin that mediates immediate hypersensitivity reactions by causing the release of mediators from mast cells and basophils after exposure to allergens.
[0086] "Isolated" means altered from or removed from its natural state. For example, a nucleic acid or peptide naturally present in a living animal is not "isolated," but the same nucleic acid or peptide partially or completely separated from the coexisting materials of its natural state is "isolated." An isolated nucleic acid or protein can exist in a substantially purified form or can exist in a non-natural environment, such as a host cell.
[0087] As used herein, "substantially purified" cells are cells that are substantially free of other cell types. Substantially purified cells also refer to cells that have been separated from other cell types with which they are normally associated in their naturally occurring state. In some cases, a substantially purified cell population refers to a homogenous cell population. In other cases, the term refers only to cells that have been separated from cells with which they are naturally associated in their natural state. In some embodiments, the cells are cultured in vitro. In other embodiments, the cells are not cultured in vitro.
[0088] Unless otherwise specified, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and encode the same amino acid sequence. The phrase "nucleotide sequence encoding a protein or RNA" may also include introns, and to the extent a nucleotide sequence encoding a protein may be in a form containing introns.
[0089] The term "operably linked" refers to a functional bond between a regulatory sequence and a heterologous nucleic acid sequence that results in expression of the heterologous nucleic acid sequence. For example, a first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For example, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Typically, operably linked DNA sequences are contiguous and, where necessary, join two protein coding regions in the same reading frame.
[0090] As used herein, the term "polynucleotide" is defined as a chain of nucleotides. In addition, a nucleic acid is a polymer of nucleotides. Therefore, as used herein, nucleic acid and polynucleotide are interchangeable. It is common knowledge among those skilled in the art that nucleic acids are polynucleotides, which can be hydrolyzed into monomeric "nucleotides." Monomeric nucleotides can be hydrolyzed into nucleosides. As used herein, polynucleotides include, but are not limited to, all nucleic acid sequences obtained by any means available in the art, including, but not limited to, recombinant means, i.e., cloning nucleic acid sequences from a recombinant library or cell genome using conventional cloning techniques and PCR, etc.; and by synthetic means.
[0091] As used herein, the terms "peptide," "polypeptide," and "protein" are used interchangeably and refer to compounds composed of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and there is no limit on the maximum number of amino acids that can constitute a protein or peptide sequence. Polypeptides include any peptide or protein composed of two or more amino acids linked to each other by peptide bonds. As used herein, the term refers to short chains, which are also commonly referred to in the art as, for example, peptides, oligopeptides, and oligomers; and longer chains, which are generally referred to in the art as proteins, of which there are many types. "Polypeptide" includes, among other things, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, polypeptide variants, modified polypeptides, derivatives, analogs, fusion proteins. Polypeptides include natural peptides, recombinant peptides, synthetic peptides, or a combination thereof.
[0092] As used herein, the term "promoter" is defined as a DNA sequence that is recognized by or introduced into the synthetic machinery of a cell and that is required for the specific transcription of an initiating polynucleotide sequence. As used herein, the term "promoter / regulatory sequence" means a nucleic acid sequence required for the expression of a gene product that is operably linked to the promoter / regulatory sequence. In some cases, this sequence may be a core promoter sequence, and in other cases, this sequence may also include an enhancer sequence and other regulatory elements required for the expression of the gene product. A promoter / regulatory sequence may be, for example, a sequence that expresses a gene product in a tissue-specific manner. A "constitutive" promoter is a nucleotide sequence that, when operably linked to a polynucleotide encoding a gene product, causes the gene product to be produced in a cell under most or all physiological conditions of the cell. An "inducible" promoter is a nucleotide sequence that, when operably linked to a polynucleotide encoding or specifying a gene product, causes the gene product to be produced in a cell generally only when an inducing agent corresponding to the promoter is present in the cell. A "tissue-specific" promoter is a nucleotide sequence that, when operably linked to a polynucleotide encoding a gene, causes the gene product to be produced in a cell substantially only when the cell is of the tissue type corresponding to the promoter.
[0093] The term "overexpressed" tumor antigen or "overexpression" of a tumor antigen is intended to indicate an abnormal expression level of a tumor antigen in cells from a diseased area of a patient (such as a solid tumor within a specific tissue or organ) relative to the expression level in normal cells from the tissue or organ. Patients with solid tumors or hematological malignancies characterized by overexpression of a tumor antigen can be identified by standard assays known in the art.
[0094] As used herein, the term "regulation" refers to the detectable increase or decrease of the activity (for example, the expression of protein in the reaction or cell in the subject) level in the mediation subject. The regulation activity level can be carried out in the presence of treatment or compound or in the absence of treatment or compound. For example, regulating the chimeric antigen receptor (CAR) expression level on the CAR T cell surface modified with the CAR gene containing an adjustable destabilizing domain (RDD) means that the CAR T cell is exposed to small molecules / drugs (which stabilize RDD) and increases the expression of CAR compared to the CAR expression level in the absence of small molecules / drugs. Similarly, it is possible to reduce the expression of CAR by removing stable small molecules / drugs (which stabilize RDD) compared to the CAR expression level in the presence of small molecules / drugs, regulating the chimeric antigen receptor (CAR) expression level on the CAR T cell surface modified with the CAR gene containing an adjustable destabilizing domain (RDD). The term covers interference and / or affects natural signals or reactions or non-regulated expression, thereby mediating a beneficial therapeutic response in a subject (preferably a person).
[0095] "Parenteral" administration of the immunogenic composition includes, for example, subcutaneous (sc), intravenous (iv), intramuscular (im) or intrasternal injection, or infusion techniques.
[0096] The terms "patient," "subject," "individual," and the like are used interchangeably herein and are intended to include living organisms (e.g., mammals) in which an immune response can be elicited. Examples of subjects include humans, dogs, cats, mice, rats, and transgenic species thereof.
[0097] As used herein, the term "specific binding" refers to an antibody that recognizes a specific antigen but generally does not recognize or bind to other molecules in the sample. For example, an antibody that specifically binds to an antigen from one species may also bind to antigens from one or more species. However, this cross-species reactivity itself does not change the specific classification of the antibody. In another embodiment, an antibody that specifically binds to an antigen may also bind to different allelic forms of the antigen. However, this cross-reactivity itself does not change the specific classification of the antibody. In some cases, the term "specific binding" or "specifically binds" can be used with respect to the interaction of an antibody, protein or peptide with a second chemical species, meaning that the interaction depends on the presence of a specific structure (e.g., antigenic determinant or epitope) on the chemical species; for example, antibodies generally recognize and bind to a specific protein structure rather than a protein. If the antibody is specific for epitope "A", then the presence of a molecule containing epitope A (or free, unlabeled A) in the reaction containing labeled "A" and the antibody will reduce the amount of labeled A bound to the antibody.
[0098] The term "stimulation" refers to a primary response induced by binding of a stimulatory molecule (e.g., a TCR / CD3 complex) to its cognate ligand, thereby mediating a signal transduction event, such as, but not limited to, signal transduction via the TCR / CD3 complex. Stimulation can mediate altered expression of certain molecules, such as downregulation of TGF-β, increased expression of IL-2 and / or IFN-γ, and / or remodeling of cytoskeletal structure, among others.
[0099] As used herein, the term "stimulatory molecule" refers to a molecule on a T cell that specifically binds to a cognate stimulatory ligand present on an antigen presenting cell.
[0100] As used herein, "stimulatory ligand" means a ligand that, when present on an antigen-presenting cell (e.g., a dendritic cell, a B cell, etc.), can specifically bind to a cognate binding partner on a T cell, thereby mediating a primary response by the T cell, including but not limited to activation, initiation of an immune response, proliferation, etc. Stimulatory ligands are well known in the art and encompass, among others, peptide-loaded MHC class I molecules, anti-CD3 antibodies, superagonist anti-CD28 antibodies, and superagonist anti-CD2 antibodies.
[0101] As used herein, the terms "sensitization" and "sensitization" refer to making an animal or a cell within an animal more susceptible or responsive to the biological effects of a second agent (e.g., promoting or hindering one aspect of cell function, including but not limited to cell division, cell growth, proliferation, invasion, angiogenesis, necrosis, or apoptosis) by administering a first agent. The sensitizing effect of a first agent on a target cell can be measured as the difference in the expected biological effect (e.g., promoting or hindering one aspect of cell function, including but not limited to cell growth, proliferation, invasion, angiogenesis, or apoptosis) observed after administering the second agent with and without the first agent. The response of the sensitized cells is enhanced by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 150%, at least about 200%, at least about 250%, at least 300%, at least about 350%, at least about 400%, at least about 450%, or at least about 500% compared to the response in the absence of the first agent.
[0102] As used herein, the term "subject suspected of having cancer" refers to a subject who exhibits one or more symptoms indicating cancer (e.g., an obvious lump or mass) or is being screened for cancer (e.g., during a routine physical examination). A subject suspected of having cancer may also have one or more risk factors for developing cancer. Subjects suspected of having cancer have not typically been screened for cancer. However, "subject suspected of having cancer" includes individuals who have received a preliminary diagnosis (e.g., a CT scan showing a mass) but have not yet undergone confirmatory testing (e.g., a biopsy and / or histology) or an unknown type and / or stage of cancer. The term also includes people who previously had cancer (e.g., individuals in remission). "Subject suspected of having cancer" is sometimes diagnosed with cancer and sometimes is found to be free of cancer.
[0103] As used herein, the term "a subject diagnosed with cancer" refers to a subject that has been tested and found to have cancer cells. Cancer can be diagnosed using any suitable method, including but not limited to biopsy, x-rays, blood tests, etc.
[0104] As used herein, the term "subject at risk for cancer" refers to a subject who has one or more risk factors for developing a particular cancer. Risk factors include, but are not limited to, sex, age, genetic susceptibility, environmental exposures, and previous cancer events, pre-existing non-cancer diseases, and lifestyle.
[0105] As used herein, the term "characterizing a cancer in a subject" refers to identifying one or more characteristics of a cancer sample in a subject, including but not limited to the presence of benign, precancerous, or cancerous tissue and the stage of the cancer. DETAILED DESCRIPTION
[0106] The present invention is based on the following discovery: transient inhibition or regulation of TCR signal transduction by regulating the surface expression of chimeric antigen receptor (CAR) in CAR T cells, thereby preventing or reversing CAR T cell exhaustion and restoring CAR T cell function. CAR-expressing T cells undergo nourishing, antigen-independent signal transduction and replicate the basic biological process of T cell exhaustion due to receptor clustering, as shown by the following: high levels of expression of PD-1, TIM-3 and LAG-3; antigen-induced cytokine production is reduced and excessive programmed cell death. GD2.28z CAR (GD2.28z.FKBP) fused to the FKBP12 destabilizing domain (DD) and adjustable DD (RDD) destabilizes CAR and induces rapid CAR protein degradation (see Banaszynski et al., Cell 2006). It was observed that surface expression was rapidly and dose-dependently regulated by adding or reducing trimethoprim or stabilizing rapalog shield-1 (S1) in the culture medium. Similar regulatable ability of CAR expression was also achieved using an E. coli DHFR mutant (GD2.28z.DHFR) fused to CAR, which was regulated in a dose-dependent manner with trimethoprim (see Examples 1 and 2, Figure 2 、 12 -13, 22-24).
[0107] Because trophic signal transduction is highly dependent on the level of CAR receptors in CAR T cells, control of CAR expression levels can be used to regulate the level of trophic signal transduction (e.g., in vitro or in vivo). Since trophic signal transduction is highly dependent on the level of CAR receptors, precise control of CAR expression levels can also precisely regulate the level of trophic signal transduction. Drug regulation controls the expression level of CAR, thereby allowing regulation of the duration and intensity of GD2.28z CAR trophic signal transduction. Using this system, once CAR signal transduction is stopped, the phenotypic and functional changes associated with exhaustion are reversed (see Examples 1 and 2). Small molecules or drugs (S1 or trimethoprim) are removed from the culture medium and the surface CAR is subsequently removed on day 7 after activation. Typical exhaustion marker expression will be reversed to control levels by day 10 (see Example 1, Figure 2 This was demonstrated by measuring the levels of triple-expressing PD-1 / TIM-3 / LAG-3 cells, which are highly specific for dysfunctional, exhausted T cells. By day 10, levels of triple-expressing exhausted cells were elevated, but removal of S1 at day 7 normalized these levels by day 10. Similar results were obtained on day 14 (see Example 1).
[0108] Therefore, in some embodiments, the present invention provides the ability to accurately control CART cell signal transduction and / or activity via regulating the surface expression of CAR. For example, as described in detail herein (see Example 2), the present invention provides the following ability: downward titration of the dosage of the stable drug causes a rapid decrease in CAR expression, which in turn inhibits and / or eliminates CAR T cell signal transduction and / or activity.
[0109] Therefore, in some embodiments, adjustable DD-CAR technology can be used to solve several important problems currently faced by the field of CAR T cell therapy. First, the rapid on / off of DD-CAR surface expression in response to the drug allows precise regulation of CAR activity, and thus provides an opportunity to reduce CAR T cell toxicity (e.g., cytokine release syndrome (CRS) or on-target off-tumor toxicity) while maintaining the option of continuing treatment after the toxicity subsides (see Example 2). Secondly, the expansion of CAR T cells in the absence of stable drugs prevents CAR nourishing signal transduction and improves the functional capacity of these cells (see Example 2). Finally, switching DD-CAR expression in vivo via repeated administration can be a method of preventing or reversing CAR T cell exhaustion and / or inducing memory (see Example 2).
[0110] Therefore, the present invention provides CAR T cells modified to express CAR fused to RDD (e.g., FKBP RDD or DHFR RDD), the RDD providing control of CAR expression on the surface of CAR T cells in a dose- and time-dependent manner. The ability to control CAR expression on the surface of CAR T cells allows unmodified CAR T cells (i.e., CAR T cells lacking CAR fused to RDD domains) to exhibit T cell exhaustion or lack of function under conditions of maintaining CAR T cell function. In this way, the compositions and methods of the present invention can be used to prevent the exhaustion of CAR T cells and the improvement of CAR T cell function (e.g., activity against cancer or infectious diseases).
[0111] The present invention is not limited by the type of CAR T cell function that is maintained, restored or improved (e.g., prolonged). In fact, compositions comprising CAR T cells modified to express CAR fused to the RDD domain and methods of use thereof can be used to maintain, restore or improve CAR T cell function, including but not limited to: cytotoxic activity against tumor cells; promoting CAR T cell survival and function; inducing cytokine expression such as interleukin-2 (IL-2) expression to promote T cell survival, Fas ligand (FasL) and / or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression to induce tumor cell apoptosis, and / or inducing interferon (IFN)-γ to activate innate immune response (e.g., anti-cancer); and / or strengthening cell cycle inhibition and / or apoptosis induction. In some embodiments, the CAR T cells of the present invention sensitize cancer cells to induce cell cycle inhibition and / or apoptosis, including cells that are generally resistant to such induced stimulation.
[0112] CAR T cells are modified to express CAR fused to an RDD domain (e.g., mutant FKBP or DHFR), thereby significantly improving the function of CAR T cells exposed to conditions that induce CAR T cell exhaustion (see, e.g., Examples 1 and 2). Although the practice of the present invention does not require an understanding of the mechanism, and although the present invention is not limited to any particular mechanism of action, the reduction in CAR expression on the surface of CAR T cells prevents dysfunction of CAR T cells associated with CAR T cell exhaustion. In some embodiments, T cells modified to express a CAR comprising the RDD of the present invention are used to extend the anti-tumor response of CAR T cells compared to CART cells expressing the same CAR but without RDD.
[0113] Therefore, the present invention provides compositions and methods for reducing CAR T cell exhaustion, which include CAR T cells modified to express CAR fused to RDD domains (e.g., FKBP12 or mutant DHFR), thereby providing the ability to strictly regulate the CAR expression level on the surface of CAR T cells. The present invention is not limited to the disease or condition for which the modified CAR T cells of the present invention can be used. In fact, the compositions and methods provided herein may be applicable to any disease for which the increase in the activity of CAR T cells can provide a therapeutic benefit.
[0114] Therefore, the present invention provides a composition comprising CAR T cells, which are modified to express CAR fused to the RDD domain. The present invention is not limited by the modified CAR T cell type. In some embodiments, CAR T cells are CD3+ T cells (e.g., CD4+ and / or CD8+ T cells). In certain embodiments, CAR T cells are CD8+ T cells. In other embodiments, CAR T cells are CD4+ T cells. In some embodiments, CAR T cells are natural killer (NK) T cells. In some embodiments, CAR T cells are γδT cells. In some embodiments, CAR T cells are αβT cells. In some embodiments, CAR T cells are a combination of CD4+ and CD8 T+ cells (e.g., CD3+). In certain embodiments, CAR T cells are memory T cells. In certain embodiments, CAR T cells are a combination of CD8+ T cells, CD4+ T cells, NK T cells, memory T cells, αβT cells and / or γδT cells. In some embodiments, CART cells are cytokine-induced killer T cells. In some embodiments, CAR T cells are tumor infiltrating lymphocytes. In some embodiments, CAR T cells are engineered to express tumor antigen-specific CAR. In another embodiment, CAR T cells are engineered to express CAR specific for infectious disease antigens. In some embodiments, CAR T cells are anti-tumor T cells. In some embodiments, the composition further comprises a pharmaceutically acceptable carrier (e.g., a buffer).
[0115] Therefore, in one aspect, the present invention provides compositions and methods for treating cancer and other diseases. The cancer can be a hematological malignancy, a solid tumor, a primary or metastatic tumor. Other diseases that can be treated with the compositions and methods of the present invention include viral, bacterial and parasitic infections and autoimmune diseases.
[0116] In some embodiments, the present invention provides a T cell engineered to express CAR, wherein the CART cells exhibit anti-tumor properties. The CAR of the present invention can be engineered to include an extracellular domain with an antigen binding domain, which is fused to the intracellular signal transduction domain of the CD3 ζ chain. The CAR of the present invention can redirect antigen recognition based on antigen binding specificity when expressed in T cells. An exemplary antigen is GD2, as this antigen is expressed on a variety of cancers including neuroblastoma, osteosarcoma, and some sarcomas (see, e.g., Thomas et al., PLoS One, 2016. 11(3): p.e0152196; Long et al., Nature Medicine, 2015. 21(6): p.581-590; Long et al., Cancer Immunology Research, 2016. 4(10): p.869-880; Yu et al., N Engl J Med, 2010. 363(14): p.1324-34; Perez Horta et al., Immunotherapy, 2016. 8(9): p.1097-117; Heczey et al., Molecular Therapy). However, the present invention is not limited to targeting GD2. More specifically, the present invention includes any antigen binding portion that, when bound to its cognate antigen, affects tumor cells such that they cannot grow, tend to die, or are otherwise affected, thereby reducing or eliminating the tumor burden in the patient. The antigen binding portion is preferably fused to an intracellular domain selected from one or more of a costimulatory molecule, a CD3 zeta chain, and an RDD.
[0117] The present invention provides a chimeric antigen receptor (CAR) comprising an extracellular and intracellular domain. In some embodiments, the CAR of the present invention is fully human. The extracellular domain comprises a target-specific binding element, otherwise referred to as an antigen binding portion. The intracellular domain or the cytoplasmic domain further comprises a costimulatory signal transduction region and a ζ chain portion. The costimulatory signal transduction region refers to a portion of the CAR comprising the intracellular domain of a costimulatory molecule. Costimulatory molecules are cell surface molecules required for the effective response of lymphocytes to antigens, rather than antigen receptors or their ligands.
[0118] Between the extracellular domain and the transmembrane domain of CAR, or between the cytoplasmic domain and the transmembrane domain of CAR, a spacer domain may be incorporated. As used herein, the term "spacer domain" generally means any oligopeptide or polypeptide for connecting a domain (e.g., connecting a transmembrane domain to an extracellular domain or a cytoplasmic domain in a polypeptide chain). The spacer domain may include up to 300 amino acids, preferably 10 to 100 amino acids and most preferably 25 to 50 amino acids.
[0119] Chimeric antigen receptor constructs
[0120] As described herein, the CAR T cells of the present invention are genetically modified to express CAR fused to RDD, and the CAR T cells may contain a CAR comprising a target-specific binding element, which is otherwise referred to as an antigen binding portion. The selection of part depends on the type and quantity of the ligands defining the surface of the target cell. For example, the antigen binding domain can be selected to recognize a ligand that is used as a cell surface marker on a target cell associated with a specific disease state. Examples of cell surface markers that can serve as ligands for the antigen portion domain of the CAR include those associated with viral, bacterial and parasitic infections, autoimmune diseases and cancer cells.
[0121] As used herein, the term "antigen" refers to a molecule that can be bound by an antibody or a T cell receptor. In addition, antigens can induce humoral immune responses and / or cellular immune responses, resulting in the production of B and / or T lymphocytes. Embodiments of the present invention relate to nucleic acids, including nucleic acids encoding the following substances: antigen-specific chimeric antigen receptor (CAR) polypeptides, including CAR (hCAR) that has been humanized to reduce immunogenicity; transmembrane domain; one or more intracellular signal transduction domains (e.g., co-stimulatory domains and / or CD3ζ); and RDD domains. It is expected that human CAR nucleic acids are human genes that enhance cellular immunotherapy for human patients. In certain embodiments, CAR recognizes an epitope consisting of a shared space between one or more antigens. In some embodiments, CAR is specific for carbohydrate antigens.
[0122] In some embodiments, the antigen binding domain of human antibodies is used to construct chimeric antigen receptors. However, a potential problem of using non-human antigen binding domains such as mouse monoclonal antibodies is the lack of human effector functions. In addition, non-human monoclonal antibodies can be identified as foreign proteins by the human host, and therefore, repeated injections of such foreign antibodies can induce immune responses, resulting in the production of harmful hypersensitivity reactions. For mouse-based monoclonal antibodies, this is generally referred to as human anti-mouse antibodies (HAMA) responses. Therefore, in some embodiments, the antigen binding domain of human antibodies is used (for example, because they do not induce strong HAMA responses). In some embodiments, the antigen binding domains can be chimeric (that is, human / mouse chimeras) or humanized so that this immunogenicity is minimized. However, in other embodiments, the antigen binding domain of mouse antibodies is used.
[0123] In some embodiments, the CAR comprises: a) an extracellular domain comprising an antigen binding region, b) a transmembrane domain, c) an intracellular signal transduction domain, and d) an RDD. For example, in some embodiments, the CAR comprises an anti-GD2 antigen binding domain; a CD28 transmembrane domain; a CD3-ζ, CD28 and / or 4-1BB stimulatory domain; and an RDD (e.g., DHFR or FKBPDD). As described in detail herein, many different CARs containing RDDs and methods of using the same are possible. In one embodiment, the CAR comprises: a) an extracellular domain comprising an antigen binding region comprising SEQ ID NO: 44, b) a transmembrane domain comprising SEQ ID NO: 48, c) an intracellular signal transduction domain comprising SEQ ID NO: 50 and / or SEQ ID NO: 52, and d) an RDD comprising SEQ ID NO: 54. In another embodiment, the CAR comprises: a) an extracellular domain comprising an antigen binding region comprising SEQ ID NO: 60, b) a transmembrane domain comprising SEQ ID NO: 64, c) an intracellular signaling domain comprising SEQ ID NO: 66 and / or SEQ ID NO: 68, and d) an RDD comprising SEQ ID NO: 70. In another embodiment, the CAR comprises: a) an extracellular domain comprising an antigen binding region comprising SEQ ID NO: 76, b) a transmembrane domain comprising SEQ ID NO: 80, c) an intracellular signaling domain comprising SEQ ID NO: 82 and / or SEQ ID NO: 84, and d) an RDD comprising SEQ ID NO: 86. In yet another embodiment, the CAR comprises: a) an extracellular domain comprising an antigen binding region comprising SEQ ID NO: 92, b) a transmembrane domain comprising SEQ ID NO: 96, c) an intracellular signaling domain comprising SEQ ID NO: 98 and / or SEQ ID NO: 100, and d) an RDD comprising SEQ ID NO: 102. In another embodiment, the CAR comprises: a) an extracellular domain comprising an antigen binding region comprising SEQ ID NO: 108, b) a transmembrane domain comprising SEQ ID NO: 112, c) an intracellular signaling domain comprising SEQ ID NO: 114 and / or SEQ ID NO: 116, and d) an RDD comprising SEQ ID NO: 118. In another embodiment, the CAR comprises: a) an extracellular domain comprising an antigen binding region comprising SEQ ID NO: 124, b) a transmembrane domain comprising SEQ ID NO: 130, c) an intracellular signaling domain comprising SEQ ID NO: 132 and / or SEQ ID NO: 134, and d) an RDD comprising SEQ ID NO: 136.
[0124] Antigen binding region
[0125] In certain embodiments, the binding region comprises a complementarity determining region (CDR) of a monoclonal antibody, a variable region of a monoclonal antibody, and / or an antigen binding fragment thereof. CDRs are short amino acid sequences found in the variable domains of antigen receptor (e.g., immunoglobulins and T-cell receptor) proteins that are complementary to the antigen and thereby provide a receptor specific for that particular antigen. Each polypeptide chain of an antigen receptor contains three CDRs (CDR1, CDR2, and CDR3). Since antigen receptors are typically composed of two polypeptide chains, each antigen receptor (e.g., an antibody or TCR) that can contact an antigen has six CDRs—three CDRs for each heavy and light chain. Because most of the sequence variations associated with immunoglobulins and T-cell receptors are found in the CDRs, these regions are sometimes referred to as hypervariable domains.
[0126] CAR can be engineered so that it targets the target tumor antigen by engineering a desired antigen-binding portion that specifically binds to an antigen on a tumor cell. As used herein, "tumor antigen" or "hyperproliferative disorder antigen" or "antigen associated with a hyperproliferative disorder" or "cancer antigen" refers to an antigen common to a specific hyperproliferative disorder such as cancer. The exemplary antigens mentioned herein are included as examples. These examples are not exclusive and further examples will be readily apparent to those skilled in the art.
[0127] Tumor antigens are moieties (e.g., proteins, carbohydrates, etc.) produced by tumor cells that elicit an immune response, particularly a T cell-mediated immune response. Thus, the antigen binding moiety can be selected based on the type of specific cancer to be treated. Tumor antigens are well known in the art and include, for example, glioma-associated antigen, carcinoembryonic antigen (CEA), β-human chorionic gonadotropin, alpha-fetoprotein (AFP), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, RU1, RU2 (AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostate-specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostein, PSMA, Her2 / neu, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), MAGE, ELF2M, neutrophil elastase, ephrinB2, CD22, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor, mesothelin, and other tumor antigens described herein or known in the art.
[0128] Tumor antigens can comprise one or more antigenic cancer antigens / epitopes relevant to malignant tumors. Malignant tumors express many proteins that can serve as target antigens for immune attack. These molecules include but are not limited to tissue-specific antigens, such as melanoma antigen 1 (MART-1), tyrosinase and GP100 identified by T cells in melanoma, and prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA) in prostate cancer. Other target molecules belong to the group of transformation-related molecules, such as oncogenes HER-2 / Neu / ErbB-2. Another group of target antigens is carcinoembryonic antigens, such as carcinoembryonic antigen (CEA). In B-cell lymphomas, tumor-specific idiotypic immunoglobulins constitute real tumor-specific immunoglobulin antigens, which are unique to individual tumors. B-cell differentiation antigens such as CD19, CD20 and CD37 are other candidates for target antigens in B-cell lymphomas.
[0129] Tumor antigens may also be tumor-specific antigens (TSAs) or tumor-associated antigens (TAAs). TSAs are specific to tumor cells and do not appear on other cells in the body. TAAs are not specific to tumor cells, and on the contrary, are expressed on some normal cells under conditions that fail to induce a state of immune tolerance to the antigen. The expression of antigens on tumors can occur under conditions where the immune system is able to respond to the antigen. TAAs may be antigens that are expressed on normal cells during fetal development when the immune system is immature and unable to respond, or they may be antigens that are normally present at very low levels on normal cells but expressed at much higher levels on tumor cells.
[0130] Examples of TSAs or TAAs include, but are not limited to, differentiation antigens such as MART-1 / MelanA (MART-1), gp100 (Pmel17), tyrosinase, TRP-1, TRP-2, and tumor-specific multi-lineage antigens such as MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, p15; overexpressed embryonic antigens such as CEA; overexpressed oncogenes and mutated tumor suppressor genes such as p53, Ras, HER-2 / neu; idiotypic tumor antigens generated by chromosomal translocations; such as BCR-ABL, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR; and viral antigens such as Epstein-Barr virus antigen EBVA and human papillomavirus (HPV) antigens E6 and E7. Other large protein-based antigens include TSP-180, MAGE-4, MAGE-5, MAGE-6, RAGE, NY-ESO-1, p185erbB2, p180erbB-3, c-met, nm-23H1, PSA, TAG-72, CA 19-9, CA 72-4, CAM 17.1, NuMa, K-ras, β-catenin, CDK4, Mum-1, p15, p16, 43-9F, 5T4, 791Tgp72, alpha-fetoprotein, β-HCG, BCA225, BTAA, CA 125, CA 15-3\CA 27.291\BCAA, CA 195, CA 242, CA-50, CAM43, CD68\P1, CO-029, FGF-5, G250, Ga733\EpCAM, HTgp-175, M344, MA-50, MG7-Ag, MOV18, NB / 70K, NY-CO-1, RCAS1, SDCCAG16, TA-90\Mac-2 binding protein\cyclophilin C-related protein, TAAL6, TAG72, TLP and TPS.
[0131] In some embodiments, intracellular tumor-associated antigens such as HA-1, survivin, WT1, and p53 are targeted. This can be accomplished by expressing a CAR on a T cell that recognizes a processed peptide derived from an intracellular tumor-associated antigen in the context of HLA.
[0132] Depending on the desired antigen to be targeted, CAR can be engineered to include an appropriate antigen binding portion specific for the desired antigen target. For example, if GD2 is the desired antigen to be targeted, then an antibody to GD2 (e.g., 14G2a, ch14.18, hu14.18K322A, m3F8, hu3F8-IgG1, hu3F8-IgG4, HM3F8, UNITUXIN, DMAb-20, or any other antibody that specifically binds to GD2) can be used as an antigen binding portion to be incorporated into the CAR of the present invention.
[0133] In some embodiments, the antigen is a pathogen-specific antigen. The present invention is not limited by pathogen-specific antigen types. Pathogen-specific antigens can be from any pathogen including but not limited to fungi, bacteria or viruses. Exemplary viral pathogens include those of the following virus families: Adenoviridae, Epstein-Barr Virus (EBV), Cytomegaloviridae (CMV), Respiratory Syncytial Virus (RSV), JC Virus, BK Virus, HSV, HHV Virus, Picornaviridae, Herpesviridae, Hepadnaviridae, Flaviviridae, Retroviridae, Orthomyxoviridae, Paramyxoviridae, Papoviridae, Polyomaviridae, Rhabdoviridae and Togaviridae. Exemplary pathogenic viruses cause smallpox, influenza, mumps, measles, varicella, Ebola and rubella. Exemplary pathogenic fungi include Candida, Aspergillus, Cryptococcus, Histoplasma, Pneumocystis and Stachybotrys. Exemplary pathogenic bacteria include Streptococcus, Pseudomonas, Shigella, Campylobacter, Staphylococcus, Helicobacter, Escherichia coli, Rickettsia, Bacillus, Bordetella, Chlamydia, Spirochete and Salmonella. In one embodiment, pathogen receptor Dectin-1 is used to produce CAR, and CAR recognizes the sugar structure on the fungal cell wall. T cells modified by gene recognition based on the specific expression CAR of Dectin-1 recognize Aspergillus and target (e.g., inhibit) hyphae growth. In another embodiment, CAR is based on antibodies that recognize viral determinants (e.g., glycoproteins from CMV or Ebola), which block viral infection and pathological conditions.
[0134] In some embodiments, the present invention includes full-length CAR cDNA or coding region.Antigen binding region or domain may include a fragment of the VH and VL chains of a single-chain variable fragment (scFv) derived from a specific human monoclonal antibody, such as those described in the following documents: U.S. Patent No. 7,109,304; 8,822,196; 9,868,774; 9,790,282; 9,765,342; 9,624,306; 9,522,915; 9,359,447; 9,845,362; 9,815,901; 9,777,061; 9,598,489; 9,394,368; 9,446,105; and 9,334,330, each of which is incorporated herein by reference. The fragment may also be many different antigen-binding domains of human antigen-specific antibodies. In a more specific embodiment, the fragment is an antigen-specific scFv encoded by a sequence optimized for human codons for expression in human cells.
[0135] Antibodies can be multimeric, such as diabodies or multimers. Multimers can be formed by cross-pairing the variable portions of the light and heavy chains into the mentioned diabodies (see Winter et al., Protein Eng. 1996 Mar; 9 (3): 299-305). The hinge portion of the construct can have a variety of replacements: complete deletion, retention of the first cysteine, proline instead of serine substitution, truncation to the first cysteine. The Fc portion can be deleted. Any protein that is stable and / or dimerized can be used for this purpose (for example, a single Fc domain can be used, such as CH2 or CH3 from a human immunoglobulin). Hinge, CH2, and CH3 regions of human immunoglobulins modified to improve dimerization can also be used.
[0136] The antigen binding domain of CAR can be any domain that binds to an antigen, including but not limited to monoclonal antibodies, polyclonal antibodies, synthetic antibodies, human antibodies, humanized antibodies and fragments thereof. In some cases, it is advantageous for the antigen binding domain to be derived from the same species in which the CAR will ultimately be used. For example, for humans, it may be advantageous for the antigen binding domain of CAR to comprise a human antibody or a fragment thereof. Therefore, in one embodiment, the antigen binding domain portion comprises a human antibody or a fragment thereof.
[0137] For in vivo use of antibodies in humans, human antibodies are preferably used. Fully human antibodies are particularly suitable for therapeutic treatment of human subjects. Human antibodies can be made by a variety of methods known in the art, including phage display methods using antibody libraries derived from human immunoglobulin sequences, including improvements on these techniques. See also U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT Publications WO 98 / 46645, WO 98 / 50433, WO 98 / 24893, WO 98 / 16654, WO 96 / 34096, WO 96 / 33735, and WO 91 / 10741; each of which is incorporated herein by reference in its entirety. A human antibody can also be one in which the heavy and light chains are encoded by nucleotide sequences derived from one or more sources of human DNA.
[0138] Human antibodies can also be produced using transgenic mice that are unable to express functional endogenous immunoglobulins but can express human immunoglobulin genes. For example, human heavy and light chain immunoglobulin gene complexes can be introduced into mouse embryonic stem cells randomly or by homologous recombination. Alternatively, in addition to human heavy and light chain genes, human variable regions, constant regions, and diversity regions can also be introduced into mouse embryonic stem cells. Mouse heavy and light chain immunoglobulin genes can be rendered non-functional, either alone or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. For example, homozygous deletion of the antibody heavy chain joining region (JH) gene in chimeric and germline mutant mice has been described to completely suppress endogenous antibody production. Modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then raised to produce homozygous offspring that can express human antibodies. Transgenic mice are immunized in the normal manner with the selected antigen. Anti-tumor antigen antibodies against tumor antigens can be obtained from immunized transgenic mice using conventional hybridoma technology. The human immunoglobulin transgene carried by the transgenic mouse rearranges during B cell differentiation and subsequently undergoes class switching and somatic mutation. For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, for example, PCT Publication Nos. WO 98 / 24893, WO 96 / 34096, and WO 96 / 33735; and U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; and 5,939,598, each of which is incorporated herein by reference in its entirety. In addition, companies such as Abgenix, Inc. (Freemont, Calif.) and Genpharm (San Jose, Calif.) can provide human antibodies to selected antigens using techniques similar to those described above. For a detailed discussion of transferring the human germline immunoglobulin gene array in germline mutant mice, thereby generating human antibodies upon antigen challenge, see, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551 (1993); Jakobovits et al., Nature, 362:255-258 (1993); Bruggermann et al., Year in Immunol., 7:33 (1993); and Duchosal et al., Nature, 355:258 (1992).
[0139] Human antibodies can also be derived from phage display libraries (Hoogenboom et al., J. Mol. Biol., 227: 381 (1991); Marks et al., J. Mol. Biol., 222: 581-597 (1991); Vaughan et al., Nature Biotech., 14: 309 (1996)). Phage display technology (McCafferty et al., Nature, 348: 552-553 (1990)) can be used to produce human antibodies and antibody fragments in vitro from immunoglobulin variable (V) domain gene repertoires from unimmunized donors. According to this technology, the antibody V domain gene is cloned in frame into the major or minor coat protein gene of a filamentous phage, such as M13 or fd, and displayed as functional antibody fragments on the surface of the phage particle. Because the filamentous particle contains a single-stranded DNA copy of the phage genome, selection based on the functional properties of the antibody also achieves selection of genes encoding antibodies that exhibit those properties. Thus, phages mimic some of the properties of B cells. Phage display can be performed in a variety of formats; for a review, see, for example, Johnson, Kevin S, and Chiswell, David J., Current Opinion in Structural Biology 3:564-571 (1993). Several sources of V-gene segments can be used for phage display. Clackson et al., Nature, 352:624-628 (1991) isolated a range of different anti-oxazolone antibodies from a small random combinatorial library of V genes from the spleens of unimmunized mice. V gene repertoires from unimmunized human donors can be constructed and antibodies against a range of different antigens (including self-antigens) can be essentially isolated according to the techniques described by Marks et al., J. Mol. Biol., 222:581-597 (1991) or Griffith et al., EMBO J., 12:725-734 (1993). See also US Patent Nos. 5,565,332 and 5,573,905, each of which is incorporated herein by reference in its entirety.
[0140] Human antibodies can also be generated by in vitro activated B cells (see U.S. Patent Nos. 5,567,610 and 5,229,275, each of which is incorporated herein by reference in its entirety). Human antibodies can also be generated in vitro using hybridoma technology as described, but not limited to, by Roder et al. (Methods Enzymol., 121: 140-167 (1986)).
[0141] Alternatively, in some embodiments, non-human antibodies are humanized, wherein specific sequences or regions of the antibody are modified to increase similarity to antibodies naturally produced in humans. In one embodiment, the antigen binding domain portion is humanized.
[0142] Humanized antibodies can be produced using a variety of techniques known in the art, including, but not limited to, CDR grafting (see, e.g., European Patent No. EP 239,400; International Publication No. WO 91 / 09967; and U.S. Patent Nos. 5,225,539, 5,530,101, and 5,585,089, each of which is incorporated herein by reference in its entirety); veneering or reshaping (see, e.g., European Patent Nos. EP 592,106 and EP 519,596; Padlan, 1991, Molecular Immunology, 28(4 / 5):489-498; Studnicka et al., 1994, Protein Engineering, 7(6):805-814; and Roguska et al., 1994, PNAS, 91:969-973, each of which is incorporated herein by reference in its entirety); chain shuffling (see, e.g., U.S. Patent No. 5,565,332, which is incorporated herein by reference in its entirety); and techniques disclosed in, e.g., U.S. Patent Application Publication No. US2005 / 0042664, U.S. Patent Application Publication No. US2005 / 0048617, U.S. Patent No. 6,407,213, U.S. Patent No. 5,766,886, International Publication No. WO 9317105; Tan et al., J. Immunol., 169:1119-25 (2002); Caldas et al., Protein Eng., 13(5): 353-60 (2000); Morea et al., Methods, 20(3): 267-79 (2000); Baca et al., J. Biol. Chem., 272(16): 10678-84 (1997); Roguska et al., Protein Eng., 9(10): 895-904 (1996); Couto et al., Cancer Res., 55(23 Suppl): 5973s-5977s (1995); Couto et al., Cancer Res., 55(8): 1717-22 (1995); Sandhu JS, Gene, 150(2):409-10 (1994); and Pedersen et al., J. Mol. Biol., 235(3):959-73 (1994), each of which is incorporated herein by reference in its entirety. Typically, framework residues within the framework region will be substituted with corresponding residues from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, for example, by modeling the interactions between the CDRs and framework residues to identify framework residues that are important for antigen binding, and by sequence comparison to identify unusual framework residues at specific positions.(See, eg, Queen et al., US Pat. No. 5,585,089; and Riechmann et al., 1988, Nature, 332:323, which are herein incorporated by reference in their entireties).
[0143] Humanized antibodies have one or more amino acid residues introduced from non-human sources. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from the "import" variable domains. Therefore, humanized antibodies comprise one or more CDRs from non-human immunoglobulin molecules and framework regions from humans. Humanization of antibodies is well known in the art and can essentially be performed by following the method of Winter and colleagues (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)) by replacing rodent CDRs or CDR sequences with the corresponding sequences of a human antibody, i.e., CDR grafting (EP 239,400; PCT Publication No. WO 91 / 09967; and U.S. Pat. Nos. 4,816,567; 6,331,415; 5,225,539; 5,530,101; 5,585,089; 6,548,640, the contents of which are incorporated herein by reference in their entireties). In such humanized chimeric antibodies, substantially less than an intact human variable domain has been replaced by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some framework (FR) residues are replaced by residues from analogous sites in rodent antibodies. Humanization of antibodies can also be accomplished by veneering or remodeling (EP 592,106; EP 519,596; Padlan, 1991, Molecular Immunology, 28(4 / 5):489-498; Studnicka et al., Protein Engineering, 7(6):805-814 (1994); and Roguska et al., PNAS, 91:969-973 (1994)) or chain recombination (U.S. Pat. No. 5,565,332), the contents of which are incorporated herein by reference in their entirety.
[0144] In some cases, human scFvs can also be derived from yeast display libraries.
[0145] The selection of human variable domains (light and heavy chains) when preparing humanized antibodies is to reduce antigenicity. According to the so-called "best fit" method, the variable domain sequences of rodent antibodies are screened for the entire library of known human variable domain sequences. The human sequence closest to the rodent sequence is regarded as the human framework (FR) of the humanized antibody (Sims et al., J. Immunol., 151: 2296 (1993); Chothia et al., J. Mol. Biol., 196: 901 (1987), the contents of which are incorporated herein by reference in their entirety). Another method uses a specific framework derived from the consensus sequence of all human antibodies of a specific light or heavy chain subgroup. The same framework can be used for several different humanized antibodies (Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285 (1992); Presta et al., J. Immunol., 151:2623 (1993), the contents of which are herein incorporated by reference in their entireties).
[0146] Antibodies can be humanized while maintaining high affinity to the target antigen and having other favorable biological properties. According to one aspect of the invention, humanized antibodies are prepared by analyzing parental sequences and various conceptually humanized products using a three-dimensional model of the parental and humanized sequences. Three-dimensional immunoglobulin models are common and well known to those skilled in the art. Available computer programs have illustrated and demonstrated the possible three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays allows analysis of the possible effects of residues in the candidate immunoglobulin sequence function, i.e., analysis of the residues that influence the ability of the candidate immunoglobulin to bind the target antigen. In this way, FR residues can be selected from the recipient and the input sequence and combined to obtain desired antibody characteristics, such as the affinity for the increase in the target antigen. Generally speaking, CDR residues directly and in vivo participate in the process that affects antigen binding.
[0147] "Humanized" antibodies retain antigenic specificity similar to the original antibody, i.e., the ability to bind to human GD2 in the present invention. However, using certain humanization methods, the binding affinity and / or specificity of the antibody for human GD2 can be improved using "directed evolution" methods such as those described by Wu et al., J. Mol. Biol., 294:151 (1999), the contents of which are incorporated herein by reference in their entirety.
[0148] In one embodiment, the antigen binding portion of the CAR of the present invention targets GD2. In some embodiments, the antigen binding portion in the CAR of the present invention is a fully human anti-GD2 scFV. In some embodiments, the nucleic acid sequence of the anti-GD2 scFV comprises the sequence listed in SEQ ID NO: 43. In one embodiment, the anti-GD2 scFV comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 44. In another embodiment, the anti-GD2 scFV portion of the CAR of the present invention comprises the amino acid sequence listed in SEQ ID NO: 44. In other embodiments, the nucleic acid sequence of the anti-GD2 scFV comprises the sequence listed in SEQ ID NO: 87. In one embodiment, the anti-GD2 scFV comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 88. In another embodiment, the anti-GD2 scFV portion of the CAR of the present invention comprises the amino acid sequence listed in SEQ ID NO: 88.
[0149] In other embodiments, the antigen binding portion of the CAR of the present invention targets Her2. In some embodiments, the nucleic acid sequence of the anti-Her2 scFV comprises the sequence listed in SEQ ID NO: 123. In one embodiment, the anti-Her2 scFV comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 124. In another embodiment, the anti-Her2 scFV portion of the CAR of the present invention comprises the amino acid sequence listed in SEQ ID NO: 124.
[0150] In other embodiments, the antigen binding portion of the CAR of the present invention targets CD19. In some embodiments, the nucleic acid sequence of the anti-CD19 scFV comprises the sequence listed in SEQ ID NO: 11. In one embodiment, the anti-CD19 scFV comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 12. In another embodiment, the anti-CD19 scFV portion of the CAR of the present invention comprises the amino acid sequence listed in SEQ ID NO: 12.
[0151] transmembrane domain
[0152] About transmembrane domain, CAR can be designed to include the transmembrane domain fused to the extracellular domain of CAR.In one embodiment, a transmembrane domain naturally combined with a domain in CAR is used.In some embodiments, transmembrane domain is selected or modified by amino acid substitution to avoid such domains from being bound to the transmembrane domain of the same or different surface membrane proteins, so as to minimize the interaction with other members of the receptor complex.
[0153] The transmembrane domain can be derived from a natural or synthetic source. When the source is natural, the domain can be derived from any membrane-bound or transmembrane protein. Transmembrane regions with specific uses in the present invention include, but are not limited to, transmembrane regions derived from the following substances (i.e., transmembrane regions comprising at least the following substances): α or β chain of the T cell receptor, CD28, CD3ζ, CD3ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, or CD154. In some embodiments, a variety of human hinges can be used, including human Ig (immunoglobulin) hinges.
[0154] In some embodiments, the membrane-spanning domain is synthetic, in which case it mainly comprises hydrophobic residues, such as leucine and valine. In some embodiments, a triplet of phenylalanine, tryptophan and valine will be found at each end of the synthetic membrane-spanning domain. Optionally, a short oligopeptide or polypeptide linker (preferably, a length between 2 and 10 amino acids) forms a key between the membrane-spanning domain and the cytoplasmic signal transduction domain of CAR.
[0155] In one embodiment, the transmembrane domain in the CAR of the present invention is a CD28 transmembrane domain. In one embodiment, the CD28 transmembrane domain comprises a nucleic acid sequence of SEQ ID NO: 15. In one embodiment, the CD28 transmembrane domain comprises a nucleic acid sequence encoding an amino acid sequence of SEQ ID NO: 16. In another embodiment, the CD28 transmembrane domain comprises an amino acid sequence of SEQ ID NO: 16.
[0156] In some embodiments, the CD28 hinge region is connected to the CD28 transmembrane domain of the CAR. In one embodiment, the CD28 hinge domain comprises the nucleic acid sequence of SEQ ID NO: 13. In one embodiment, the CD28 hinge domain comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 14. In another embodiment, the CD28 hinge domain comprises the amino acid sequence of SEQ ID NO: 14.
[0157] Intracellular or cytoplasmic domain
[0158] The intracellular signal transduction domain of the CAR of the present invention is responsible for activating at least one normal effector function of the T cell in which the chimeric receptor has been placed. The term "effector function" refers to a special function of a differentiated cell. For example, the effector function of a T cell may be cytolytic activity or auxiliary activity, including the secretion of cytokines. The effector function in naive, memory or memory T cells includes antigen-dependent proliferation. Therefore, the term "intracellular signal transduction domain" refers to a portion of a protein that transduces effector function signals and instructs cells to perform special functions. Although the entire intracellular signal transduction domain is generally used, in many cases it is not necessary to use the entire intracellular polypeptide. If a truncated portion of the intracellular signal transduction domain can be utilized, then such a truncated portion can be used to replace the complete chain, as long as it still transduces the effector function signal. The term intracellular signal transduction domain is therefore intended to include any truncated portion of the intracellular signal transduction domain that is sufficient to transduce the effector function signal.
[0159] Examples of intracellular signal transduction domains include, but are not limited to, cytoplasmic sequences of T cell receptors (TCRs) and co-receptors (which coordinate for initiating signal transduction after antigen receptor binding) and any derivatives or variants of these sequences and any synthetic sequences with the same functional capabilities. It is known that the signal generated by TCR alone is insufficient to fully activate T cells and also requires a second or costimulatory signal. Therefore, T cell activation can be mediated by two different categories of cytoplasmic signal transduction sequences: those that induce antigen-dependent first activation through TCR (first cytoplasmic signal transduction sequences) and those that act in an antigen-independent manner to provide a second or costimulatory signal (second cytoplasmic signal transduction sequences).
[0160] The first cytoplasmic signaling sequence regulates the first activation of the TCR complex in a stimulatory or inhibitory manner. The first cytoplasmic signaling sequence that acts in a stimulatory manner may contain a signaling motif known as an immunoreceptor tyrosine-based activation motif or ITAM.
[0161] Examples of the first cytoplasmic signal transduction sequence containing ITAM particularly used in the present invention include those derived from the following substances: CD3 ζ, FcR γ, FcR β, CD3 γ, CD3 δ, CD3 ε, CD5, CD22, CD79a, CD79b and CD66d. In some embodiments, the cytoplasmic signal transduction molecule in the CAR of the present invention comprises a cytoplasmic signal transduction sequence derived from CD3 ζ.
[0162] The cytoplasmic domain of CAR can be designed to include CD3-ζ signal transduction domain alone or in combination with any other desired cytoplasmic domains applicable to the present invention CAR. For example, the cytoplasmic domain of CAR may include CD3-ζ chain portion and costimulatory signal transduction region or domain. Costimulatory signal transduction region refers to a part of the CAR comprising the intracellular domain of costimulatory molecules. Costimulatory molecules are cell surface molecules required for the effective response of lymphocytes to antigens, rather than antigen receptors or their ligands. Examples of such molecules include CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, ligands specifically bound to CD83, etc. In some embodiments, CAR as described herein includes CD3-ζ domains containing ITAM and CD28 or 4-1BB in combination as costimulatory signal transduction elements. In some embodiments, the CARs described herein comprise an ITAM-containing CD3-zeta domain in combination with at least one other costimulatory domain within the scope of the invention.
[0163] Intracellular signal transduction domain can comprise any one of CD3-ζ or its homologue (for example, η, δ, γ or ε), MB1 chain, B29, Fc RIII, Fc RI and the combination of signal transduction molecules, such as, CD3-ζ and CD28, CD27, 4-1BB, DAP-10, OX40 and combination thereof. Intracellular signal transduction portion of other members of the activating protein family can be used, such as FcγRIII and FcγRI (about the disclosure of cTCR using these alternative transmembrane and intracellular domains, see Gross et al. (1992), Stancovski et al. (1993), Moritz et al. (1994), Hwu et al. (1995), Weijtens et al. (1996) and Hekele et al. (1996).
[0164] The cytoplasmic signal transduction sequences in the cytoplasmic signal transduction portion of the CAR of the present invention can be connected to each other in any order. Optionally, a short oligopeptide or polypeptide linker preferably between 2 and 10 amino acid lengths can form a key. Glycine-serine doublets provide particularly suitable linkers. The antigen-specific extracellular domain and the intracellular signal transduction domain can be connected by a transmembrane domain such as human IgG4Fc hinge and Fc region. Alternatives include human CD4 transmembrane domains, human CD28 transmembrane domains, human CD3-ζ transmembrane domains, or cysteine-mutated human CD3-ζ transmembrane domains, or other transmembrane domains from other human transmembrane signal transduction proteins, such as CD16 and CD8 and erythropoietin receptors.
[0165] In some embodiments, any portion of the endogenous T cell receptor complex is utilized in the intracellular domain. One or more cytoplasmic domains may be employed, such as so-called third generation CARs, which have at least two or three signal transduction domains fused together, for example, for additive or synergistic effects.
[0166] In one embodiment, the cytoplasmic domain comprises the signal transduction domain of CD3-ζ and the signal transduction domain of CD28. In another embodiment, the cytoplasmic domain comprises the signal transduction domain of CD3-ζ and the signal transduction domain of 4-1BB and / or OX-40.
[0167] In one embodiment, the cytoplasmic domain in the CAR of the present invention comprises the signal transduction domain of CD28 and the signal transduction domain of CD3-ζ, wherein the signal transduction domain of CD28 comprises the nucleic acid sequence listed in SEQ ID NO: 17 and the signal transduction domain of CD3-ζ comprises the nucleic acid sequence listed in SEQ ID NO: 19. In one embodiment, the signal transduction domain of CD28 comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 18. In another embodiment, the signal transduction domain of CD28 comprises an amino acid sequence of SEQ ID NO: 18. In one embodiment, the signal transduction domain of CD3-ζ comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 20. In another embodiment, the signal transduction domain of CD3-ζ comprises an amino acid sequence of SEQ ID NO: 20.
[0168] Regulatable destabilizing domain
[0169] The regulatable destabilizing domain (RDD) of the CAR of the present invention is utilized to regulate (e.g., reduce) the expression of CAR on the surface of T cells in a time and / or dose-dependent manner. In this way, CAR T cell exhaustion can be prevented / inhibited or reversed, so that the function of CAR T cells is maintained, restored or improved (e.g., prolonged effector function).
[0170] For example, in some embodiments, CAR T cells genetically engineered to express a CAR containing an RDD (e.g., fused to a CAR) are labeled for ubiquitin-mediated degradation of the CAR so that when a stable small molecule is present in combination with the RDD, CAR degradation is prevented, and the removal or absence of a stable small molecule in combination with the RDD allows CAR to degrade. In some embodiments, CAR protein levels and CAR surface expression are regulated via the fusion of RDD with CAR, thereby reversing the exhaustion of CAR T cells, and a marker of T cell exhaustion due to nourishing CAR signal transduction has been developed. For example, CAR T cells exposed to stable small molecules exhibit all phenotypic and functional markers of T cell exhaustion. However, when the stable small molecule is removed by protein degradation and the CAR protein level is reduced, the phenotypic and functional indicators of T cell exhaustion are reversed and T cell function is restored.
[0171] The present invention is not limited to any specific RDD. In fact, any of the following RDDs can be used in the present invention, which impart CAR instability so that when RDD is unstable (but its structure or presence in CAR does not destroy CAR function) by the presence of its homologous small molecules, rapid protein degradation occurs. A non-limiting example of RDD is derived from FK506 binding protein (FKBP), referred to herein as FKBP DD (see Banaszynski et al., Cell 2006). The surface expression of CAR containing FKBP RDD can be rapidly and dose-dependently regulated by adding or reducing stable rapalog shield-1 (S1) in CAR T cells or in organisms treated with CAR T cells comprising FKBP DD. Another non-limiting example of RDD is derived from Escherichia coli dihydrofolate reductase (DHFR), referred to herein as DHFR DD, which can be rapidly and dose-dependently regulated with stable small molecule drug trimethoprim. As used herein, in some embodiments, CAR expression is achieved in vivo using a clinically determined and best tolerated dose of trimethoprim (see Kremers et al., J Clin Pharmacol. 1974 Feb-Mar; 14 (2): 112-7). For example, the maximum expression of a CAR comprising a trimethoprim-controlled DHFR RDD occurs at about 500 nM trimethoprim, which is well within the EC50 of the compound of 50 nM. When 160 mg (1.72 μg / mL, about 6 μM) is administered twice daily, this will be well within the average steady-state plasma concentration of trimethoprim. In some embodiments, CAR expression is achieved in vivo using a dose lower than the clinically determined trimethoprim dose.
[0172] In some embodiments, the DHFR DD is derived from E. coli DHFR. In some embodiments, the DHFR DD is derived from human DHFR. Similarly, the present invention is not limited by the type of RDD used. For example, any DHFR containing a mutation can be used that achieves destabilization of the DHFR domain and any protein attached thereto. For example, any of the following RDDs (DHFR or FKBP DD) can be used that imparts instability / destabilization so that when the RDD is destabilized (but its structure or presence within the CAR does not destroy the CAR effector function) using, for example, trimethoprim or S1, rapid protein degradation occurs. In some embodiments, the E. coli DHFR DD of SEQ ID NO.6 is used, which contains mutations at amino acids 12 and 100.
[0173] The present invention is not limited by the position of RDD in CAR. For example, in some embodiments, RDD is fused (such as gene connection) on the N-terminus or C-terminus of CAR. CAR can be expressed when RDD is fused to the intracellular component of CAR, fused to the extracellular component of CAR or fused to the hinge or transmembrane region. Exemplary intracellular components of CAR include but are not limited to costimulatory domains or CD3-ζ domains. In some embodiments, the intracellular domain is a CD3-ζ domain.
[0174] The intracellular components of CAR (e.g., CD3-ζ) can be connected to RDD in a random or specified order. Optionally, a short oligopeptide or polypeptide linker can form a bond, and the linker length is preferably between 2 and 10 amino acids.
[0175] CAR expression vectors and gene-modified T cells
[0176] The present invention includes a DNA construct comprising a sequence of a CAR, wherein the sequence comprises a nucleic acid sequence (such as a tumor antigen binding domain or a pathogen antigen binding domain) of an antigen binding moiety, which is operably connected to a nucleic acid sequence of an intracellular domain, which is operably connected to a nucleic acid sequence of an RDD. Exemplary intracellular domains that can be used in the CAR of the present invention include but are not limited to the intracellular domains of CD3-ζ, CD27, CD28, etc. In some cases, CAR may include any combination of CD3-ζ, CD28, 4-1BB, etc. Exemplary DDs that can be used in the CAR of the present invention include but are not limited to DHFR DD and FKBP DD.
[0177] In one embodiment, the CAR of the present invention comprises an anti-GD2 scFv, a human CD28 hinge and transmembrane domain, and CD28 and CD3-ζ signaling domains. In one embodiment, the anti-GD2 scFv is fully human. In one embodiment, the CAR of the present invention comprises the nucleic acid sequence set forth in SEQ ID NO: 7. In another embodiment, the CAR of the present invention comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 8. In another embodiment, the CAR of the present invention comprises the amino acid sequence set forth in SEQ ID NO: 8.
[0178] In some embodiments, the CAR of the present invention comprises the nucleic acid sequence set forth in SEQ ID NO: 23. In another embodiment, the CAR of the present invention comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 24. In another embodiment, the CAR of the present invention comprises the amino acid sequence set forth in SEQ ID NO: 24.
[0179] In other embodiments, the CAR of the present invention comprises the nucleic acid sequence set forth in SEQ ID NO: 39. In another embodiment, the CAR of the present invention comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 40. In another embodiment, the CAR of the present invention comprises the amino acid sequence set forth in SEQ ID NO: 40.
[0180] In still other embodiments, the CAR of the present invention comprises the nucleic acid sequence set forth in SEQ ID NO: 55. In other embodiments, the CAR of the present invention comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 56. In other embodiments, the CAR of the present invention comprises the amino acid sequence set forth in SEQ ID NO: 56.
[0181] In still other embodiments, the CAR of the present invention comprises the nucleic acid sequence set forth in SEQ ID NO: 71. In other embodiments, the CAR of the present invention comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 72. In other embodiments, the CAR of the present invention comprises the amino acid sequence set forth in SEQ ID NO: 72.
[0182] In other embodiments, the CAR of the present invention comprises the nucleic acid sequence set forth in SEQ ID NO: 87. In other embodiments, the CAR of the present invention comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 88. In other embodiments, the CAR of the present invention comprises the amino acid sequence set forth in SEQ ID NO: 88.
[0183] In other embodiments, the CAR of the present invention comprises the nucleic acid sequence set forth in SEQ ID NO: 103. In other embodiments, the CAR of the present invention comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 104. In other embodiments, the CAR of the present invention comprises the amino acid sequence set forth in SEQ ID NO: 104.
[0184] In some embodiments, the CAR of the present invention comprises the nucleic acid sequence set forth in SEQ ID NO: 119. In other embodiments, the CAR of the present invention comprises a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 120. In other embodiments, the CAR of the present invention comprises the amino acid sequence set forth in SEQ ID NO: 120.
[0185] In some embodiments, the present invention provides an isolated nucleic acid segment and an expression cassette incorporated with a DNA sequence encoding a CAR fused to an RDD. The vector of the present invention is primarily designed to deliver the desired gene to immune cells (preferably T cells) under the control of a regulatable eukaryotic promoter (e.g., EF1α promoter, MNDU3 promoter, CMV promoter, or ubiquitin promoter). If there are no other reasons, the vector may also contain a selectable marker to facilitate its manipulation in vitro. In other embodiments, CAR can be expressed by mRNA, which is transcribed in vitro by a DNA template.
[0186] The CAR molecules fused to the RDD are recombinant and characterized by their ability to bind antigens and transduce activation signals via the immune receptor activation motifs (ITAM's) present in their cytoplasmic tails. CAR constructs utilizing antigen-binding moieties (e.g., produced by single-chain antibodies (scFv)) provide the additional advantage of HLA independence: they do not require antigen presentation by major histocompatibility complex (MHC) proteins, but instead bind to natural antigens on the surface of target cells in an HLA-independent manner.
[0187] Nucleic acid sequences encoding the desired molecules can be obtained using recombinant methods known in the art, for example, by screening libraries from cells expressing the gene, by deriving the gene from a vector known to contain the gene using standard techniques, or by direct isolation from cells and tissues containing the gene. Alternatively, the gene of interest can be produced synthetically rather than cloned.
[0188] The present invention also provides vectors into which the DNA of the present invention is inserted. Vectors derived from retroviruses such as lentiviruses are suitable tools for achieving long-term gene transfer because they allow long-term, stable integration of transgenic genes and their proliferation in daughter cells. Lentiviral vectors have additional advantages over vectors derived from tumor retroviruses such as murine leukemia viruses because they can transduce non-proliferating cells, such as hepatocytes. They also have the additional advantage of low immunogenicity. In another embodiment, the desired CAR can be expressed in cells by a transposon.
[0189] The expression of natural or synthetic nucleic acids encoding CAR is generally achieved by operably linking the nucleic acid encoding the CAR polypeptide or a portion thereof to a promoter and incorporating the construct into an expression vector. The vector is suitable for replication and integration into eukaryotic organisms. Typical cloning vectors contain transcription and translation terminators, initiation sequences, and promoters suitable for regulating the expression of the desired nucleic acid sequence.
[0190] The expression constructs of the present invention can also be used for nucleic acid immunization and gene therapy using standard gene delivery protocols. Gene delivery methods are known in the art. See, for example, U.S. Patent Nos. 5,399,346, 5,580,859, and 5,589,466, which are incorporated herein by reference in their entireties. In another embodiment, the present invention provides a gene therapy vector.
[0191] Nucleic acids can be cloned into many types of vectors. For example, nucleic acids can be cloned into vectors including, but not limited to, plasmids, phagemids, phage derivatives, animal viruses, and cosmids. Vectors of particular interest include expression vectors, replication vectors, probe generation vectors, and sequencing vectors.
[0192] In addition, expression vectors can be provided to cells in the form of viral vectors. Viral vector technology is well known in the art and is described in, for example, Sambrook et al. (2001, Molecular Cloning:A Laboratory Manual, Cold Spring Harbor Laboratory, New York) and other virology and molecular biology manuals. Suitable viruses for use as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, and slow viruses. Generally speaking, suitable vectors contain a functional origin of replication, promoter sequence, convenient restriction endonuclease sites, and one or more selectable markers (e.g., WO 01 / 96584; WO 01 / 29058; and U.S. Patent number 6,326,193) in at least one organism.
[0193] Many virus-based systems have been developed for transferring genes into mammalian cells. For example, retroviruses provide a convenient platform for gene delivery systems. The selected gene can be inserted into a vector and packaged into retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to the cells of a subject in vivo or ex vivo. Many retroviral systems are known in the art. In some embodiments, lentiviral vectors are used. In other embodiments, adenoviral vectors are used. Many adenoviral vectors are known in the art.
[0194] Additional promoter elements, such as enhancers, can be used to regulate the frequency of transcription initiation. Typically, these promoters are located in the region 30-110 bp upstream of the start site, although many promoters have recently been found to contain functional elements downstream of the start site. The spacing between promoter elements is usually flexible so that when the elements are relatively inverted or moved, the function of the promoter is retained. In the thymidine kinase (tk) promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to wane. Single elements can activate transcription collaboratively or independently.
[0195] In some embodiments, the vector comprises a promoter. In some embodiments, the promoter is a constitutive promoter. In some embodiments, the constitutive promoter comprises an immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence that is capable of driving high-level expression of any polynucleotide sequence operably linked thereto. In some embodiments, the constitutive promoter comprises a eukaryotic translation elongation factor-1α promoter sequence. In some embodiments, the constitutive promoter is selected from the group consisting of: simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, avian leukosis virus promoter, Epstein-Barr virus immediate early promoter, and Rous sarcoma virus promoter. In some embodiments, the constitutive promoter is selected from the group consisting of: actin I promoter, myosin promoter, hemoglobin promoter, and creatine kinase promoter. In some embodiments, the promoter is an inducible promoter. The use of an inducible promoter provides a molecular switch that can turn on expression of a polynucleotide sequence to which it is operably linked when such expression is desired, or turn off expression when such expression is not desired. Examples of inducible promoters include, but are not limited to, the metallothionein promoter, the glucocorticoid promoter, the progesterone promoter, and the tetracycline promoter.
[0196] In order to evaluate the expression of the CAR polypeptide or part thereof, the expression vector to be introduced into the cell may also contain a selectable marker gene or a reporter gene or both to facilitate identification and selection of expressing cells from a cell population that is managed to be transfected or infected by a viral vector. In other aspects, the selectable marker can be carried on a separate DNA piece and used in a co-transfection process. Both the selectable marker and the reporter gene can be flanked by appropriate regulatory sequences to achieve expression in the host cell. Useful selectable markers include, for example, antibiotic resistance genes such as neo and the like.
[0197] Reporter gene is used to identify the cells of potential transfection and to evaluate the function of regulatory sequence. Generally speaking, reporter gene is a gene that is not present in recipient organism or tissue or is not expressed by it, and it encodes a polypeptide, and the expression of this polypeptide is expressed by some easily detectable characteristics (such as enzymatic activity). The expression of reporter gene is measured at the appropriate time after DNA has been introduced into recipient cell. Suitable reporter gene can include the gene of coding luciferase, beta-galactosidase, chloramphenicol acetyltransferase, secretory alkaline phosphatase or green fluorescent protein gene (for example, Ui-Tei et al., 2000FEBS Letters 479:79-82). Suitable expression system is well known and can be prepared using known technology or can be commercially available. Generally speaking, the construct with the minimum 5 ' flanking region showing the highest expression level of reporter gene is identified as promoter. This promoter region can be connected to reporter gene and used to evaluate the ability of factor-regulated promoter-driven transcription.
[0198] Methods for introducing genes and expressing them in cells are known in the art. In the case of expression vectors, the vectors can be readily introduced into host cells (e.g., mammalian, bacterial, yeast, or insect cells) by any method in the art. For example, expression vectors can be transferred into host cells by physical, chemical, or biological means.
[0199] Physical methods for introducing polynucleotides into host cells include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, and the like. Methods for generating cells containing vectors and / or exogenous nucleic acids are well known in the art. See, for example, Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York). A preferred method for introducing polynucleotides into host cells is calcium phosphate transfection.
[0200] Chemical means for introducing polynucleotides into host cells include colloidal dispersion systems, such as macromolecular complexes, nanocapsules, microspheres, beads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes. An exemplary colloidal system for use as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle).
[0201] In the case of utilizing a non-viral delivery system, an exemplary delivery vehicle is a liposome. It is expected that a lipid formulation will be used to introduce nucleic acids into a host cell (in vitro, in vitro or in vivo). On the other hand, nucleic acids can be associated with lipids. Nucleic acids associated with lipids can be encapsulated in the aqueous interior of the liposome; dispersed in the lipid bilayer of the liposome; attached to the liposome via a linker molecule associated with the liposome and the oligonucleotide; trapped in the liposome; compounded with the liposome; dispersed in a solution containing lipids; mixed with lipids; combined with lipids; contained in lipids as a suspension; contained or compounded together with micelles; or otherwise associated with lipids. The compositions associated with lipids, lipid / DNA or lipid / expression vectors are not limited to any specific structure in the solution. For example, they can exist in a double-layer structure in the form of micelles, or exist in a "collapsed" structure. They can also be simply dispersed in the solution, possibly forming aggregates of uneven size or shape. Lipids are naturally occurring fatty substances or synthetic lipids. For example, lipids include the fat droplets naturally present in the cytoplasm as well as the class of compounds comprising long-chain aliphatic hydrocarbons and their derivatives such as fatty acids, alcohols, amines, amino alcohols, and aldehydes.
[0202] Suitable lipids for use are available from commercial sources. For example, dimyristylphosphatidylcholine ("DMPC") is available from Sigma, St. Louis, Mo.; dicetyl phosphate ("DCP") is available from K&K Laboratories (Plainview, NY); cholesterol ("Choi") is available from Calbiochem-Behring; dimyristylphosphatidylglycerol ("DMPG") and other lipids are available from Avanti Polar Lipids, Inc. (Birmingham, Ala.). "Liposome" is a general term that includes various unilamellar and multilamellar lipid vehicles that are formed by the formation of closed lipid bilayers or aggregates. Liposomes can be characterized as having a vesicular structure with a phospholipid bilayer membrane and an internal aqueous medium. Multilamellar liposomes have multiple lipid layers separated by an aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before forming a closed structure and entrap water and dissolved solutes between the lipid bilayers (Ghosh et al., 1991 Glycobiology 5:505-10). However, compositions that have structures that differ from the normal porous structure in solution are also encompassed. For example, lipids may exhibit micellar structures or exist simply as heterogeneous aggregates of lipid molecules. Lipofectamine-nucleic acid complexes are also included.
[0203] In some embodiments, a nucleic acid encoding a CAR construct is delivered to a cell using a lentiviral or retroviral vector. Transduced cells can be used as a transferrin or encapsulated, combined or naked vectors for cell-free local or systemic delivery to deliver CAR-expressing lentiviral or adenoviral vectors to different types of eukaryotic cells and tissues and intact organisms. The method used can be used for purposes requiring or fully utilizing stable expression.
[0204] In another embodiment, the desired CAR can be expressed in the cell via a transposon.
[0205] The disclosed methods can be used to modulate T cell activity in basic research and therapy in the fields of cancer, stem cells, acute and chronic infections, and autoimmune diseases, including evaluating the ability of genetically modified T cells to kill target cancer cells.
[0206] Types and sources of T cells
[0207] On the one hand, the CAR T cells provided herein are autologous CAR T cells. In some embodiments, autologous CART cells are made from T cells obtained from a subject or patient to be treated. In some embodiments, T cells obtained from a subject are separated from samples including: peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue from an infected site, ascites, pleural effusion, spleen tissue, and tumors. In certain embodiments, many T cell strains available in the art can be used. In certain embodiments of the present invention, T cells can be isolated using many techniques known to skilled artisans (such as FICOLL TM The cells are collected from a sample of a subject using a single collection method (separation) obtained from a blood unit collected from a subject. In some embodiments, cells from the circulating blood of an individual are obtained by apheresis. The apheresis product typically contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets. In one embodiment, the cells collected by apheresis can be washed to remove the plasma portion and the cells are placed in an appropriate buffer or medium for subsequent processing steps. In one embodiment of the invention, the cells are washed with phosphate buffered saline (PBS). In an alternative embodiment, the washing solution lacks calcium, magnesium, and other divalent cations. After washing, the cells can be resuspended in a variety of biocompatible buffers, such as a Ca-free 2+ , Mg-free 2+ Alternatively, the aliquots can be stripped of unwanted components and the cells resuspended directly in culture medium.
[0208] In another embodiment, the monocytes are depleted by lysing the erythrocytes, for example by PERCOLL TM T cells are isolated from peripheral blood mononuclear cells by gradient centrifugation or by counterflow centrifugal elutriation.
[0209] Specific subsets of T cells can be further isolated by positive or negative selection techniques. Exemplary subsets of T cells include CD3 + 、CD28 + 、CD4 + 、CD8 + 、CD45RA + and CD45RO + For example, in one embodiment, T cells are expressed by using anti-CD3 / anti-CD28 conjugated beads such as DYNABEADS TMM-450 CD3 / CD28 T cells are cultivated for a period sufficient to positively select the desired T cells for isolation. In one embodiment, the period is about 30 minutes. In another embodiment, the period is in the range of 30 minutes to 36 hours or longer and all integer values therebetween. In another embodiment, the period is at least 1, 2, 3, 4, 5 or 6 hours. In still another preferred embodiment, the period is 10 to 24 hours. In a preferred embodiment, the cultivation period is 24 hours. For isolating T cells from patients with leukemia, using longer cultivation times such as 24 hours can increase cell yield. Longer cultivation times can be used to isolate T cells in any of the following situations: there are fewer T cells compared to other cell types, such as when isolating tumor infiltrating lymphocytes (TILs) from tumor tissue or from immunocompromised individuals. In addition, using longer cultivation times can increase the capture of CD8 + The efficiency of T cells. Therefore, only by shortening or extending the time allowing T cells to bind to CD3 / CD28 beads and / or by increasing or decreasing the ratio of beads to T cells, T cell subsets can be preferentially selected at the beginning of culture or at other time points during the process. In addition, by increasing or decreasing the ratio of anti-CD3 and / or anti-CD28 antibodies on beads or other surfaces, T cell subsets can be preferentially selected at the beginning of culture or at other required time points. Skilled artisans recognize that multiple rounds of selection can also be performed under the circumstances of the present invention. In certain embodiments, it is desirable to perform a selection process and use "unselected" cells in activation and amplification processes. "Unselected" cells can also undergo more rounds of selection.
[0210] Enrichment of T cell populations by negative selection can be achieved by a combination of antibodies against surface markers unique to the negatively selected cells. One approach is cell sorting and / or selection via negative magnetic immunoadhesion or flow cytometry using a cocktail of monoclonal antibodies against cell surface markers present on the negatively selected cells. For example, to enrich CD4 + Cells, the monoclonal antibody cocktail typically contains antibodies against CD14, CD20, CD11b, CD16, HLA-DR, and CD8. In certain embodiments, it is desirable to enrich or positively select regulatory T cells, which typically express CD4 + 、CD25 + 、CD62L hi , GITR + and FoxP3 + Alternatively, in certain embodiments, T regulatory cells are depleted by anti-C25-conjugated beads or other similar selection methods.
[0211] The T cells may also be frozen after the washing steps. In some embodiments, the freezing and subsequent thawing steps provide a more homogeneous product by removing granulocytes and, to some extent, monocytes from the cell population. Following the washing steps to remove plasma and platelets, the cells may be suspended in a freezing solution.
[0212] In certain embodiments, cryopreserved cells are thawed and washed as described herein and allowed to rest at room temperature (eg, for an hour or more) prior to use in accordance with the methods of the invention.
[0213] The situation of the present invention also encompasses collecting blood samples or single-collection products from a subject over a period of time before the amplification cells as described herein may be needed. Thus, the source of cells to be amplified can be collected at any necessary time point, and the desired cells, such as T cells, are separated and frozen for later use in T cell therapies for many diseases or conditions (such as those described herein) that will benefit from T cell therapies. In one embodiment, a blood sample or single collection is taken from a generally healthy subject. In certain embodiments, a blood sample or a single collection component is taken from a generally healthy subject who is at risk of developing a disease but has not yet developed a disease, and the target cells are separated and frozen for stand-by use. In certain embodiments, T cells can be amplified, frozen, and used later. In certain embodiments, the sample is collected from the patient shortly after a specific disease as described herein is diagnosed, but before any treatment.
[0214] T cell activation and expansion
[0215] Whether before or after genetically modifying T cells to express a desired CAR, T cells can generally be activated and expanded using methods such as those described in the following patents: U.S. Patent Nos. 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041; and U.S. Patent Application Publication No. 20060121005, each of which is incorporated by reference.
[0216] In general, the T cells of the present invention can be expanded by surface contact with factors that stimulate CD3 / TCR complex-related signals and ligands that stimulate co-stimulatory molecules on the surface of T cells. Specifically, T cell populations can be stimulated as described herein, such as by contact with anti-CD3 antibodies or their antigen-binding fragments or anti-CD2 antibodies immobilized on the surface, or by contact with protein kinase C agonists (e.g., bryostatin) together with calcium ion carriers. For co-stimulation of auxiliary molecules on the surface of T cells, ligands that bind auxiliary molecules are used. For example, T cell populations can be contacted with anti-CD3 antibodies and anti-CD28 antibodies under conditions suitable for stimulating T cell proliferation. In order to stimulate CD4 + T cells or CD8 + T cell proliferation can be performed using anti-CD3 and anti-CD28 antibodies. Examples of anti-CD28 antibodies include B-T3 and XR-CD28 (Diaclone, Besancon, France), as well as other methods generally known in the art (see Berg et al., Transplant Proc. 30(8):3975-3977, 1998; Haanen et al., J. Exp. Med. 190(9):1319-328, 1999; Garland et al., J. Immunol Meth. 227(1-2):53-63, 1999).
[0217] In certain embodiments, the first stimulation signal and the costimulatory signal of T cell can be provided by different schemes.For example, the factor providing each signal can be in solution or coupled to the surface.When coupled to the surface, the factor can be coupled to the same surface (that is, " cis " structure) or a single surface (that is, " trans " structure).Or, a kind of factor can be coupled to the surface and another factor is in solution.In one embodiment, the factor providing the costimulatory signal is bound to the cell surface, and the factor providing the first activation signal is in solution or coupled to the surface.In certain embodiments, two factors can be in solution.In another embodiment, these factors can be in soluble form, then cross-linked to the surface, such as expressing Fc receptors or antibodies or by cells bound to other binding factors of the factor.In this regard, about the artificial antigen presenting cells (aAPC) expected to be used for activating and amplifying T cells in the present invention, see, for example, U.S. Patent Application Publication Nos. 20040101519 and 20060034810.
[0218] In one embodiment, two factors are immobilized on beads, either on the same bead, i.e., "cis," or on separate beads, i.e., "trans." For example, the factor providing the first activation signal is an anti-CD3 antibody or an antigen-binding fragment thereof and the factor providing the co-stimulatory signal is an anti-CD28 antibody or an antigen-binding fragment thereof; and both factors are co-immobilized on the same bead at equal molecular weight.
[0219] In other embodiments of the present invention, T cells are combined with factor-coated beads, which are then separated from the cells before the cells are cultured. In an alternative embodiment, the factor-coated beads and cells are not separated prior to culture, but are cultured together. In yet another embodiment, the beads and cells are first concentrated by applying a force, such as a magnetic force, to enhance the binding of cell surface markers, thereby inducing cell stimulation.
[0220] For example, cell surface proteins can be linked by allowing paramagnetic beads to which anti-CD3 and anti-CD28 are attached to contact the T cells. 4 to 10 9 T cells) and beads (e.g., DYNABEADS TM M-450 CD3 / CD28 T paramagnetic beads, ratio 1: 1) are combined in a buffer, preferably PBS (without divalent cations such as calcium and magnesium). Therefore, any number of cells is within the context of the present invention. In certain embodiments, it is desirable to significantly reduce the volume in which the particles and cells are mixed (i.e., increase the concentration of the cells) to ensure maximum contact between the cells and the particles. For example, in one embodiment, a concentration of about 2 billion cells / ml is used. In another embodiment, greater than 100 million cells / ml is used. In yet another embodiment, a cell concentration of 10, 15, 20, 25, 30, 35, 40, 45, or 50 million cells / ml is used. In still another embodiment, a cell concentration of 75, 80, 85, 90, 95, or 100 million cells / ml is used. In other embodiments, a concentration of 125 or 150 million cells / ml may be used.
[0221] In one embodiment of the invention, the mixture can be cultured for several hours (about 3 hours) to about 14 days or any hour integer value therebetween. In another embodiment, the mixture can be cultured for 21 days. In one embodiment of the invention, beads are cultured together with T cells for about 8 days. In another embodiment, beads are cultured together with T cells for 2-3 days. It is also possible to need several cycles of stimulation so that the culture time of T cells can reach 60 days or longer. Conditions suitable for T cell culture include appropriate culture medium (e.g., minimum essential medium or RPMI culture medium 1640 or X-vivo 15 (Lonza)), which can contain factors necessary for proliferation and viability, including serum (e.g., fetal bovine or human serum), interleukin-2 (IL-2), insulin, IFN-γ, IL-4, IL-7, GM-CSF, IL-10, IL-12, IL-15, TGFβ and TNF-α or any other additive known to those skilled in the art for cell growth. Other additives for cell growth include, but are not limited to, surfactants, human plasma protein powder, and reducing agents such as N-acetyl-cysteine and 2-mercaptoethanol. Culture media may include RPMI 1640, AIM-V, DMEM, MEM, α-MEM, F-12, X-Vivo 15, and X-Vivo 20, Optimizer, supplemented with amino acids, sodium pyruvate, and vitamins, serum-free or supplemented with an appropriate amount of serum (or plasma) or a defined hormone panel and / or an amount of cytokines sufficient for the growth and expansion of T cells. Antibiotics such as penicillin and streptomycin may also be included. Target cells are maintained under conditions necessary to support growth, such as an appropriate temperature (e.g., 37°C) and atmosphere (e.g., air plus 5% CO2).
[0222] As described herein, when CAR is expressed on the surface of T cells, CAR T cells undergo trophic signal transduction in the absence of tumor antigens. Trophic signal transduction is demonstrated by Western blot, where the CAR CD3-ζ domain is phosphorylated at baseline (see Example 2, Figure 16). Trophic signaling causes T cell exhaustion, rendering CAR T cells ineffective. Trophic signaling is prevented in RDD-CAR T cells by amplifying the cells in the absence of a stabilizing drug. When CAR expression is reduced or inhibited and not expressed on the T cell surface (in the absence of appropriate small molecules - in this case, shield-1 - CAR is not expressed on the cell surface - "always off"), or if CAR is expressed at a certain point but then removed from the surface for a period of time (e.g., 72 hours - CAR off D7), a decrease in CD3-ζ phosphorylation is observed. In addition, when CAR is not expressed on the surface (no shield-1, "CAR is always off") or when cultured in shield-1 for 7 days and then removed, only a small portion of cells co-expressing exhaustion markers are observed (see Example 2, Figure 17 ). Therefore, in some embodiments, the present invention provides a method of inhibiting CAR expression using the RDD-CAR of the present invention, which has a profound effect on how CAR T cells are regulated at the transcriptional level by preventing or reversing CAR nourishing signal transduction.
[0223] Thus, in some embodiments, because the CAR undergoes nourishing signaling in the absence of antigen (e.g., during culture), expanding the RDD-CAR T cells in the absence of a stabilizing drug such that CAR expression on the surface is suppressed will enhance the effector function of the CAR T cells when the RDD-CAR T cells are used therapeutically in a patient compared to T cells in which the CAR is continuously expressed (e.g., when expanded in vitro or ex vivo).
[0224] In some embodiments, compared to CAR T cells in which CAR expression is not suppressed during in vitro expansion, CAR expression is suppressed during in vitro expansion to produce and / or obtain healthier, more functional CAR T cells (e.g., with normal effector functions). Therefore, in some embodiments, during culture and expansion, the CAR expression in T cells containing the CAR of the present invention comprising RDD (e.g., DHFR DD regulated by trimethoprim) is regulated (e.g., reduced) by adding drugs to increase expression or removing drugs to reduce expression. In some embodiments, CAR expression is suppressed during culture and / or expansion to suppress nutrient signal transduction in vitro, obtaining or producing T cells with better effector functions than T cells in which nutrient signal transduction is not suppressed in the case of the condition or disease of the subject being treated.
[0225] T cells exposed to different stimulation times may exhibit different characteristics. For example, a typical blood or apheresis peripheral blood mononuclear cell product has a larger than cytotoxic or suppressive T cell population (T C , CD8+) helper T cell population (TH , CD4+). Ex vivo expansion of T cells by stimulation of CD3 and CD28 receptors will produce a T cell population that, prior to about 8-9 days, consists primarily of T H cells, and after about 8-9 days, the T cell population contains more and more T C Therefore, depending on the purpose of treatment, it will mainly contain T H Similarly, if a T cell population has been isolated, it may be advantageous to infuse the T cell population into a subject. C If an antigen-specific subset of cells is expressed, it may be beneficial to expand this subset to a greater extent.
[0226] Furthermore, phenotypic markers other than CD4 and CD8 also showed significant variation but were largely reproducible during cell expansion. This reproducibility therefore enables customized activated T cell products for specific purposes.
[0227] Therapeutic applications
[0228] In some embodiments, the present invention provides a kind of cell (such as T cell), it is modified to express CAR, and the CAR combines the antigen recognition domain of specific antibody with CD3-ζ, CD28, 4-1BB or the intracellular domain and RDD of any combination thereof.Therefore, in the presence of its target antigen, the modified T cell triggers CAR-mediated T cell response.
[0229] The present invention provides the use of CAR to redirect the specificity of primary T cells to tumor antigens. Therefore, the present invention also provides a method for stimulating a T cell-mediated immune response against a target cell population or tissue in a subject, the method comprising administering to the subject a T cell expressing CAR, wherein the CAR comprises a binding portion that specifically interacts with a predetermined target, a ζ chain portion comprising, for example, an intracellular domain of human CD3-ζ, a costimulatory signal transduction region, and an RDD.
[0230] In some embodiments, the present invention provides a cell therapy in which T cells are genetically modified to express CAR containing RDD and CAR T cells are infused into recipients in need thereof. The infused cells are capable of killing tumor cells expressing CAR T cell target antigens in the recipient. Unlike other biological therapies, CAR T cells are able to replicate in vivo, producing long-term persistence, thereby achieving sustained control of tumors. In some embodiments, CAR T cells comprising CAR containing RDD exhibit prolonged anti-tumor responses (e.g., compared to CAR T cells comprising CAR lacking RDD). In some embodiments, RDD is included in CAR to act as a safety switch to inhibit CAR T cell activity / function (e.g., for reducing CAR toxicity). For example, in some embodiments, the removal of stable small molecules or drugs (e.g., trimethoprim) from CAR T cells causes a rapid decrease or inhibition of CAR expression on the surface of CAR T cells, thereby effectively shutting down or preventing the targeting and effector functions of CAR T cells. Specifically, as shown in Example 2, it was observed that IC50 (the time taken for 50% surface CAR degradation) was less than 2 hours in the absence of stable drugs / molecules (see Example 2, Figure 13 ). Therefore, in some embodiments, removing the stabilizing drug from a patient receiving DD-CAR can act as a rapid and reversible safety switch. Therefore, in some embodiments, the present invention provides the ability to mitigate or eliminate toxic events that may occur during CAR T cell therapy, such as but not limited to cytokine release syndrome (CRS) or on-target off-tumor toxicity. In addition, in the case of on-target off-tumor toxicity, in some embodiments, the present invention makes it possible to achieve the following ability: titrate down the dose of the stabilizing drug so that the CAR T cell therapy recognizes the desired target (e.g., tumor antigen) without recognizing healthy tissue.
[0231] In one embodiment, the CAR T cells of the present invention undergo robust in vivo T cell expansion and persist for an extended period of time. In another embodiment, the CAR T cells of the present invention evolve into specific memory T cells that can be reactivated to inhibit any additional tumor formation or growth. For example, the GD2-specific CAR T cells of the present invention can undergo robust in vivo T cell expansion and persist at high levels in the blood and bone marrow for an extended period of time and form specific memory T cells.
[0232] The anti-tumor immune response elicited by CAR-modified T cells can be an active or passive immune response. Additionally, CAR-mediated immune responses can be part of adoptive immunotherapy, in which CAR-modified T cells induce an immune response specific for the antigen-binding portion of the CAR. For example, GD2-specific CAR T cells elicit an immune response specific for cells expressing GD2.
[0233] Although the data disclosed herein specifically describe a lentiviral vector comprising an anti-GD2 scFv (e.g., 14G2a scFv), a CD28 hinge and transmembrane domain, a CD28 and CD3-ζ signaling domain, and an RDD of FKBP or DHFR, the present invention should be interpreted as including many variations of each component of the construct as described elsewhere herein. That is, the present invention includes the use of any antigen binding portion in CAR to produce a CAR-mediated T cell response that is specific to the antigen binding portion. For example, the antigen binding portion in the CAR of the present invention can target tumor antigens for the purpose of treating cancer. Similarly, the present invention includes the use of any hinge, transmembrane domain, stimulatory domain, and / or adjustable destabilizing domain in CAR to produce a CAR-mediated T cell response. In fact, the methods described herein provide the ability to characterize and identify CAR T cells that have the desired effector function and can be regulated by incorporating RDD into CAR.
[0234] In one embodiment, the antigen binding portion of the CAR of the present invention is designed to treat specific cancers. GD2 is expressed on a variety of cancers including neuroblastoma, osteosarcoma, and some sarcomas (see, e.g., Thomas et al., PLoS One, 2016.11(3): p.e0152196; Long et al., Nature Medicine, 2015.21(6): p.581-590; Long et al., Cancer Immunology Research, 2016.4(10): p.869-880; Yu et al., N Engl J Med, 2010.363(14): p.1324-34; Perez Horta et al., Immunotherapy, 2016.8(9): p.1097-117; Heczey et al., Molecular Therapy). Therefore, CARs designed to target GD2 can be used to treat any disease or condition, including neuroblastoma, osteosarcoma, and other sarcomas, all of which are characterized by cells and / or tissues that display or overexpress GD2. However, the present invention is not limited to targeting GD2. In fact, the present invention includes any antigen-binding portion that, when bound to its cognate antigen, affects tumor cells so that they cannot grow, tend to die, or are otherwise affected so that the tumor burden in the patient is reduced or eliminated. For example, FRα is a glycosylphosphatidylinositol-anchored protein that is overexpressed on the surface of cancer cells of various epithelial malignancies, but is limited in normal tissues. Thus, CARs designed to target FRα can be used to treat any disease or condition, including but not limited to epithelial cancer, which is characterized by cells and / or tissues that display overexpression of FRα. For example, CARs designed to target FRα can be used to treat cancers and conditions, including but not limited to ovarian cancer, lung cancer, breast cancer, kidney cancer, colorectal cancer, other solid cancers, and the like.
[0235] The CAR-modified T cells of the present invention can also serve as a type of vaccine for ex vivo immunization and / or in vivo treatment in mammals. The mammal is preferably a human. With regard to ex vivo immunization, prior to administering the cells to the mammal, at least one of the following occurs in vitro: i) amplifying the cells, ii) introducing the nucleic acid encoding the CAR into the cells, and / or iii) cryopreserving the cells.
[0236] In vitro procedures are well known in the art. In short, cells are isolated from mammals (preferably humans) and genetically modified (i.e., in vitro transduction or transfection) with a vector expressing a CAR disclosed herein. CAR-modified cells are administered to a mammalian recipient to provide therapeutic benefits. The mammalian recipient may be a human and the CAR-modified cells may be autologous to the recipient. Alternatively, the cells may be allogeneic, syngeneic, or xenogeneic to the recipient.
[0237] The procedures for ex vivo expansion of hematopoietic stem and progenitor cells are described in U.S. Patent No. 5,199,942, which is incorporated herein by reference, and the procedures can be used with the cells of the present invention. The present invention is not limited to any specific method for ex vivo expansion of cells. Briefly, the ex vivo culture and expansion of T cells comprises: (1) collecting CD34+ hematopoietic stem and progenitor cells from a peripheral blood harvest or bone marrow explant of a mammal; and (2) expanding such cells ex vivo. In addition to the cell growth factors described in U.S. Patent No. 5,199,942, other factors such as flt3-L, IL-1, IL-3, and c-kit ligand can also be used to culture and expand cells.
[0238] In addition to ex vivo immunization using cell-based vaccines, the present invention also provides compositions and methods for in vivo immunization to elicit an immune response to an antigen in a patient.
[0239] Specifically, the CAR-modified T cells of the present invention are used to treat cancer. In certain embodiments, the cells of the present invention are used to treat patients at risk of developing cancer. Therefore, the present invention provides a method for treating or preventing cancer, the method comprising administering a therapeutically effective amount of a CAR-modified T cell of the present invention to a subject in need thereof.
[0240] The CAR modified T cells of the present invention can be administered alone or as a pharmaceutical composition in combination with a diluent and / or other components such as IL-2 or other cytokines or cell groups. In short, the pharmaceutical composition of the present invention may include CAR T cells as described herein in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Such compositions may include buffers such as neutral buffered saline, phosphate buffered saline, etc.; sugars such as glucose, mannose, sucrose or dextran, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives. The present compositions are preferably formulated for intravenous administration.
[0241] The pharmaceutical composition of the present invention can be used in a manner suitable for the disease to be treated (or prevented). The amount and frequency of use will be determined by factors such as the patient's condition, and the patient's disease type and severity, but appropriate dosage can be determined by clinical trials.
[0242] When an "immunologically effective amount," "anti-tumor effective amount," "tumor suppressive effective amount," or "therapeutic amount" is indicated, the exact amount of the composition of the present invention to be administered can be determined by a physician after taking into account individual differences such as the patient's (subject's) age, weight, tumor size, degree of infection or metastasis, and condition. The pharmaceutical composition comprising the CAR T cells described herein can be administered in the following doses: 10 4 to 10 9 cells / kg body weight, preferably 10 5 to 10 6 Cells / kg body weight, including all integer values within these ranges. T cell compositions can also be administered multiple times at these doses. These cells can be administered using infusion techniques commonly known in immunotherapy (see, for example, Rosenberg et al., New Eng. J. of Med. 319: 1676, 1988). The optimal dose and treatment regimen for a particular patient can be easily determined by one of ordinary skill in the art by monitoring the patient's disease signs and adjusting the treatment accordingly.
[0243] In certain embodiments, it may be desirable to administer genetically modified T cells to a subject, then redraw blood (or perform apheresis), activate the T cells obtained therefrom according to the present invention, and re-infuse these activated and expanded T cells into the patient. This process can be repeated several times over several weeks.
[0244] The administration of the compositions described herein can be carried out in any convenient manner. In some embodiments, the T cell compositions of the present invention are preferably administered by intravenous injection. However, the administration is not limited to this route. The T cell compositions can be injected directly into a tumor, lymph node, or site of infection. The compositions described herein can be administered to a patient subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, by intravenous (iv) injection, or intraperitoneally. The compositions can also be administered, for example, by injection, infusion, implantation, or transplantation.
[0245] In certain embodiments of the present invention, cells activated and expanded using the methods described herein or other methods known in the art (wherein T cells are expanded to therapeutic levels) are administered to a patient along with (e.g., before, simultaneously with, or after) a number of treatment modalities (e.g., for cancer or infectious diseases). Exemplary treatment modalities include, but are not limited to, treatment with agents such as antivirals, cidofovir, and interleukin-2; cytarabine (also known as ARA-C) or natalizumab treatment for MS patients; or efalizumab treatment for psoriasis patients. In other embodiments, the T cells of the present invention can be used in combination with the following treatments: chemotherapy, radiation, immunosuppressants such as cyclosporine, azathioprine, methotrexate, mycophenolic acid, and FK506; antibodies or other immune clearing agents such as CAM PATH, anti-CD3 antibodies or other antibody therapies, cytotoxins, fludarabine, cyclosporine, FK506, rapamycin, mycophenolic acid, steroids, FR901228, cytokines, and radiation. These drugs inhibit the calcium-dependent phosphatase calcineurin (cyclosporine and FK506) or inhibit p70S6 kinase (rapamycin), which is important for growth factor-induced signal transduction (Liu et al., Cell 66: 807-815, 1991; Henderson et al., Immun. 73: 316-321, 1991; Bierer et al., Curr. Opin. Immun. 5: 763-773, 1993). In another embodiment, the cell composition of the present invention is administered to the patient together with (e.g., before, at the same time, or after) the following treatments: bone marrow transplantation; T cell depletion therapy using chemotherapeutic agents such as fludarabine, external beam radiation therapy (XRT), cyclophosphamide, or antibodies such as OKT3 or CAMPATH. In another embodiment, the cell composition of the present invention is administered after B cell depletion therapy such as an agent that reacts with CD20 (e.g., Rituxan). For example, in one embodiment, the subject may receive standard treatment with high-dose chemotherapy followed by peripheral blood stem cell transplantation. In certain embodiments, following transplantation, the subject receives an infusion of the expanded immune cells of the invention. In an additional embodiment, the expanded cells are administered before or after surgery.
[0246] The effect of any method described herein can be tested in various models (such as clinical or preclinical models) known in the art. Suitable preclinical models are exemplified in this article. For any exemplary model, after tumor formation, mice are randomly included in the treatment group receiving treatment or control treatment. Tumor size (such as tumor volume) is measured during treatment, and overall survival rate is also monitored.
[0247] In some embodiments, a sample is obtained before treatment with T cells (e.g., alone or in combination with another therapy described herein) as a baseline for measuring the response to treatment. In some embodiments, the sample is a tissue sample (e.g., formalin-fixed and paraffin-embedded (FFPE), archived, fresh or frozen). In some embodiments, the sample is whole blood. In some embodiments, whole blood comprises immune cells, circulating tumor cells, and any combination thereof.
[0248] Responsiveness to treatment may refer to one or more of the following: prolonging survival (including overall survival and progression-free survival); producing a target response (including complete response or partial response); or improving the signs or symptoms of cancer. In some embodiments, responsiveness may refer to an improvement in one or more factors according to the published RECIST guideline set, i.e., response, stability, or progression, which is used to determine the tumor status of a cancer patient. For a more detailed discussion of these guidelines, see Eisenhauer et al., Eur J Cancer 2009; 45: 228-47; Topalian et al., N Engl J Med 2012; 366: 2443-54; Wolchok et al., Clin Can Res 2009; 15: 7412-20; and Therasse, P., et al. J. Natl. Cancer Inst. 92: 205-16 (2000). A responsive subject may refer to a subject whose cancer shows improvement, for example, according to one or more factors based on RECIST criteria. A non-responsive subject can refer to a subject whose cancer does not show improvement, for example, according to one or more factors based on RECIST criteria.
[0249] Conventional response criteria may not be sufficient to characterize the anti-tumor activity of immunotherapeutics because immunotherapeutics can produce delayed responses, before which initial overt radiographic progression, including the appearance of new lesions, may occur. Therefore, modified response criteria have been developed to account for the possible appearance of new lesions and to allow for confirmation of radiographic progression in subsequent assessments. Thus, in some embodiments, responsiveness may refer to an improvement in one or more factors according to immune-related response criteria 2 (irRC). See, for example, Wolchok et al., Clin Can Res 2009; 15: 7412-20. In some embodiments, new lesions are added to the defined tumor burden and used for radiographic progression in subsequent assessments. In some embodiments, the presence of non-target lesions is included in the complete response assessment and is not included in the assessment of radiographic progression. In some embodiments, radiographic progression may be determined solely based on measurable disease and / or may be confirmed by continuous assessment for >4 weeks from the date of first recording.
[0250] The present invention may be implemented in other specific ways without departing from the spirit or essential characteristics of the present invention. Therefore, the above-described embodiments are to be considered in all respects as illustrative and not limiting of the invention described herein. Therefore, the scope of the present invention is indicated by the appended claims rather than by the foregoing description, and all variations within the meaning and range of the equivalents of the claims are intended to be included therein. All publications, patents, and patent applications cited herein are incorporated by reference in their entirety for all purposes.
[0251] Example
[0252] The following examples illustrate but do not limit the compounds, compositions and methods of the present invention.Other suitable modifications and improvements to the variety of conditions and parameters normally encountered in clinical therapy and obvious to those skilled in the art are within the spirit and scope of the present invention.
[0253] Example 1
[0254] Methods for preventing or reversing T cell exhaustion by inhibiting or modulating TCR signaling
[0255] introduction
[0256] We have previously reported that T cells expressing GD2-CAR undergo functional exhaustion within 10 days of culture and are characterized by co-expression of inhibitory receptors, inability to secrete cytokines in response to tumor antigens, and abnormal metabolic function (Long et al., Nat Med 2015). Control cultures included untransduced T cells (simulation) and those expressing CD19-CAR, which did not show trophic signal transduction or exhaustion in vitro. Previous studies have also demonstrated that the ζ chain is required for exhaustion in this system, where CD28 signal transduction increases the effectiveness of signal stimulation-induced exhaustion. Using this model system, a robust, controllable, and reproducible in vitro human model of T cell exhaustion has now been optimized to evaluate methods for preventing or reversing T cell exhaustion.
[0257] result
[0258] We engineered the GD2.28z CAR fused to the FKBP12 mutant destabilizing domain (Banaszynski et al., Cell 2006) (GD2.28z.FKBP), which destabilizes the CAR and induces rapid protein degradation. Surface expression was observed to be rapidly and dose-dependently modulated by addition or removal of the stabilizing rapalog shield-1 (S1) in the culture medium ( Figure 1 Similar regulatable CAR expression was also achieved using an E. coli DHFR mutant (GD2.28z.DHFR, not shown), which was regulated by trimethoprim, a clinically used antibiotic.
[0259] Since trophic signaling is highly dependent on GD2-CAR receptor levels, precise control of CAR expression levels also precisely regulates the level of trophic signaling. Pharmacological regulation of CAR expression levels also allows for modulation of the duration and intensity of GD2.28z trophic signaling. Using this system, we demonstrated that phenotypic and functional changes associated with depletion are reversed upon cessation of CAR signaling. Figure 2 As shown, removal of S1 drug from the culture medium and subsequent removal of surface CAR at day 7 post-activation reversed typical exhaustion marker expression to control levels by day 10 ( Figure 2 , n=3). This was best demonstrated by measuring the levels of triple-expressing PD-1 / TIM-3 / LAG-3 cells, which are highly specific for dysfunctional, exhausted T cells. We demonstrated that depletion on day 10 induced an increase in the levels of triple-expressing exhausted cells, but removal of S1 on day 7 resulted in normalization of these levels by day 10. Similar results were obtained on day 14 for cells in which S1 was removed from the culture medium on day 7 or day 10 (not shown).
[0260] Additionally, removal of S1 on day 7 or day 10, thereby allowing transient degradation of the CAR protein, resulted in retention of memory markers (e.g., CD62L) and prevention of apoptosis (i.e., Annexin V staining) by day 14 compared to T cells (S1) that received S1 for the entire duration of culture ( Figure 3 ).
[0261] Because phenotypic markers may not fully predict T cell function, we also performed functional experiments on CAR T cells transiently exposed to drugs in culture. CAR T cells were washed, resuspended in medium containing S1, and mixed at a 1:1 ratio with Nalm6 leukemia cells stably expressing surface GD2. Approximately 24 hours later, culture supernatants were collected and cytokine levels assessed by ELISA.
[0262] Similar to the GD2.28z CAR that lacks the destabilizing domain and thus has sustained high levels of CAR signaling, cells expressing the GD2.28z.FKBP CAR that received continuous drug treatment ( Figure 4, gray columns) secrete minimal IL-2 on both days 10 and 14 after activation, consistent with T cell exhaustion. Alternatively, CAR T cells that are not exposed to drugs (black columns) during culture and therefore do not undergo trophic signal transduction show significant biological activity, as measured by IL-2 production. Ultimately, CAR T cells that are exposed to drugs during the initial 7 or 10 days of culture and therefore obtain phenotypic and functional evidence of T cell exhaustion but that remove the drug from the culture medium on day 7 or 10 (blue and red columns, respectively) demonstrate a restored ability to secrete IL-2 in response to tumor antigens.
[0263] Significantly, T cells exhausted at day 10 (grey bars, day 10 ELISA) can be revitalized by removing S1 from the culture medium and only "rest" for 4 days (red bars, day 14 ELISA). Similar but less significant enhancement of IFNγ secretion was also observed under conditions where S1 was removed from the culture medium. These functional data cannot be attributed to differential CAR surface expression, as all groups exhibited similar surface CAR levels at the end of this co-culture assay (not shown).
[0264] We then compared whether preventing or reversing T cell exhaustion by removing surface CAR was more effective or less effective than treatment with the well-characterized anti-PD-1 checkpoint inhibitor nivolumab (Nivo). CAR T cells were treated with continuous S1 (and thus exhibiting continuous trophic signaling), continuous S1 + nivolumab, or no S1 until the time of the co-culture assay. Interestingly, nivolumab treatment resulted in only a modest increase in IL-2 secretion at day 10, which persisted until day 14, suggesting that nivolumab only partially prevented the onset of T cell exhaustion in this system ( Figure 5 ).
[0265] In contrast, CAR T cells were cultured without S1 and then added back to the culture medium just before the co-culture assay began (left panel, blue column), resulting in far superior exhaustion prevention (black column) because IL-2 secretion was enhanced 5-10 times compared to CAR T cells receiving continuous S1 (black column). In addition, removing trophic signaling by removing S1 from the culture medium on day 7 also resulted in superior IL-2 secretion compared to CAR T cells receiving continuous S1 and those receiving continuous S1 and simultaneously treated with S1. Overall, these data illustrate that modulation of trophic signaling exhibits a more effective effect on preventing or reversing exhaustion than PD-1 blockade.
[0266] Functional studies performed by several groups (including our laboratory) have demonstrated that the co-expression of PD-1, TIM-3, and LAG-3 (triple positive, TP) represents a highly dysfunctional subset of exhausted cells. We therefore sought to analyze whether the cessation of trophic signaling in this subset of cells could reverse their phenotype and restore their ability to secrete IL-2 in response to tumor antigens. A high-affinity form of the GD2.28z CAR (HA-GD2.28z), which exhibits an even more pronounced exhaustion phenotype, was fused to the FKBP12 mutant destabilizing domain to control its surface expression. On day 10 after activation, HA-GD2.28z.FKBP CAR T cells that had received continuous S1 treatment were sorted to isolate pure PD-1 / TIM-3 / LAG-3 exhaustion populations. The “triple positive” exhausted cells were then re-cultured with or without S1 to test whether the removal of trophic signaling could restore their function. FACS and co-culture assays were performed 4 days later.
[0267] Removal of S1 resulted in a significant reversal of the exhaustion phenotype. After only 4 days in the absence of S1 in the culture medium, pre-sorted triple-positive cells exhibited much less expression of exhaustion markers in both CD4+ and CD8+ CAR T cells ( Figure 6 Importantly, these phenotypic changes also conferred a functional enhancement in IL-2 secretion, as depletion of S1 resulted in a 2-fold increase in IL-2 secretion compared to triple-positive cells that received continuous S1 treatment from day 10-14 onwards ( Figure 6 ).
[0268] We speculate that the effect of removing surface CARs and the resulting trophic signal transduction can be reproduced simply by inhibiting the kinases in the TCR signal transduction pathway (also integrated into CAR signal transduction). One such kinase is Lck, which is used to phosphorylate CD3-ζ in response to TCR or CAR connections. Dasatinib, a potent receptor tyrosine kinase inhibitor and BCR / ABL antagonist, has also been shown to inhibit T cell activation, proliferation, and cytokine secretion by binding to and inhibiting Lck at low concentrations (Schade et al., Blood, 2008 and Lee et al., Leukemia, 2010).
[0269] At concentrations of 100 nM and 1 μM, dasatinib effectively inhibited cytokine secretion by CD19.28z CAR T cells in response to tumor antigens on day 14 after activation ( Figure 7 ), demonstrating that dasatinib disrupts CAR signaling.
[0270] We then wondered whether transient dasatinib exposure could reverse T cell exhaustion by treating HA-GD2.28z CAR T cells with dasatinib on days 10-14 after activation. The cells were treated with dasatinib for 4 days, the drug was extensively washed out of the culture medium, and the cells were cultured for an additional 24 hours before examining their phenotype and function via FACS and tumor co-culture assays. Interestingly, 4-day treatment with dasatinib reversed exhaustion marker expression and co-expression ( Figure 8 ).
[0271] Furthermore, dasatinib treatment preserved T cell memory by maintaining CD62L expression in a dose-dependent manner ( Figure 9 ).
[0272] Finally, similar to surface CAR removal, dasatinib treatment rejuvenated exhausted T cells in a functionally significant manner, as dasatinib-treated CAR T cells secreted more IL-2 (and, to a lesser extent, IFNγ) in response to tumor antigens than those that had never received dasatinib ( Figure 10 ).
[0273] Collectively, these data suggest that selective inhibition or modulation of TCR signaling can substantially enhance the function of exhausted T cells undergoing continuous antigen exposure in the context of cancer or chronic infection. In future studies, we will conduct in vivo studies to assess the feasibility of reversing exhaustion in this setting and whether such reversal can enhance antitumor effects in murine models.
[0274] Example 2
[0275] Preventing CAR T cell exhaustion and enhancing CAR T cell effector function by introducing a destabilizing domain into CAR
[0276] Experiments were conducted to test whether it was possible to control CAR T cell activity by adjusting CAR T cell surface expression, thereby providing a method for "turning off" CAR T cells in patients who were experiencing toxicity without completely eliminating the cells (in stark contrast to a suicide switch). Experiments were also conducted during the development of embodiments of the present invention to determine whether the expansion of CAR T cells in vitro in the absence of surface CAR would reduce CAR's nourishing signal transduction, thereby potentially producing a healthier and more effective infusion product. Finally, experiments were conducted to test whether regulating CAR surface expression using an adjustable drug sensitivity destabilizing domain could prevent or reverse T cell exhaustion and / or maintain / induce T cell memory.
[0277] Materials and methods
[0278] Cells and culture conditions
[0279] NALM6-GL (an acute lymphoblastic leukemia cell line stably transfected with GFP and luciferase) and NALM6-GL-GD2 (stably transfected to overexpress GD2 synthase) cell lines were cultured in RPMI-1640. 293T and 143B cell lines were cultured in DMEM (Life Technologies). DMEM and RPMI-1640 were supplemented with 10% heat-inactivated FBS (Gibco, Life Technologies), 10 mM HEPES, 100 U / mL penicillin, 100 μg / ml streptomycin, and 2 mM L-glutamine (Gibco, Life Technologies).
[0280] Primary human T cells were obtained from healthy donor buffy coats using the Pan T cell negative selection kit (Miltenyi Biotec). Donor T cells were then aliquoted and stored in Cryostor (StemCell Technologies) in liquid nitrogen. T cells were cultured in AimV (Gibco, Life Technologies) supplemented with 5% heat-inactivated FBS, 10 mM HEPES, 1% glutamax (Gibco, Life Technologies), and 100 u / uL recombinant human IL-2 (Peprotech). Unless otherwise specified, Shield-1 and trimethoprim lactate (Sigma Aldrich or Alfa Aesar) were cultured at 1 μM.
[0281] Lentiviral production and T cell transduction
[0282] All DD-CAR lentiviral supernatants were produced via transient transfection of 293T cell lines. In brief, 293T cells were transfected with plasmids encoding CAR and packaging proteins Gag-Pol, REV, and envelope protein VSVG via Lipofectamine 2000 (Life Technologies). Supernatants were collected 24 and 48 hours after transfection and immediately frozen or first concentrated by ultracentrifuge at 30,000 RPM and then frozen and stored at -80°C.
[0283] Once thawed, anti-CD3 / anti-CD28 coated magnetic beads (Dynabeads, Thermo Fisher) were used at 1×10 6 T cells were activated at a concentration of 10 cells / mL at a bead:cell ratio of 3:1. On day 1 after activation, lentivirus was added directly to the T cells. On day 4 after activation, magnetic beads were removed from the culture and added daily thereafter at a concentration of 0.5x106 T cells were cultured at 100 cells / mL. Medium supplemented with IL-2 and stabilizing agents was replaced every other day. For all CARs, transduction efficiencies were routinely 70-90%.
[0284] Flow cytometry
[0285] All samples were analyzed using LSR Fortessa (BD Bioscience) or Cytoflex (Beckman Coulter) and data were analyzed using FlowJo. Cells were washed twice with PBS and centrifuged at 1×10 6 Cells / mL were labeled with dye and then washed twice with FACS buffer (PBS supplemented with 2% FBS and 0.4% 0.5M EDTA). GD2 CAR was detected with 14g2a anti-idiotypic antibody (clone 1A7). CD19 CAR was detected with FMC63 anti-idiotypic antibody (clone 136.20.1). T cell phenotype was assessed by the following: CD4 (OKT4, Biolegend), CD8 (SK1, Biolegend), PD-1 (eBioJ105, eBioscience), TIM-3 (F38-2E2, Biolegend), LAG-3 (3DS223H, eBioscience), CD45RO (UCHL1, eBioscience), CCR7 (150503, BD Biosciences), CD69 (FN50, Biolegend), IL-2 (MQ1-17H12, Biolegend), and IFNγ (4S.B3, Biolegend). For co-culture assays in which cytokine production was assessed, tumor cells and CAR T cells were co-cultured in the presence of 1:1000 monensin (eBioscience) for at least 6 hours. When evaluating IL-2 and IFNγ, cells were surface stained, fixed, and permeabilized (eBioscience) before incubation with intracellular antibodies. All FACS plots showing CAR T cell phenotypic data were pre-gated on CAR+ cells. For mock-transduced T cells, the entire T cell population was used for analysis.
[0286] CyTOF
[0287] T cells are removed from the culture, fixed in 2% PFA for 10 minutes at room temperature, precipitated and frozen at -80°C. After thawing, each sample is barcoded with a 20-plex Pd barcode kit (Fluidigm). Cell samples are then collected and stained for 30 minutes at room temperature with regard to the surface marker expression of the heavy metal-conjugated antibody. The cells are then permeabilized in methanol and subsequently stained with heavy metal-conjugated anti-human T-bet (4B10, Biolegend) and anti-human Blimp-1 (ROS195G, Biolegend) for 30 minutes at room temperature. Samples are run on a Helios mass blood cell counter (Fluidigm) and analyzed using Cytobank online software.
[0288] Incucyte assay
[0289] 50,000 NALM6-GL-GD2 tumor cells were co-cultured with T cells in 200 μL of complete AimV medium without IL-2 supplementation in each well of a 96-well plate at an E:T ratio of 1:2 or 1:8. The plates were loaded into an incucyte and 488 nm fluorescence images were collected every 2 hours for 48-72 hours. GFP+ tumor cells were identified by size and fluorescence intensity masking, and the total integrated GFP intensity of all counted tumor cells in each individual well was quantified. Values were normalized to t = 0, and the average of replicate wells was taken for data display.
[0290] For experiments in which HA-GD2.28z.FKBP T cells were expanded in the absence of shield-1, 1 μM shield-1 was added to CAR T cells 18–24 h prior to co-culture with tumor cells.
[0291] Cytokine release assay
[0292] 50,000 NALM6-GL-GD2 tumor cells were co-cultured with T cells at a 1:1 E:T ratio in each well of a 96-well plate in 200 μL of complete AimV medium without IL-2 supplementation. After 24 hours, the supernatant was removed and stored at -20°C. IL-2 and IFNγ secretion were assessed by ELISA (Biolegend).
[0293] For experiments in which HA-GD2.28z.FKBP T cells were expanded in the absence of shield-1, 1 μM shield-1 was added to CAR T cells 18–24 h prior to co-culture with tumor cells.
[0294] Western blotting
[0295] 2x10 6 Individual CAR T cells were removed from the culture, pelleted, and resuspended in 100 μL of RIPA lysis buffer (10 mM Tris-Cl pH 8.0, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl) supplemented with phosphatase and protease inhibitors (Thermo Fisher). After incubation at 4°C for 30 minutes, the supernatant was cleared by centrifugation at 14,000 RPM for 20 minutes at 4°C. The protein concentration in the cleared lysate was measured by colorimetric reaction (BioRad).
[0296] 15 μg protein lysate was mixed with 6x loading buffer and loaded onto a 10% SDS-PAGE gel, which was assembled into a mini-protean electrophoresis system (BioRad). Electrophoresis was performed at 100V in tri-glycine-SDS buffer (BioRad) for 20 minutes, then increased to 150V for 50 minutes. Protein was transferred to an Immobilon-FL PVDF membrane at 100V in tri-glycine buffer (BioRad#1610771) for 1 hour. The primary antibody targeting CD3-ζ (Cellsignaling) and pY142-CD3-ζ (Cell Signaling) was used. Odyssey (LI-COR) imaging system, LI-COR buffer, and LI-COR secondary antibodies (goat anti-mouse IgG antibody-800CW-conjugated and goat anti-rabbit IgG antibody-680LT-conjugated) were used for protein detection.
[0297] In vivo experiments
[0298] 1x10 6 NALM6-GL-GD2 cells were implanted into 6-8 week old NSG mice. On day 7 after implantation, 1-5x10 6 GD2.28z.DHFR or HA-GD2.28z.DHFR CAR+ T cells. NALM6-GL-GD2 tumor burden was assessed using a Xenogen IVIS Lumina (Caliper Life Sciences). Mice were first injected intraperitoneally with 3 mg of D-luciferin (Caliper Life Sciences) and then imaged 4 minutes later with a 30-second exposure time, or with "self" exposure selected if signal saturation occurred at 30 seconds. Luminescent images were analyzed using Living Image software (Caliper Life Sciences).
[0299] Mice treated with trimethoprim were injected intraperitoneally at a concentration of 300 mg / kg. Mice treated with vehicle were injected intraperitoneally with an equal volume of water.
[0300] Blood samples were collected via retro-orbital bleeding and stored briefly in EDTA-coated microvettes (Kent Scientific). Spleens were mechanically disrupted by passing through a 70-μm filter (BD Biosciences). Blood and spleen were lysed in ACK lysis buffer (Fisher Scientific) for 5 minutes and subsequently stained with surface marker antibodies for FACS analysis.
[0301] Construction of CAR vector
[0302] All CAR sequences are inserted into the pELNS lentiviral backbone under the control of the EF-1α promoter. The destabilizing domain sequence is inserted into the downstream of the CD3z domain by the gene fragment (IDT Technologies) customized by subclone, and the customized gene fragment includes a part of CD3z sequence (starting from the intrinsic BmgBI restriction site), followed by destabilizing domain sequence, stop codon and SalI restriction site. Avoid the additional restriction sites not present in CD3z or DD sequences.
[0303] Each CAR comprises a signal peptide, a single-chain variable fragment (scFv), an extracellular hinge region, a transmembrane domain, an intracellular costimulatory domain, and an intracellular CD3-ζ domain.
[0304] result
[0305] First, the dose-dependent regulation of DD-CAR surface expression was tested for three different CARs fused to two different RDDs. CD19.28z, GD2.28z, and high-affinity GD2.28z (HA-GD2.28z) were each fused to a 12 kDa FK506 binding protein (FKBP) DD or an E. coli-derived dihydrofolate reductase (DHFR) DD. In separate experiments, the regulation of Her2.28z CAR fused to FKBP DD was also tested ( Figure 24 ). The rapalog shield-1 (S1) was used to stabilize the FKBP-fused CAR, while the FDA-approved antibiotic trimethoprim (TMP) was used to stabilize the DHFR-fused CAR. The stabilizing drug was incubated with DD-CART cells for at least 48 hours, after which surface CAR expression was assessed via FACS. The data showed that for all 7 tested CARs, there was an accurate dose-dependent regulation of surface CAR (see Figure 12 、 24 DD-CAR's different EC50 value( Figure 22 B) shows heterogeneity in the sensitivity of a given DD-CAR protein to stable drugs, regardless of the DD to which the CAR is fused. These studies also show intrinsic differences in DDs, as DHFR-fused CARs exhibit greater sensitivity to stable drugs than their FKBP-fused counterparts (see Figure 22 ). In addition, it was observed that not all RDDs confer instability on CAR proteins, even though they do so on other proteins (see Figure 23 Two previously published replicates of DHFR DD were tested on GD2.28z CAR (see Iwamoto et al., Chemistry & Biology 17, 981-988 (2010)), and one of them allowed drug-dependent modulation (see Figure 12 、 22 ,twenty three).
[0306] Next, the kinetics of drug-dependent regulation of DD-CAR was tested and characterized. DD-CAR T cells were cultured for at least 48 hours in the presence or absence of 1 μM stabilizing drug. For DD-CAR T cells cultured in the absence of drug, drug was introduced into the culture and samples were removed over the course of 48 hours to assess the increase in CAR surface expression (see Figure 13 , left side of each figure). In contrast, for DD-CAR T cells cultured in the presence of drug, the drug was removed from the culture to assess the reduction of CAR surface expression (see Figure 13 , right side of each figure). These studies indicate that DD-CAR surface expression gradually increases over the course of 24 hours after drug exposure. However, drug removal induces a rapid loss of approximately half of the DD-CAR surface expression within the first 2 hours, followed by a gradual loss of the remaining surface CAR over the next 46 hours. The rapid "off" kinetics of DD-CAR suggest that this CAR modulation approach offers a realistic therapeutic opportunity to mitigate CAR toxicity in a clinical setting.
[0307] The next step was to determine whether differences in DD-CAR surface expression would elicit different antitumor responses. Therefore, we assessed whether drug-dependent modulation of DD-CAR surface expression could also modulate T cell activation. Indeed, when DD-CAR T cells were co-cultured with antigen-bearing tumor cells in the absence of drug, negligible levels of cytokine secretion were observed compared to DD-CAR T cells co-cultured in the presence of stable drug (see Figure 14 A) and cytotoxicity (see Figure 14 B) Experiments were also performed in an in vivo setting.
[0308] Antigen-bearing tumors were implanted into mice, followed by infusion of CAR T cells. Mice were then injected daily with either stable drug or vehicle control. After only one dose of stable drug, drug-dependent upregulation of CAR expression similar to that observed in vitro was observed (see Figure 15 A). Higher levels of CD69 were also observed in mice given stable drugs, indicating that DD-CAR T cells with higher surface expression became more activated in response to tumors. Finally, on day 7 after CAR infusion, a significant reduction in tumor burden was observed in mice receiving stable drugs compared to those receiving vehicle controls. Overall, these data provide that CAR surface expression is closely related to CAR T cell activity, and therefore, RDD-CAR T cell activity can be precisely regulated via the administration of stable drugs (or lack thereof).
[0309] As described herein, many constitutively expressed CARs exhibit trophic signaling in the absence of antigen, thereby causing them to become exhausted (see Long et al., Nature Medicine 21, 581–590 (2015)). It was determined whether expanding DD-CAR T cells in the absence of a stable drug would attenuate this trophic signaling and thereby produce a healthier, more effective CAR T cell infusion product. One readout of trophic signaling is constitutive phosphorylation of the CAR CD3-ζ domain in the absence of antigen. HA-GD2.28z.FKBP CAR T cells exhibit this phenotype when cultured in the presence of S1 (see Figure 16 , CAR is always on). However, CD3-ζ phosphorylation is absent in DD-CAR T cells cultured in the absence of S1 (CAR is always off), suggesting that low CAR surface expression mitigates trophic signaling. This phenotype is also reversible, as illustrated by the lack of CD3-ζ phosphorylation in DD-CAR T cells that were initially cultured with S1 but then had the drug removed on day 7 of culture ( Figure 16 , CAR closes D7).
[0310] We next determined whether preventing or reversing trophic signaling in CAR T cells expressing HA-GD2.28z.FKBP would alter their exhausted phenotype. DD-CAR T cells expanded in the presence of drug (CAR always on) exhibited multiple inhibitory receptors (see Figure 17 A) and transcription factors commonly associated with T cell exhaustion ( Figure 17 However, DD-CAR T cells expanded in the absence of drug (CAR always off) or those expanded in the presence of drug on days 1-7 but not thereafter exhibited significantly less co-expression of exhaustion markers ( Figure 17Similarly, exhausted DD-CAR T cells expanded in the presence of drug displayed a high frequency of effector T cells and a concomitant low frequency of memory cells ( Figure 18 ), similar to what has been observed in the literature (see Wherry and Kurachi, Nature Reviews Immunology 15, nri3862 (2015). However, rescue of DD-CAR T cell memory was observed only by expanding cells in the absence of stable drug for at least 4 days, suggesting that mitigation of trophic signaling in CAR T cells can simultaneously prevent exhaustion and promote memory formation.
[0311] Next, it was determined whether the significant phenotypic changes observed when trophic signal transduction was alleviated could also be consistent with enhanced T cell function. To test this, DD-CAR T cells were amplified in the presence of a stable drug (CAR is always on) or in the absence of a stable drug (CAR is always off). In order to explore the plasticity of exhausted CAR T cells becoming rejuvenated, the cells were amplified in the presence of the drug for 7 or 10 days, and then the drug was removed, and the T cells were "rested" (CAR off D7 and CAR off D10, respectively). CART cells were then co-cultured with antigen-carrying tumors for 24 hours, and cytokine secretion was assessed via ELISA ( Figure 19 ) or they were co-cultured in incucyte for 72 h during the evaluation of cytotoxicity ( Figure 20 Importantly, regardless of the conditions in which DD-CAR T cells were cultured, drug was added to each condition 18–24 h prior to the co-culture assay to ensure normalization of CAR expression during the assay. CAR T cells expanded under drug (CAR always on) secreted low levels of IL-2 and IFNγ in response to tumors ( Figure 19 ) and exhibited weakened cytotoxicity ( Figure 20 ), consistent with the phenotype of exhausted T cells. In contrast, CAR T cells grown in the absence of drug secreted 2-10 times more cytokines ( Figure 19 ) and can limit tumor growth ( Figure 20 ), indicating that mitigation of trophic signaling profoundly enhances the functional capacity of CAR T cells. Furthermore, CAR T cells that underwent trophic signaling for 7 or 10 days but were provided with a 4-7 day “rest” before co-culture assays were functionally rejuvenated ( Figure 19 and 20 , CAR-off D7 and CAR-off D10). These observations suggest that DD-CAR T cells benefit from a “resting” period during which DD-CAR expression is low and allows the cells to become quiescent and form memory.
[0312] Based on in vitro functional studies, we determined whether switching DD-CAR T cell expression in vivo could provide an opportunity to prolong CAR T cell anti-tumor responses by limiting chronic antigen exposure and alleviating CAR T cell exhaustion. To test this, NSG mice were implanted with antigen-bearing tumor cells and subsequently infused with T cells expressing 2-5E6 HA-GD2.28z.DHFR. Thereafter, mice were given TMP daily.
[0313] Following infusion of DD-CAR, rapid antitumor responses were observed, but disease eventually relapsed, suggesting that CAR T cells can become dysfunctional or exhausted (see Figure 21 ). The mice were then given vehicle for 4 days to provide a period during which the DD-CAR T cells could recover (see Figure 21 During this time, tumor burden increased at a faster rate than in the early stage of TMP administration, indicating that the anti-tumor response was actually being down-regulated. After TMP was infused for 3 days ( Figure 21 , "restim"), profound rejuvenation of antitumor responses was observed in all mice tested ( Figure 21 ), similar to the in vitro observations ( Figure 19 、 20 Furthermore, two of three mice exhibited reduced tumor burden after reinfusion of TMP compared to before the resting period, suggesting that the benefit of repeated dosing may outweigh the temporary acceleration of tumor growth during vehicle infusion.
[0314] All publications and patents mentioned in the above specification are incorporated herein by reference. Various modifications and variations of the methods and systems of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the present invention has been described in conjunction with specific preferred embodiments, it should be understood that the claimed invention should not be unduly limited to such specific embodiments. Of course, it will be apparent to those skilled in the relevant art that various modifications may be made to the manner in which the present invention is practiced within the scope of the following claims. Sequence Listing <110> The Board of Trustees of the Leland Stanford Junior University <120> Methods for treating T cell exhaustion by inhibiting or modulating T cell receptor signaling <130> STDU2-35233 / WO-1 / ORD <150> US 62 / 479,930 <151> 2017-03-31 <160> 136 <170> PatentIn version 3.5 <210> 1 <211> 321 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 1 atggtgcagg tggaaaccat ctccccagga gacgggcgca ccttccccaa gcgcggccag 60 acctgcgtgg tgcactacac cgggatgctt ggagatggaa agaaagttga ctcctcccgg 120 gacagaaaca agccctttaa gtttatgcta ggcaagcagg aggtgatccg aggctgggaa 180 gaaggggttg cccagatgag tgtgggtcag ggagccaaac tgactatatc tccagattat 240 gcctatggtg ccactgggca cccaggcatc atcccaccac atgccactct cgtcttcgat 300 gtggagcttc tagaactgga a 321 <210> 2 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 2 Met Val Gln Val Glu Thr Ile Ser Pro Gly Asp Gly Arg Thr Phe Pro 1 5 10 15 Lys Arg Gly Gln Thr Cys Val Val His Tyr Thr Gly Met Leu Gly Asp 20 25 30 Gly Lys Lys Val Asp Ser Ser Arg Asp Arg Asn Lys Pro Phe Lys Phe 35 40 45 Met Leu Gly Lys Gln Glu Val Ile Arg Gly Trp Glu Glu Gly Val Ala 50 55 60 Gln Met Ser Val Gly Gln Gly Ala Lys Leu Thr Ile Ser Pro Asp Tyr 65 70 75 80 Ala Tyr Gly Ala Thr Gly His Pro Gly Ile Ile Pro Pro His Ala Thr 85 90 95 Leu Val Phe Asp Val Glu Leu Leu Glu Leu Glu 100 105 <210> 3 <211> 477 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 3 atgatcagtc tgattgcggc gttagcggta gatcacgtta tcggcatgga aaccgtcatg 60 ccgtggaacc tgcctgccga tctcgcctgg tttaaacgca acaccttaaa taaacccgtg 120 attatgggcc gccatacctg ggaatcaatc ggtcgtccgt tgccaggacg caaaaatatt 180 atcctcagca gtcaaccgag tacggacgat cgcgtaacgt gggtgaagtc ggtggatgaa 240 gccatcgcgg cgtgtggtga cgtaccagaa atcatggtta ttggcggcgg tcgcgtttat 300 gaacagttct tgccaaaagc gcaaaaactg tatctgacgc atatcgacgc agaagtggaa 360 ggcgacaccc atttcccgga ttacgagccg gatgactggg aatcggtatt cagcgaattc 420 cacgatgctg atgcgcagaa ctctcacagc tattgctttg agattctgga gcggcga 477 <210> 4 <211> 159 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 4 Met Ile Ser Leu Ile Ala Ala Leu Ala Val Asp His Val Ile Gly Met 1 5 10 15 Glu Thr Val Met Pro Trp Asn Leu Pro Ala Asp Leu Ala Trp Phe Lys 20 25 30 Arg Asn Thr Leu Asn Lys Pro Val Ile Met Gly Arg His Thr Trp Glu 35 40 45 Ser Ile Gly Arg Pro Leu Pro Gly Arg Lys Asn Ile Ile Leu Ser Ser 50 55 60 Gln Pro Ser Thr Asp Asp Arg Val Thr Trp Val Lys Ser Val Asp Glu 65 70 75 80 Ala Ile Ala Ala Cys Gly Asp Val Pro Glu Ile Met Val Ile Gly Gly 85 90 95 Gly Arg Val Tyr Glu Gln Phe Leu Pro Lys Ala Gln Lys Leu Tyr Leu 100 105 110 Thr His Ile Asp Ala Glu Val Glu Gly Asp Thr His Phe Pro Asp Tyr 115 120 125 Glu Pro Asp Asp Trp Glu Ser Val Phe Ser Glu Phe His Asp Ala Asp 130 135 140 Ala Gln Asn Ser His Ser Tyr Cys Phe Glu Ile Leu Glu Arg Arg 145 150 155 <210> 5 <211> 477 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 5 atgatcagtc tgattgcggc gttagcggta gattacgtta tcggcatgga aaacgccatg 60 ccgtggaacc tgcctgccga tctcgcctgg tttaaacgca acaccttaaa taaacccgtg 120 attatgggcc gccatacctg ggaatcaatc ggtcgtccgt tgccaggacg caaaaatatt 180 atcctcagca gtcaaccgag tacggacgat cgcgtaacgt gggtgaagtc ggtggatgaa 240 gccatcgcgg cgtgtggtga cgtaccagaa atcatggtga ttggcggcgg tcgcgttatt 300 gaacagttct tgccaaaagc gcaaaaactg tatctgacgc atatcgacgc agaagtggaa 360 ggcgacaccc atttcccgga ttacgagccg gatgactggg aatcggtatt cagcgaattc 420 cacgatgctg atgcgcagaa ctctcacagc tattgctttg agattctgga gcggcga 477 <210> 6 <211> 159 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 6 Met Ile Ser Leu Ile Ala Ala Leu Ala Val Asp Tyr Val Ile Gly Met 1 5 10 15 Glu Asn Ala Met Pro Trp Asn Leu Pro Ala Asp Leu Ala Trp Phe Lys 20 25 30 Arg Asn Thr Leu Asn Lys Pro Val Ile Met Gly Arg His Thr Trp Glu 35 40 45 Ser Ile Gly Arg Pro Leu Pro Gly Arg Lys Asn Ile Ile Leu Ser Ser 50 55 60 Gln Pro Ser Thr Asp Asp Arg Val Thr Trp Val Lys Ser Val Asp Glu 65 70 75 80 Ala Ile Ala Ala Cys Gly Asp Val Pro Glu Ile Met Val Ile Gly Gly 85 90 95 Gly Arg Val Ile Glu Gln Phe Leu Pro Lys Ala Gln Lys Leu Tyr Leu 100 105 110 Thr His Ile Asp Ala Glu Val Glu Gly Asp Thr His Phe Pro Asp Tyr 115 120 125 Glu Pro Asp Asp Trp Glu Ser Val Phe Ser Glu Phe His Asp Ala Asp 130 135 140 Ala Gln Asn Ser His Ser Tyr Cys Phe Glu Ile Leu Glu Arg Arg 145 150 155 <210> 7 <211> 1806 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 7 atgctgctgc tcgtgacatc tctgctgctg tgcgagctgc cccaccccgc ctttctgctg 60 atccccgata tcgacatcca gatgacacag actacatcct ccctgtctgc ctctctggga ...... gacagagtca ccatcagttg cagggcaagt caggacatta gtaaatattt aaattggtat 180 cagcagaaac cagatggaac tgttaaactc ctgatctacc atacatcaag attacactca 240 ggagtcccat caaggttcag tggcagtggg tctggaacag attattctct caccattagc 300 aacctggagc aagaagatat tgccacttac ttttgccaac agggtaatac gcttccgtac 360 acgttcggag gggggactaa gttggaaata acaggctcca cctctggatc cggcaagccc 420 ggatctggcg agggatccac caagggcgag gtgaaactgc aggagtcagg acctggcctg 480 gtggcgccct cacagagcct gtccgtcaca tgtactgtct caggggtctc attacccgac 540 tatggtgtaa gctggattcg ccagcctcca cgaaagggtc tggagtggct gggagtaata 600 tggggtagtg aaaccacata ctataattca gctctcaaat ccagactgac catcatcaag 660 gacaactcca agagccaagt tttcttaaaa atgaacagtc tgcaaactga tgacacagcc 720 attactact gtgccaaaca ttattactac ggtggtagct atgctatgga ctactggggt 780 caaggaacct cagtcaccgt ctcctcagct agcttcgaaa ttgaagttat gtatcctcct 840 ccttacctag acaatgagaa gagcaatgga accattatcc atgtgaaagg gaaacacctt 900 tgtccaagtc ccctatttcc cggaccttct aagccctttt gggtgctggt ggtggttggg 960 ggagtcctgg cttgctatag cttgctagta acagtggcct ttatatttt ctgggtgagg 1020 agtaagaga gcaggctcct gcacagtgac tacatgaaca tgactccccg ccgccccgggg 1080 cccacccgca agcattacca gccctatgcc ccaccacgcg acttcgcagc ctatcgctcc 1140 catatgagag tgaagttcag caggagcgca gacgccccg cgtacaagca gggccagaac 1200 1260 cgtggccggg accctgagat gggggaaag ccgagaagga agaaccctca ggaaggcctg 1320 1380 gagcgccgga ggggcaaggg gcacgatggc ctttaccagg gtctcagtac agccaccaag 1440 gacacctacg acgcccttca catgcaggcc ctgccccctc gcggagtgca ggtggaaacc 1500 atctccccag gagacgggcg caccttcccc aagcgcggcc agacctgcgt ggtgcactac 1560 accgggatgc ttggagatgg aaagaaagtt gactcctccc gggacagaaa caagcccttt 1620 aagtttatgc taggcaagca ggaggtgatc cgaggctggg aagaaggggt tgcccagatg 1680 agtgtgggtc agggagccaa actgactata tctccagatt atgcctatgg tgccactggg 1740 cacccaggca tcatcccacc acatgccact ctcgtcttcg atgtggagct tctagaactg 1800 gaatga 1806 <210> 8 <211> 601 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 8 Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro 1 5 10 15 Ala Phe Leu Leu Ile Pro Asp Ile Asp Ile Gln Met Thr Gln Thr Thr 20 25 30 Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg 35 40 45 Ala Ser Gln Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro 50 55 60 Asp Gly Thr Val Lys Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser 65 70 75 80 Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser 85 90 95 Leu Thr Ile Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys 100 105 110 Gln Gln Gly Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu 115 120 125 Glu Ile Thr Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu 130 135 140 Gly Ser Thr Lys Gly Glu Val Lys Leu Gln Glu Ser Gly Pro Gly Leu 145 150 155 160 Val Ala Pro Ser Gln Ser Leu Ser Val Thr Cys Thr Val Ser Gly Val 165 170 175 Ser Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro Arg Lys 180 185 190 Gly Leu Glu Trp Leu Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr 195 200 205 Asn Ser Ala Leu Lys Ser Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys 210 215 220 Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala 225 230 235 240 Ile Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met 245 250 255 Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ser Phe 260 265 270 Glu Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser 275 280 285 Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro 290 295 300 Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly 305 310 315 320 Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile 325 330 335 Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met 340 345 350 Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro 355 360 365 Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser His Met Arg Val 370 375 380 Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn 385 390 395 400 Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val 405 410 415 Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg 420 425 430 Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys 435 440 445 Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg 450 455 460 Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys 465 470 475 480 Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg Gly Val 485 490 495 Gln Val Glu Thr Ile Ser Pro Gly Asp Gly Arg Thr Phe Pro Lys Arg 500 505 510 Gly Gln Thr Cys Val Val His Tyr Thr Gly Met Leu Gly Asp Gly Lys 515 520 525 Lys Val Asp Ser Ser Arg Asp Arg Asn Lys Pro Phe Lys Phe Met Leu 530 535 540 Gly Lys Gln Glu Val Ile Arg Gly Trp Glu Glu Gly Val Ala Gln Met 545 550 555 560 Ser Val Gly Gln Gly Ala Lys Leu Thr Ile Ser Pro Asp Tyr Ala Tyr 565 570 575 Gly Ala Thr Gly His Pro Gly Ile Ile Pro Pro His Ala Thr Leu Val 580 585 590 Phe Asp Val Glu Leu Leu Glu Leu Glu 595 600 <210> 9 <211> 66 <212> DNA <213> Artificial Sequence <220> <223> synthesis <400> 9 atgctgctgc tcgtgacatc tctgctgctg tgcgagctgc cccaccccgc ctttctgctg 60 atcccc 66 <210> 10 <211> twenty two <212> PRT <213> Artificial Sequence <220> <223> synthesis <400> 10 Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro 1 5 10 15 Ala Phe Leu Leu Ile Pro 20 <210> 11 <211> 735 <212> DNA <213> Artificial Sequence <220> <223> Synthesis <400> 11 gacatccaga tgacacagac tacatcctcc ctgtctgcct ctctgggaga cagagtcacc 60 atcagttgca gggcaagtca ggacattagt aaatatttaa attggtatca gcagaaacca 120 gatggaactg ttaaactcct gatctaccat acatcaagat tacactcagg agtcccatca 180 aggttcagtg gcagtgggtc tggaacagat tattctctca ccattagcaa cctggagcaa 240 gaagatattg ccacttactt ttgccaacag ggtaatacgc ttccgtacac gttcggaggg 300 gggactaagt tggaaataac aggctccacc tctggatccg gcaagcccgg atctggcgag 360 ggatccacca agggcgaggt gaaactgcag gagtcaggac ctggcctggt ggcgccctca 420 cagagcctgt ccgtcacatg tactgtctca ggggtctcat tacccgacta tggtgtaagc 480 tggattcgcc agcctccacg aaagggtctg gagtggctgg gagtaatatg gggtagtgaa 540 accacatact ataattcagc tctcaaatcc agactgacca tcatcaagga caactccaag 600 agccaagttt tcttaaaaat gaacagtctg caaactgatg acacagccat ttactactgt 660 gccaaacatt attactacgg tggtagctat gctatggact actggggtca aggaacctca 720 gtcaccgtct cctca 735 <210> 12 <211> 245 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 12 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40 45 Tyr His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr Gly Ser Thr Ser Gly 100 105 110 Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Val Lys 115 120 125 Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser Leu Ser 130 135 140 Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly Val Ser 145 150 155 160 Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly Val Ile 165 170 175 Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser Arg Leu 180 185 190 Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Met Asn 195 200 205 Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys His Tyr 210 215 220 Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 225 230 235 240 Val Thr Val Ser Ser 245 <210> 13 <211> 117 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 13 attgaagtta tgtatcctcc tccttaccta gacaatgaga agagcaatgg aaccattatc 60 catgtgaaag ggaaacacct ttgtccaagt cccctatttc ccggaccttc taagccc 117[[ID=*6]] <210> 14 <211> 39 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 14 Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn 1 5 10 15 Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu 20 25 30 Phe Pro Gly Pro Ser Lys Pro 35 <210> 15 <211> 81 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 15 ttttgggtgc tggtggtggt tgggggagtc ctggcttgct atagcttgct agtaacagtg 60 gcctttatta ttttctgggt g 81 <210> 16 <211> 27 <212> PRT <213> Artificial Sequence <220> <223> Synthesis <400> 16 Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu 1 5 10 15 Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val 20 25 <210> 17 <211> 123 <212> DNA <213> Artificial Sequence <220> <223> Synthesis <400> 17 aggagtaaga ggagcaggct cctgcacagt gactacatga acatgactcc ccgccgcccc 60 gggcccaccc gcaagcatta ccagccctat gccccaccac gcgacttcgc agcctatcgc 120 tcc 123 <210> 18 <211> 41 <212> PRT <213> Artificial Sequence <220> <223> Synthesis <400> 18 Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr 1 5 10 15 Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro 20 25 30 Pro Arg Asp Phe Ala Ala Tyr Arg Ser 35 40 <210> 19 <211> 336 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 19 agagtgaagt tcagcaggag cgcagacgcc cccgcgtaca agcagggcca gaaccagctc 60 tataacgagc tcaatctagg acgaagagag gagtacgatg ttttggacaa gagacgtggc 120 cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat 180 gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc 240 cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc 300 tacgacgccc ttcacatgca ggccctgccc cctcgc 336 <210> 20 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 20 Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly 1 5 10 15 Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr 20 25 30 Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys 35 40 45 Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys 50 55 60 Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg 65 70 75 80 Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala 85 90 95 Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 100 105 110 <210> 21 <211> 321 <212> DNA0001185<213> Artificial Sequence <220> <223> Synthetic <400> 21 ggagtgcagg tggaaaccat ctccccagga gacgggcgca ccttccccaa gcgcggccag 60 acctgcgtgg tgcactacac cgggatgctt ggagatggaa agaaagttga ctcctcccgg 120 gacagaaaca agccctttaa gtttatgcta ggcaagcagg aggtgatccg aggctgggaa 180 It should be noted that in the original text, there is an apparent error in the tag . It is written as but has an extra closing tag "]" in the example you provided. I have translated it as 0001185 to maintain the integrity of the translation while indicating that the original might have an issue. If this is not what you intended, please correct the original text for a more accurate translation.gaaggggttg cccagatgag tgtgggtcag ggagccaaac tgactatatc tccagattat 240 gcctatggtg ccactgggca cccaggcatc atcccaccac atgccactct cgtcttcgat 300 gtggagcttc tagaactgga a 321 <210> 22 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 22 Gly Val Gln Val Glu Thr Ile Ser Pro Gly Asp Gly Arg Thr Phe Pro 1 5 10 15 Lys Arg Gly Gln Thr Cys Val Val His Tyr Thr Gly Met Leu Gly Asp 20 25 30 Gly Lys Lys Val Asp Ser Ser Arg Asp Arg Asn Lys Pro Phe Lys Phe 35 40 45 Met Leu Gly Lys Gln Glu Val Ile Arg Gly Trp Glu Glu Gly Val Ala 50 55 60 Gln Met Ser Val Gly Gln Gly Ala Lys Leu Thr Ile Ser Pro Asp Tyr 65 70 75 80 Ala Tyr Gly Ala Thr Gly His Pro Gly Ile Ile Pro Pro His Ala Thr 85 90 95 Leu Val Phe Asp Val Glu Leu Leu Glu Leu Glu 100 105 <210> 23 <211> 1959 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 23 atgctgctgc tcgtgacatc tctgctgctg tgcgagctgc cccaccccgc ctttctgctg 60 atccccgata tcgacatcca gatgacacag actacatcct ccctgtctgc ctctctggga 120 gacagagtca ccatcagttg cagggcaagt caggacatta gtaaatattt aaattggtat 180 cagcagaaac cagatggaac tgttaaactc ctgatctacc atacatcaag attacactca 240 ggagtcccat caaggttcag tggcagtggg tctggaacag attattctct caccattagc 300 aacctggagc aagaagatat tgccacttac ttttgccaac agggtaatac gcttccgtac 360 acgttcggag gggggactaa gttggaaata acaggctcca cctctggatc cggcaagccc 420 ggatctggcg agggatccac caagggcgag gtgaaactgc aggagtcagg acctggcctg 480 gtggcgccct cacagagcct gtccgtcaca tgtactgtct caggggtctc attacccgac 540 tatggtgtaa gctggattcg ccagcctcca cgaaagggtc tggagtggct gggagtaata 600 tggggtagtg aaaccacata ctataattca gctctcaaat ccagactgac catcatcaag 660 gacaactcca agagccaagt tttcttaaaa atgaacagtc tgcaaactga tgacacagcc 720 attactact gtgccaaaca ttattactac ggtggtagct atgctatgga ctactggggt 780 caaggaacct cagtcaccgt ctcctcagct agcttcgaaa ttgaagttat gtatcctcct 840 900 tgtccaagtc ccctatttcc cggaccttct aagccctttt gggtgctggt ggtggttggg 960 ggagtcctgg cttgctatag cttgctagta acagtggcct ttatatttt ctgggtgagg 1020 agtaagaga gcaggctcct gcacagtgac tacatgaaca tgactccccg ccgccccgggg 1080 cccacccgca agcattacca gccctatgcc ccaccacgcg acttcgcagc ctatcgctcc 1140 catatgagag tgaagttcag caggagcgca gacgccccg cgtacaagca gggccagaac 1200 1260 cgtggccggg accctgagat gggggaaag ccgagaagga agaaccctca ggaaggcctg 1320 tacaatgaac tgcagaaaga taagatggcg gaggcctaca gtgagattgg gatgaaaggc 1380 gagcgccgga ggggcaaggg gcacgatggc ctttaccagg gtctcagtac agccaccaag 1440 gacacctacg acgcccttca catgcaggcc ctgccccctc gcatcagtct gattgcggcg 1500 ttagcggtag attacgttat cggcatggaa aacgccatgc cgtggaacct gcctgccgat 1560 ctcgcctggt ttaaacgcaa caccttaaat aaacccgtga ttatgggccg ccatacctgg 1620 gaatcaatcg gtcgtccgtt gccaggacgc aaaaatatta tcctcagcag tcaaccgagt 1680 acggacgatc gcgtaacgtg ggtgaagtcg gtggatgaag ccatcgcggc gtgtggtgac 1740 gtaccagaaa tcatggtgat tggcggcggt cgcgttattg aacagttctt gccaaaagcg 1800 caaaaactgt atctgacgca tatcgacgca gaagtggaag gcgacaccca tttcccggat 1860 tacgagccgg atgactggga atcggtattc agcgaattcc acgatgctga tgcgcagaac 1920 tctcacagct attgctttga gattctggag cggcgatga 1959 <210> 24 <211> 652 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 24 Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro 1 5 10 15 Ala Phe Leu Leu Ile Pro Asp Ile Asp Ile Gln Met Thr Gln Thr Thr 20 25 30 Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg 35 40 45 Ala Ser Gln Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro 50 55 60 Asp Gly Thr Val Lys Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser 65 70 75 80 Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser 85 90 95 Leu Thr Ile Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys 100 105 110 Gln Gln Gly Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu 115 120 125 Glu Ile Thr Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu 130 135 140 Gly Ser Thr Lys Gly Glu Val Lys Leu Gln Glu Ser Gly Pro Gly Leu 145 150 155 160 Val Ala Pro Ser Gln Ser Leu Ser Val Thr Cys Thr Val Ser Gly Val 165 170 175 Ser Leu Pro Asp Tyr Gly Val Ser Trp Ile Arg Gln Pro Pro Arg Lys 180 185 190 Gly Leu Glu Trp Leu Gly Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr 195 200 205 Asn Ser Ala Leu Lys Ser Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys 210 215 220 Ser Gln Val Phe Leu Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala 225 230 235 240 Ile Tyr Tyr Cys Ala Lys His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met 245 250 255 Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ser Phe 260 265 270 Glu Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser 275 280 285 Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro 290 295 300 Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly 305 310 315 320 Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile 325 330 335 Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met 340 345 350 Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro 355 360 365 Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser His Met Arg Val 370 375 380 Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn 385 390 395 400 Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val 405 410 415 Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg 420 425 430 Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys 435 440 445 Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg 450 455 460 Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys 465 470 475 480 Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg Ile Ser 485 490 495 Leu Ile Ala Ala Leu Ala Val Asp Tyr Val Ile Gly Met Glu Asn Ala 500 505 510 Met Pro Trp Asn Leu Pro Ala Asp Leu Ala Trp Phe Lys Arg Asn Thr 515 520 525 Leu Asn Lys Pro Val Ile Met Gly Arg His Thr Trp Glu Ser Ile Gly 530 535 540 Arg Pro Leu Pro Gly Arg Lys Asn Ile Ile Leu Ser Ser Gln Pro Ser 545 550 555 560 Thr Asp Asp Arg Val Thr Trp Val Lys Ser Val Asp Glu Ala Ile Ala 565 570 575 Ala Cys Gly Asp Val Pro Glu Ile Met Val Ile Gly Gly Gly Arg Val 580 585 590 Ile Glu Gln Phe Leu Pro Lys Ala Gln Lys Leu Tyr Leu Thr His Ile 595 600 605 Asp Ala Glu Val Glu Gly Asp Thr His Phe Pro Asp Tyr Glu Pro Asp 610 615 620 Asp Trp Glu Ser Val Phe Ser Glu Phe His Asp Ala Asp Ala Gln Asn 625 630 635 640 Ser His Ser Tyr Cys Phe Glu Ile Leu Glu Arg Arg 645 650 <210> 25 <211> 66 <212> DNA <213> Artificial Sequence <220> <223> synthesis <400> 25 atgctgctgc tcgtgacatc tctgctgctg tgcgagctgc cccaccccgc ctttctgctg 60 atcccc 66 <210> 26 <211> twenty two <212> PRT <213> Artificial Sequence <220> <223> synthesis <400> 26 Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro 1 5 10 15 Ala Phe Leu Leu Ile Pro 20 <210> 27 <211> 735 <212> DNA <213> Artificial Sequence <220> <223> Synthesis <400> 27 gacatccaga tgacacagac tacatcctcc ctgtctgcct ctctgggaga cagagtcacc 60 atcagttgca gggcaagtca ggacattagt aaatatttaa attggtatca gcagaaacca 120 gatggaactg ttaaactcct gatctaccat acatcaagat tacactcagg agtcccatca 180 aggttcagtg gcagtgggtc tggaacagat tattctctca ccattagcaa cctggagcaa 240 gaagatattg ccacttactt ttgccaacag ggtaatacgc ttccgtacac gttcggaggg 300 gggactaagt tggaaataac aggctccacc tctggatccg gcaagcccgg atctggcgag 360 ggatccacca agggcgaggt gaaactgcag gagtcaggac ctggcctggt ggcgccctca 420 cagagcctgt ccgtcacatg tactgtctca ggggtctcat tacccgacta tggtgtaagc 480 tggattcgcc agcctccacg aaagggtctg gagtggctgg gagtaatatg gggtagtgaa 540 accacatact ataattcagc tctcaaatcc agactgacca tcatcaagga caactccaag 600 agccaagttt tcttaaaaat gaacagtctg caaactgatg acacagccat ttactactgt 660 gccaaacatt attactacgg tggtagctat gctatggact actggggtca aggaacctca 720 gtcaccgtct cctca 735 <210> 28 <211> 245 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 28 Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Lys Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40 45 Tyr His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr Gly Ser Thr Ser Gly 100 105 110 Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Val Lys 115 120 125 Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser Leu Ser 130 135 140 Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly Val Ser 145 150 155 160 Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly Val Ile 165 170 175 Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser Arg Leu 180 185 190 Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Met Asn 195 200 205 Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys His Tyr 210 215 220 Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 225 230 235 240 Val Thr Val Ser Ser 245 <210> 29 <211> 117 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 29 attgaagtta tgtatcctcc tccttaccta gacaatgaga agagcaatgg aaccattatc 60 catgtgaaag ggaaacacct ttgtccaagt cccctatttc ccggaccttc taagccc 117 <210> 30 <211> 39 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 30 Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn 1 5 10 15 Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu 20 25 30 Phe Pro Gly Pro Ser Lys Pro 35 <210> 31 <211> 81 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 31 ttttgggtgc tggtggtggt tgggggagtc ctggcttgct atagcttgct agtaacagtg 60 gcctttatta ttttctgggt g 81 <210> 32 <211> 27 <212> PRT <213> Artificial Sequence <220> <223> Synthesis <400> 32 Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu 1 5 10 15 Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val 20 25 <210> 33 <211> 123 <212> DNA <213> Artificial Sequence <220> <223> Synthesis <400> 33 aggagtaaga ggagcaggct cctgcacagt gactacatga acatgactcc ccgccgcccc 60 gggcccaccc gcaagcatta ccagccctat gccccaccac gcgacttcgc agcctatcgc 120 tcc 123 <210> 34 <211> 41 <212> PRT <213> Artificial Sequence <220> <223> Synthesis <400> 34 Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr 1 5 10 15 Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro 20 25 30 Pro Arg Asp Phe Ala Ala Tyr Arg Ser 35 40 <210> 35 <211> 336 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 35 agagtgaagt tcagcaggag cgcagacgcc cccgcgtaca agcagggcca gaaccagctc 60 tataacgagc tcaatctagg acgaagagag gagtacgatg ttttggacaa gagacgtggc 120 cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat 180 gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc 240 cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc 300 tacgacgccc ttcacatgca ggccctgccc cctcgc 336 <210> 36 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 36 Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly 1 5 10 15 Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr 20 25 30 Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys 35 40 45 Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys 50 55 60 Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg 65 70 75 80 Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala 85 90 95 Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 100 105 110 <210> 37 <211> 474 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 37 atcagtctga ttgcggcgtt agcggtagat tacgttatcg gcatggaaaa cgccatgccg 60 tggaacctgc ctgccgatct cgcctggttt aaacgcaaca ccttaaataa acccgtgatt 120 atgggccgcc atacctggga atcaatcggt cgtccgttgc caggacgcaa aaatattatc 180 ctcagcagtc aaccgagtac ggacgatcgc gtaacgtggg tgaagtcggt ggatgaagcc 240 atcgcggcgt gtggtgacgt accagaaatc atggtgattg gcggcggtcg cgttattgaa 300 cagttcttgc caaaagcgca aaaactgtat ctgacgcata tcgacgcaga agtggaaggc 360 gacacccatt tcccggatta cgagccggat gactgggaat cggtattcag cgaattccac 420 gatgctgatg cgcagaactc tcacagctat tgctttgaga ttctggagcg gcga 474 <210> 38 <211> 158 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 38 Ile Ser Leu Ile Ala Ala Leu Ala Val Asp Tyr Val Ile Gly Met Glu 1 5 10 15 Asn Ala Met Pro Trp Asn Leu Pro Ala Asp Leu Ala Trp Phe Lys Arg 20 25 30 Asn Thr Leu Asn Lys Pro Val Ile Met Gly Arg His Thr Trp Glu Ser 35 40 45 Ile Gly Arg Pro Leu Pro Gly Arg Lys Asn Ile Ile Leu Ser Ser Gln 50 55 60 Pro Ser Thr Asp Asp Arg Val Thr Trp Val Lys Ser Val Asp Glu Ala 65 70 75 80 Ile Ala Ala Cys Gly Asp Val Pro Glu Ile Met Val Ile Gly Gly Gly 85 90 95 Arg Val Ile Glu Gln Phe Leu Pro Lys Ala Gln Lys Leu Tyr Leu Thr 100 105 110 His Ile Asp Ala Glu Val Glu Gly Asp Thr His Phe Pro Asp Tyr Glu 115 120 125 Pro Asp Asp Trp Glu Ser Val Phe Ser Glu Phe His Asp Ala Asp Ala 130 135 140 Gln Asn Ser His Ser Tyr Cys Phe Glu Ile Leu Glu Arg Arg 145 150 155 <210> 39 <211> 1791 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 39 atgctgctgc tcgtgacatc tctgctgctg tgcgagctgc cccaccccgc ctttctgctg 60 atccccgata tcctgctgac ccagacccct ctgagcctgc ctgtgtctct gggcgatcag 120 gccagcatca gctgcagatc cagccagagc ctggtgcacc ggaacggcaa cacctacctg 180 cactggtatc tgcagaagcc cggccagagc cccaagctgc tgattcacaa ggtgtccaac 240 cggttcagcg gcgtgcccga cagattttct ggcagcggct ccggcaccga cttcaccctg 300 aagatcagcc gggtggaagc cgaggacctg ggcgtgtact tctgcagcca gtccacccac 360 gtgccccccc tgacatttgg cgccggaaca aagctggaac tgaagggcag cacaagcggc 420 agcggcaagc ctggatctgg cgagggaagc accaagggcg aagtgaagct gcagcagagc 480 ggcccctctc tggtggaacc tggcgcctct gtgatgatct cctgcaaggc cagcggcagc 540 tccttcaccg gctacaacat gaactgggtg cgccagaaca tcggcaagag cctggaatgg 600 atcggcgcca tcgaccccta ctacggcggc accagctaca accagaagtt caagggcaga 660 gccaccctga ccgtggacaa gagcagctcc accgcctaca tgcacctgaa gtccctgacc 720 agcgaggaca gcgccgtgta ctactgcgtg tccggcatgg aatactgggg ccagggcaca 780 agcgtgaccg tgtcctctgc tagcttcgaa attgaagtta tgtatcctcc tccttaccta 840 gacaatgaga agagcaatgg aaccattatc catgtgaaag ggaaacacct ttgtccaagt 900 cccctatttc ccggaccttc taagcccttt tgggtgctgg tggtggttgg gggagtcctg 960 gcttgctata gcttgctagt aacagtggcc tttattattt tctgggtgag gagtaagagg 1020 agcaggctcc tgcacagtga ctacatgaac atgactcccc gccgccccgg gcccaccgcg 1080 aagcattacc agccctatgc cccaccacgc gacttcgcag cctatcgctc cagagtgaag 1140 ttcagcagga gcgcagacgc ccccgcgtac aagcagggcc agaaccagct ctataacgag 1200 ctcaatctag your hand ggagtacgat gttttggaca agagacgtgg ccgggaccct 1260 gagatggggg gaaagccgag aaagaac cctcaggaag gcctgtacaa tgaactgcag 1320 aaagataaga tggcggaggc ctacagtgag attgggatga aaggcgagcg ccggaggggc 1380 aaggggcacg atggccttta ccagggtctc agtacagcca ccaaggacac ctacgacgcc 1440 cttcacatgc aggccctgcc ccctcgcgga gtgcaggtgg aaaccatctc cccaggagac 1500 gggcgcacct tccccaagcg cggccagacc tgcgtggtgc actacaccgg gatgcttgga 1560 gatggaaaga aagttgactc ctcccgggac agaaaagc cctttaagtt tatgctaggc 1620 aagcaggagg tgatccgagg ctgggaagaa ggggttgccc agatgagtgt gggtcaggga 1680 gccaaactga ctatatctcc agattatgcc tatggtgcca ctgggcaccc aggcatcatc 1740 ccaccacatg ccactctcgt cttcgatgtg gagcttctag aactggaatg a 1791 <210> 40 <211> 596 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 40 Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro 1 5 10 15 Ala Phe Leu Leu Ile Pro Asp Ile Leu Leu Thr Gln Thr Pro Leu Ser 20 25 30 Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser 35 40 45 Gln Ser Leu Val His Arg Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu 50 55 60 Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile His Lys Val Ser Asn 65 70 75 80 Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr 85 90 95 Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val 100 105 110 Tyr Phe Cys Ser Gln Ser Thr His Val Pro Pro Leu Thr Phe Gly Ala 115 120 125 Gly Thr Lys Leu Glu Leu Lys Gly Ser Thr Ser Gly Ser Gly Lys Pro 130 135 140 Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Val Lys Leu Gln Gln Ser 145 150 155 160 Gly Pro Ser Leu Val Glu Pro Gly Ala Ser Val Met Ile Ser Cys Lys 165 170 175 Ala Ser Gly Ser Ser Phe Thr Gly Tyr Asn Met Asn Trp Val Arg Gln 180 185 190 Asn Ile Gly Lys Ser Leu Glu Trp Ile Gly Ala Ile Asp Pro Tyr Tyr 195 200 205 Gly Gly Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr 210 215 220 Val Asp Lys Ser Ser Ser Thr Ala Tyr Met His Leu Lys Ser Leu Thr 225 230 235 240 Ser Glu Asp Ser Ala Val Tyr Tyr Cys Val Ser Gly Met Glu Tyr Trp 245 250 255 Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ser Phe Glu Ile Glu 260 265 270 Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr 275 280 285 Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro 290 295 300 Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu 305 310 315 320 Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val 325 330 335 Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr 340 345 350 Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro 355 360 365 Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser 370 375 380 Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu 385 390 395 400 Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg 405 410 415 Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln 420 425 430 Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr 435 440 445 Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp 450 455 460 Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala 465 470 475 480 Leu His Met Gln Ala Leu Pro Pro Arg Gly Val Gln Val Glu Thr Ile 485 490 495 Ser Pro Gly Asp Gly Arg Thr Phe Pro Lys Arg Gly Gln Thr Cys Val 500 505 510 Val His Tyr Thr Gly Met Leu Gly Asp Gly Lys Lys Val Asp Ser Ser 515 520 525 Arg Asp Arg Asn Lys Pro Phe Lys Phe Met Leu Gly Lys Gln Glu Val 530 535 540 Ile Arg Gly Trp Glu Glu Gly Val Ala Gln Met Ser Val Gly Gln Gly 545 550 555 560 Ala Lys Leu Thr Ile Ser Pro Asp Tyr Ala Tyr Gly Ala Thr Gly His 565 570 575 Pro Gly Ile Ile Pro Pro His Ala Thr Leu Val Phe Asp Val Glu Leu 580 585 590 Leu Glu Leu Glu 595 <210> 41 <211> 66 <212> DNA <213> Artificial Sequence <220> <223> synthesis <400> 41 atgctgctgc tcgtgacatc tctgctgctg tgcgagctgc cccaccccgc ctttctgctg 60 atcccc 66 <210> 42 <211> twenty two <212> PRT <213> Artificial Sequence <220> <223> synthesis <400> 42 Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro 1 5 10 15 Ala Phe Leu Leu Ile Pro 20 <210> 43 <211> 732 <212> DNA <213> Artificial Sequence <220> <223> synthesis <400> 43 gatatcctgc tgacccagac ccctctgagc ctgcctgtgt ctctgggcga tcaggccagc 60 atcagctgca gatccagcca gagcctggtg caccggaacg gcaacaccta cctgcactgg 120 tatctgcaga agcccggcca gagccccaag ctgctgattc acaaggtgtc caaccggttc 180 agcggcgtgc ccgacagatt ttctggcagc ggctccggca ccgacttcac cctgaagatc 240 agccgggtgg aagccgagga cctgggcgtg tacttctgca gccagtccac ccacgtgccc 300 cccctgacat ttggcgccgg aacaaagctg gaactgaagg gcagcacaag cggcagcggc 360 aagcctggat ctggcgaggg aagcaccaag ggcgaagtga agctgcagca gagcggcccc 420 tctctggtgg aacctggcgc ctctgtgatg atctcctgca aggccagcgg cagctccttc 480 accggctaca acatgaactg ggtgcgccag aacatcggca agagcctgga atggatcggc 540 gccatcgacc cctactacgg cggcaccagc tacaaccaga agttcaaggg cagagccacc 600 ctgaccgtgg acaagagcag ctccaccgcc tacatgcacc tgaagtccct gaccagcgag 660 gacagcgccg tgtactactg cgtgtccggc atggaatact ggggccaggg cacaagcgtg 720 accgtgtcct ct 732 <210> 44 <211> 244 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 44 Asp Ile Leu Leu Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Arg 20 25 30 Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile His Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser 85 90 95 Thr His Val Pro Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu 100 105 110 Lys Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser 115 120 125 Thr Lys Gly Glu Val Lys Leu Gln Gln Ser Gly Pro Ser Leu Val Glu 130 135 140 Pro Gly Ala Ser Val Met Ile Ser Cys Lys Ala Ser Gly Ser Ser Phe 145 150 155 160 Thr Gly Tyr Asn Met Asn Trp Val Arg Gln Asn Ile Gly Lys Ser Leu 165 170 175 Glu Trp Ile Gly Ala Ile Asp Pro Tyr Tyr Gly Gly Thr Ser Tyr Asn 180 185 190 Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ser Ser 195 200 205 Thr Ala Tyr Met His Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val 210 215 220 Tyr Tyr Cys Val Ser Gly Met Glu Tyr Trp Gly Gln Gly Thr Ser Val 225 230 235 240 Thr Val Ser Ser <210> 45 <211> 117 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 45 attgaagtta tgtatcctcc tccttaccta gacaatgaga agagcaatgg aaccattatc 60 catgtgaaag ggaaacacct ttgtccaagt cccctatttc ccggaccttc taagccc 117 <210> 46 <211> 39 <212> PRT <213> Artificial Sequence <220> <223> synthesis <400> 46 Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn 1 5 10 15 Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu 20 25 30 Phe Pro Gly Pro Ser Lys Pro 35 <210> 47 <211> 81 <212> DNA <213> Artificial Sequence <220> <223> synthesis <400> 47 ttttgggtgc tggtggtggt tgggggagtc ctggcttgct atagcttgct agtaacagtg 60 gcctttatta ttttctgggt g 81 <210> 48 <211> 27 <212> PRT <213> Artificial Sequence <220> <223> synthesis <400> 48 Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu 1 5 10 15 Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val 20 25 <210> 49 <211> 123 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 49 aggagtaaga ggagcaggct cctgcacagt gactacatga acatgactcc ccgccgcccc 60 gggcccaccc gcaagcatta ccagccctat gccccaccac gcgacttcgc agcctatcgc 120 tcc 123 <210> 50 <211> 41 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 50 Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr 1 5 10 15 Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro 20 25 30 Pro Arg Asp Phe Ala Ala Tyr Arg Ser 35 40 <210> 51 <211> 336 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 51 agagtgaagt tcagcaggag cgcagacgcc cccgcgtaca agcagggcca gaaccagctc 60 tataacgagc tcaatctagg acgaagagag gagtacgatg ttttggacaa gagacgtggc 120 cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat 180 gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc 240 cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc 300 tacgacgccc ttcacatgca ggccctgccc cctcgc 336 <210> 52 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 52 Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly 1 5 10 15 Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr 20 25 30 Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys 35 40 45 Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys 50 55 60 Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg 65 70 75 80 Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala 85 90 95 Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 100 105 110 <210> 53 <211> 321 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 53 ggagtgcagg tggaaaccat ctccccagga gacgggcgca ccttccccaa gcgcggccag 60 acctgcgtgg tgcactacac cgggatgctt ggagatggaa agaaagttga ctcctcccgg 120 gacagaaaca agccctttaa gtttatgcta ggcaagcagg aggtgatccg aggctgggaa 180 gaaggggttg cccagatgag tgtgggtcag ggagccaaac tgactatatc tccagattat 240 gcctatggtg ccactgggca cccaggcatc atcccaccac atgccactct cgtcttcgat 300 gtggagcttc tagaactgga a 321 <210> 54 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 54 Gly Val Gln Val Glu Thr Ile Ser Pro Gly Asp Gly Arg Thr Phe Pro 1 5 10 15 Lys Arg Gly Gln Thr Cys Val Val His Tyr Thr Gly Met Leu Gly Asp 20 25 30 Gly Lys Lys Val Asp Ser Ser Arg Asp Arg Asn Lys Pro Phe Lys Phe 35 40 45 Met Leu Gly Lys Gln Glu Val Ile Arg Gly Trp Glu Glu Gly Val Ala 50 55 60 Gln Met Ser Val Gly Gln Gly Ala Lys Leu Thr Ile Ser Pro Asp Tyr 65 70 75 80 Ala Tyr Gly Ala Thr Gly His Pro Gly Ile Ile Pro Pro His Ala Thr 85 90 95 Leu Val Phe Asp Val Glu Leu Leu Glu Leu Glu 100 105 <210> 55 <211> 1944 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 55 atgctgctgc tcgtgacatc tctgctgctg tgcgagctgc cccaccccgc ctttctgctg 60 atccccgata tcctgctgac ccagacccct ctgagcctgc ctgtgtctct gggcgatcag 120 gccagcatca gctgcagatc cagccagagc ctggtgcacc ggaacggcaa cacctacctg 180 cactggtatc tgcagaagcc cggccagagc cccaagctgc tgattcacaa ggtgtccaac 240 cggttcagcg gcgtgcccga cagattttct ggcagcggct ccggcaccga cttcaccctg 300 aagatcagcc gggtggaagc cgaggacctg ggcgtgtact tctgcagcca gtccacccac 360 gtgccccccc tgacatttgg cgccggaaca aagctggaac tgaagggcag cacaagcggc 420 agcggcaagc ctggatctgg cgagggaagc accaagggcg aagtgaagct gcagcagagc 480 ggcccctctc tggtggaacc tggcgcctct gtgatgatct cctgcaaggc cagcggcagc 540 tccttcaccg gctacaacat gaactgggtg cgccagaaca tcggcaagag cctggaatgg 600 660 gccaccctga ccgtggacaa gagcagctcc accgcctaca tgcacctgaa gtccctgacc 720 agcgaggaca gcgccgtgta ctactgcgtg tccggcatgg aatactgggg ccagggcaca 780 agcgtgaccg tgtcctctgc tagcttgaa attgaagtta tgtatcctcc tccttaccta 840 900 cccctatttc ccggaccttc taagcccttt tgggtgctgg tggtggttgg gggagtcctg 960 gcttgctata gcttgctagt aacagtggcc tttattattt tctgggtgag gagtaagagg 1020 agcaggctcc tgcacagtga ctacatgaac atgactcccc gccgccccgg gcccaccgcg 1080 aagcattacc agccctatgc cccaccacgc gacttcgcag cctatcgctc cagagtgaag 1140 ttcagcagga gcgcagacgc ccccgcgtac aagcagggcc agaaccagct ctataacgag 1200 ctcaatctag your hand ggagtacgat gttttggaca agagacgtgg ccgggaccct 1260 gagatggggg gaaagccgag aaagaac cctcaggaag gcctgtacaa tgaactgcag 1320 aaagataaga tggcggaggc ctacagtgag attgggatga aaggcgagcg ccggaggggc 1380 aaggggcacg atggccttta ccagggtctc agtacagcca ccaaggacac ctacgacgcc 1440 cttcacatgc aggccctgcc ccctcgcatc agtctgattg cggcgttagc ggtagattac 1500 gttatcggca tggaaaacgc catgccgtgg aacctgcctg ccgatctcgc ctggtttaaa 1560 cgcaacacct taaataaacc cgtgattatg ggccgccata cctgggaatc aatcggtcgt 1620 ccgttgccag gacgcaaaaa tattatcctc agcagtcaac cgagtacgga cgatcgcgta 1680 acgtgggtga agtcggtgga tgaagccatc gcggcgtgtg gtgacgtacc agaaatcatg 1740 gtgattggcg gcggtcgcgt tattgaacag ttcttgccaa aagcgcaaaa actgtatctg 1800 acgcatatcg acgcagaagt ggaaggcgac acccatttcc cggattacga gccggatgac 1860 tgggaatcgg tattcagcga attccacgat gctgatgcgc agaactctca cagctattgc 1920 tttgagattc tggagcggcg atga 1944 <210> 56 <211> 647 <212> PRT <213> Artificial Sequence <220> <223> Synthesis <400> 56 Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro 1 5 10 15 Ala Phe Leu Leu Ile Pro Asp Ile Leu Leu Thr Gln Thr Pro Leu Ser 20 25 30 Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser 35 40 45 Gln Ser Leu Val His Arg Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu 50 55 60 Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile His Lys Val Ser Asn 65 70 75 80 Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr 85 90 95 Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val 100 105 110 Tyr Phe Cys Ser Gln Ser Thr His Val Pro Pro Leu Thr Phe Gly Ala 115 120 125 Gly Thr Lys Leu Glu Leu Lys Gly Ser Thr Ser Gly Ser Gly Lys Pro 130 135 140 Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Val Lys Leu Gln Gln Ser 145 150 155 160 Gly Pro Ser Leu Val Glu Pro Gly Ala Ser Val Met Ile Ser Cys Lys 165 170 175 Ala Ser Gly Ser Ser Phe Thr Gly Tyr Asn Met Asn Trp Val Arg Gln 180 185 190 Asn Ile Gly Lys Ser Leu Glu Trp Ile Gly Ala Ile Asp Pro Tyr Tyr 195 200 205 Gly Gly Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr 210 215 220 Val Asp Lys Ser Ser Ser Thr Ala Tyr Met His Leu Lys Ser Leu Thr 225 230 235 240 Ser Glu Asp Ser Ala Val Tyr Tyr Cys Val Ser Gly Met Glu Tyr Trp 245 250 255 Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ser Phe Glu Ile Glu 260 265 270 Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr 275 280 285 Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro 290 295 300 Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu 305 310 315 320 Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val 325 330 335 Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr 340 345 350 Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro 355 360 365 Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser 370 375 380 Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu 385 390 395 400 Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg 405 410 415 Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln 420 425 430 Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr 435 440 445 Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp 450 455 460 Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala 465 470 475 480 Leu His Met Gln Ala Leu Pro Pro Arg Ile Ser Leu Ile Ala Ala Leu 485 490 495 Ala Val Asp Tyr Val Ile Gly Met Glu Asn Ala Met Pro Trp Asn Leu 500 505 510 Pro Ala Asp Leu Ala Trp Phe Lys Arg Asn Thr Leu Asn Lys Pro Val 515 520 525 Ile Met Gly Arg His Thr Trp Glu Ser Ile Gly Arg Pro Leu Pro Gly 530 535 540 Arg Lys Asn Ile Ile Leu Ser Ser Gln Pro Ser Thr Asp Asp Arg Val 545 550 555 560 Thr Trp Val Lys Ser Val Asp Glu Ala Ile Ala Ala Cys Gly Asp Val 565 570 575 Pro Glu Ile Met Val Ile Gly Gly Gly Arg Val Ile Glu Gln Phe Leu 580 585 590 Pro Lys Ala Gln Lys Leu Tyr Leu Thr His Ile Asp Ala Glu Val Glu 595 600 605 Gly Asp Thr His Phe Pro Asp Tyr Glu Pro Asp Asp Trp Glu Ser Val 610 615 620 Phe Ser Glu Phe His Asp Ala Asp Ala Gln Asn Ser His Ser Tyr Cys 625 630 635 640 Phe Glu Ile Leu Glu Arg Arg 645 <210> 57 <211> 66 <212> DNA <213> Artificial Sequence <220> <223> synthesis <400> 57 atgctgctgc tcgtgacatc tctgctgctg tgcgagctgc cccaccccgc ctttctgctg 60 atcccc 66 <210> 58 <211> twenty two <212> PRT <213> Artificial Sequence <220> <223> synthesis <400> 58 Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro 1 5 10 15 Ala Phe Leu Leu Ile Pro 20 <210> 59 <211> 732 <212> DNA <213> Artificial Sequence <220> <223> synthesis <400> 59 gatatcctgc tgacccagac ccctctgagc ctgcctgtgt ctctgggcga tcaggccagc 60 atcagctgca gatccagcca gagcctggtg caccggaacg gcaacaccta cctgcactgg 120 tatctgcaga agcccggcca gagccccaag ctgctgattc acaaggtgtc caaccggttc 180 agcggcgtgc ccgacagatt ttctggcagc ggctccggca ccgacttcac cctgaagatc 240 agccgggtgg aagccgagga cctgggcgtg tacttctgca gccagtccac ccacgtgccc 300 cccctgacat ttggcgccgg aacaaagctg gaactgaagg gcagcacaag cggcagcggc 360 aagcctggat ctggcgaggg aagcaccaag ggcgaagtga agctgcagca gagcggcccc 420 tctctggtgg aacctggcgc ctctgtgatg atctcctgca aggccagcgg cagctccttc 480 accggctaca acatgaactg ggtgcgccag aacatcggca agagcctgga atggatcggc 540 gccatcgacc cctactacgg cggcaccagc tacaaccaga agttcaaggg cagagccacc 600 ctgaccgtgg acaagagcag ctccaccgcc tacatgcacc tgaagtccct gaccagcgag 660 gacagcgccg tgtactactg cgtgtccggc atggaatact ggggccaggg cacaagcgtg 720 accgtgtcct ct 732 <210> 60 <211> 244 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 60 Asp Ile Leu Leu Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Arg 20 25 30 Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile His Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser 85 90 95 Thr His Val Pro Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu 100 105 110 Lys Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser 115 120 125 Thr Lys Gly Glu Val Lys Leu Gln Gln Ser Gly Pro Ser Leu Val Glu 130 135 140 Pro Gly Ala Ser Val Met Ile Ser Cys Lys Ala Ser Gly Ser Ser Phe 145 150 155 160 Thr Gly Tyr Asn Met Asn Trp Val Arg Gln Asn Ile Gly Lys Ser Leu 165 170 175 Glu Trp Ile Gly Ala Ile Asp Pro Tyr Tyr Gly Gly Thr Ser Tyr Asn 180 185 190 Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ser Ser 195 200 205 Thr Ala Tyr Met His Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val 210 215 220 Tyr Tyr Cys Val Ser Gly Met Glu Tyr Trp Gly Gln Gly Thr Ser Val 225 230 235 240 Thr Val Ser Ser <210> 61 <211> 117 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 61 attgaagtta tgtatcctcc tccttaccta gacaatgaga agagcaatgg aaccattatc 60 catgtgaaag ggaaacacct ttgtccaagt cccctatttc ccggaccttc taagccc 117 <210> 62 <211> 39 <212> PRT <213> Artificial Sequence <220> <223> synthesis <400> 62 Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn 1 5 10 15 Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu 20 25 30 Phe Pro Gly Pro Ser Lys Pro 35 <210> 63 <211> 81 <212> DNA <213> Artificial Sequence <220> <223> synthesis <400> 63 ttttgggtgc tggtggtggt tgggggagtc ctggcttgct atagcttgct agtaacagtg 60 gcctttatta ttttctgggt g 81 <210> 64 <211> 27 <212> PRT <213> Artificial Sequence <220> <223> synthesis <400> 64 Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu 1 5 10 15 Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val 20 25 <210> 65 <211> 123 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 65 aggagtaaga ggagcaggct cctgcacagt gactacatga acatgactcc ccgccgcccc 60 gggcccaccc gcaagcatta ccagccctat gccccaccac gcgacttcgc agcctatcgc 120 tcc 123 <210> 66 <211> 41 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 66 Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr 1 5 10 15 Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro 20 25 30 Pro Arg Asp Phe Ala Ala Tyr Arg Ser 35 40 <210> 67 <211> 336 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 67 agagtgaagt tcagcaggag cgcagacgcc cccgcgtaca agcagggcca gaaccagctc 60 tataacgagc tcaatctagg acgaagagag gagtacgatg ttttggacaa gagacgtggc 120 cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat 180 gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc 240 cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc 300 tacgacgccc ttcacatgca ggccctgccc cctcgc 336 <210> 68 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 68 Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly 1 5 10 15 Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr 20 25 30 Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys 35 40 45 Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys 50 55 60 Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg 65 70 75 80 Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala 85 90 95 Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 100 105 110 <210> 69 <211> 474 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 69 atcagtctga ttgcggcgtt agcggtagat tacgttatcg gcatggaaaa cgccatgccg 60 tggaacctgc ctgccgatct cgcctggttt aaacgcaaca ccttaaataa acccgtgatt 120 atgggccgcc atacctggga atcaatcggt cgtccgttgc caggacgcaa aaatattatc 180 ctcagcagtc aaccgagtac ggacgatcgc gtaacgtggg tgaagtcggt ggatgaagcc 240 atcgcggcgt gtggtgacgt accagaaatc atggtgattg gcggcggtcg cgttattgaa 300 cagttcttgc caaaagcgca aaaactgtat ctgacgcata tcgacgcaga agtggaaggc 360 gacacccatt tcccggatta cgagccggat gactgggaat cggtattcag cgaattccac 420 gatgctgatg cgcagaactc tcacagctat tgctttgaga ttctggagcg gcga 474 <210> 70 <211> 158 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 70 Ile Ser Leu Ile Ala Ala Leu Ala Val Asp Tyr Val Ile Gly Met Glu 1 5 10 15 Asn Ala Met Pro Trp Asn Leu Pro Ala Asp Leu Ala Trp Phe Lys Arg 20 25 30 Asn Thr Leu Asn Lys Pro Val Ile Met Gly Arg His Thr Trp Glu Ser 35 40 45 Ile Gly Arg Pro Leu Pro Gly Arg Lys Asn Ile Ile Leu Ser Ser Gln 50 55 60 Pro Ser Thr Asp Asp Arg Val Thr Trp Val Lys Ser Val Asp Glu Ala 65 70 75 80 Ile Ala Ala Cys Gly Asp Val Pro Glu Ile Met Val Ile Gly Gly Gly 85 90 95 Arg Val Ile Glu Gln Phe Leu Pro Lys Ala Gln Lys Leu Tyr Leu Thr 100 105 110 His Ile Asp Ala Glu Val Glu Gly Asp Thr His Phe Pro Asp Tyr Glu 115 120 125 Pro Asp Asp Trp Glu Ser Val Phe Ser Glu Phe His Asp Ala Asp Ala 130 135 140 Gln Asn Ser His Ser Tyr Cys Phe Glu Ile Leu Glu Arg Arg 145 150 155 <210> 71 <211> 1950 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 71 atgctgctgc tcgtgacatc tctgctgctg tgcgagctgc cccaccccgc ctttctgctg 60 atccccgata tcctgctgac ccagacccct ctgagcctgc ctgtgtctct gggcgatcag 120 gccagcatca gctgcagatc cagccagagc ctggtgcacc ggaacggcaa cacctacctg 180 cactggtatc tgcagaagcc cggccagagc cccaagctgc tgattcacaa ggtgtccaac 240 cggttcagcg gcgtgcccga cagattttct ggcagcggct ccggcaccga cttcaccctg 300 aagatcagcc gggtggaagc cgaggacctg ggcgtgtact tctgcagcca gtccacccac 360 gtgccccccc tgacatttgg cgccggaaca aagctggaac tgaagggcag cacaagcggc 420 agcggcaagc ctggatctgg cgagggaagc accaagggcg aagtgaagct gcagcagagc 480 ggcccctctc tggtggaacc tggcgcctct gtgatgatct cctgcaaggc cagcggcagc 540 tccttcaccg gctacaacat gaactgggtg cgccagaaca tcggcaagag cctggaatgg 600 atcggcgcca tcgaccccta ctacggcggc accagctaca accagaagtt caagggcaga 660 gccaccctga ccgtggacaa gagcagctcc accgcctaca tgcacctgaa gtccctgacc 720 agcgaggaca gcgccgtgta ctactgcgtg tccggcatgg aatactgggg ccagggcaca 780 agcgtgaccg tgtcctctgc tagcttcgaa attgaagtta tgtatcctcc tccttaccta 840 gacaatgaga agagcaatgg aaccattatc catgtgaaag ggaaacacct ttgtccaagt 900 cccctatttc ccggaccttc taagcccttt tgggtgctgg tggtggttgg gggagtcctg 960 gcttgctata gcttgctagt aacagtggcc tttattattt tctgggtgag gagtaagagg 1020 agcaggctcc tgcacagtga ctacatgaac atgactcccc gccgccccgg gcccaccgcg 1080 aagcattacc agccctatgc cccaccacgc gacttcgcag cctatcgctc ccatatgaga 1140 gtgaagttca gcaggagcgc agacgcccc gcgtacaagc agggccagaa ccagctctat 1200 aacgagctca atctaggacg aagagaggag tacgatgttt tggacaagag acgtggccgg 1260 gaccctgaga tgggggaaa gccgagaagg aagaaccctc aggaagcct gtacaatgaa 1320 1380 aggggcaagg ggcacgatgg cctttaccag ggtctcagta cagccaccaa ggacacctac 1440 gacgcccttc acatgcaggc cctgccccct cgcatcagtc tgattgcggc gttagcggta 1500 gattacgtta tcggcatgga aaacgccatg ccgtggaacc tgcctgccga tctcgcctgg 1560 tttaaacgca acaccttaaa taaacccgtg attatgggcc gccatacctg ggaatcaatc 1620 ggtcgtccgt tgccaggacg caaaaatatt atcctcagca gtcaaccgag tacggacgat 1680 cgcgtaacgt gggtgaagtc ggtggatgaa gccatcgcgg cgtgtggtga cgtaccagaa 1740 atcatggtga ttggcggcgg tcgcgttatt gaacagttct tgccaaaagc gcaaaaactg 1800 tatctgacgc atatcgacgc agaagtggaa ggcgacaccc atttcccgga ttacgagccg 1860 gatgactggg aatcggtatt cagcgaattc cacgatgctg atgcgcagaa ctctcacagc 1920 tattgctttg agattctgga gcggcgatga 1950 <210> 72 <211> 649 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 72 Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro 1 5 10 15 Ala Phe Leu Leu Ile Pro Asp Ile Leu Leu Thr Gln Thr Pro Leu Ser 20 25 30 Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser 35 40 45 Gln Ser Leu Val His Arg Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu 50 55 60 Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile His Lys Val Ser Asn 65 70 75 80 Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr 85 90 95 Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val 100 105 110 Tyr Phe Cys Ser Gln Ser Thr His Val Pro Pro Leu Thr Phe Gly Ala 115 120 125 Gly Thr Lys Leu Glu Leu Lys Gly Ser Thr Ser Gly Ser Gly Lys Pro 130 135 140 Gly Ser Gly Glu Gly Ser Thr Lys Gly Glu Val Lys Leu Gln Gln Ser 145 150 155 160 Gly Pro Ser Leu Val Glu Pro Gly Ala Ser Val Met Ile Ser Cys Lys 165 170 175 Ala Ser Gly Ser Ser Phe Thr Gly Tyr Asn Met Asn Trp Val Arg Gln 180 185 190 Asn Ile Gly Lys Ser Leu Glu Trp Ile Gly Ala Ile Asp Pro Tyr Tyr 195 200 205 Gly Gly Thr Ser Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr 210 215 220 Val Asp Lys Ser Ser Ser Thr Ala Tyr Met His Leu Lys Ser Leu Thr 225 230 235 240 Ser Glu Asp Ser Ala Val Tyr Tyr Cys Val Ser Gly Met Glu Tyr Trp 245 250 255 Gly Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ser Phe Glu Ile Glu 260 265 270 Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly Thr 275 280 285 Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro 290 295 300 Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu 305 310 315 320 Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val 325 330 335 Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr 340 345 350 Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro 355 360 365 Pro Arg Asp Phe Ala Ala Tyr Arg Ser His Met Arg Val Lys Phe Ser 370 375 380 Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr 385 390 395 400 Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys 405 410 415 Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn 420 425 430 Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu 435 440 445 Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly 450 455 460 His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr 465 470 475 480 Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg Ile Ser Leu Ile Ala 485 490 495 Ala Leu Ala Val Asp Tyr Val Ile Gly Met Glu Asn Ala Met Pro Trp 500 505 510 Asn Leu Pro Ala Asp Leu Ala Trp Phe Lys Arg Asn Thr Leu Asn Lys 515 520 525 Pro Val Ile Met Gly Arg His Thr Trp Glu Ser Ile Gly Arg Pro Leu 530 535 540 Pro Gly Arg Lys Asn Ile Ile Leu Ser Ser Gln Pro Ser Thr Asp Asp 545 550 555 560 Arg Val Thr Trp Val Lys Ser Val Asp Glu Ala Ile Ala Ala Cys Gly 565 570 575 Asp Val Pro Glu Ile Met Val Ile Gly Gly Gly Arg Val Ile Glu Gln 580 585 590 Phe Leu Pro Lys Ala Gln Lys Leu Tyr Leu Thr His Ile Asp Ala Glu 595 600 605 Val Glu Gly Asp Thr His Phe Pro Asp Tyr Glu Pro Asp Asp Trp Glu 610 615 620 Ser Val Phe Ser Glu Phe His Asp Ala Asp Ala Gln Asn Ser His Ser 625 630 635 640 Tyr Cys Phe Glu Ile Leu Glu Arg Arg 645 <210> 73 <211> 66 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 73 atgctgctgc tcgtgacatc tctgctgctg tgcgagctgc cccaccccgc ctttctgctg 60 atcccc 66 <210> 74 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 74 Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro 1 5 10 15 Ala Phe Leu Leu Ile Pro 20 <210> 75 <211> 732 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 75 gatatcctgc tgacccagac ccctctgagc ctgcctgtgt ctctgggcga tcaggccagc 60 atcagctgca gatccagcca gagcctggtg caccggaacg gcaacaccta cctgcactgg 120 tatctgcaga agcccggcca gagccccaag ctgctgattc acaaggtgtc caaccggttc 180 agcggcgtgc ccgacagatt ttctggcagc ggctccggca ccgacttcac cctgaagatc 240 agccgggtgg aagccgagga cctgggcgtg tacttctgca gccagtccac ccacgtgccc 300 cccctgacat ttggcgccgg aacaaagctg gaactgaagg gcagcacaag cggcagcggc 360 aagcctggat ctggcgaggg aagcaccaag ggcgaagtga agctgcagca gagcggcccc 420 tctctggtgg aacctggcgc ctctgtgatg atctcctgca aggccagcgg cagctccttc 480 accggctaca acatgaactg ggtgcgccag aacatcggca agagcctgga atggatcggc 540 gccatcgacc cctactacgg cggcaccagc tacaaccaga agttcaaggg cagagccacc 600 ctgaccgtgg acaagagcag ctccaccgcc tacatgcacc tgaagtccct gaccagcgag 660[[ID=⑨]] gacagcgccg tgtactactg cgtgtccggc atggaatact ggggccaggg cacaagcgtg 720 accgtgtcct ct 732 ; <210> 76 <211> 244[[ID=⑰]] <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 76 Asp Ile Leu Leu Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly<00024?!>1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Arg 20 25 30 Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 It should be noted that there may be some errors or unclear parts in the original text, especially the "⑨" in the English translation which seems to be a mislabeling in the original text. You may need to double-check the accuracy of the original content for a more precise translation.Pro Lys Leu Leu Ile His Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser 85 90 95 Thr His Val Pro Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu 100 105 110 Lys Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser 115 120 125 Thr Lys Gly Glu Val Lys Leu Gln Gln Ser Gly Pro Ser Leu Val Glu 130 135 140 Pro Gly Ala Ser Val Met Ile Ser Cys Lys Ala Ser Gly Ser Ser Phe 145 150 155 160 Thr Gly Tyr Asn Met Asn Trp Val Arg Gln Asn Ile Gly Lys Ser Leu 165 170 175 Glu Trp Ile Gly Ala Ile Asp Pro Tyr Tyr Gly Gly Thr Ser Tyr Asn 180 185 190 Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ser Ser 195 200 205 Thr Ala Tyr Met His Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val 210 215 220 Tyr Tyr Cys Val Ser Gly Met Glu Tyr Trp Gly Gln Gly Thr Ser Val 225 230 235 240 Thr Val Ser Ser <210> 77 <211> 117 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 77 attgaagtta tgtatcctcc tccttaccta gacaatgaga agagcaatgg aaccattatc 60 catgtgaaag ggaaacacct ttgtccaagt cccctatttc ccggaccttc taagccc 117 <210> 78 <211> 39 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 78 Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn 1 5 10 15 Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu 20 25 30 Phe Pro Gly Pro Ser Lys Pro 35 <210> 79 <211> 81 <212> DNA <213> Artificial Sequence <220> <223> synthesis <400> 79 ttttgggtgc tggtggtggt tgggggagtc ctggcttgct atagcttgct agtaacagtg 60 gcctttatta ttttctgggt g 81 <210> 80 <211> 27 <212> PRT <213> Artificial Sequence <220> <223> synthesis <400> 80 Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu 1 5 10 15 Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val 20 25 <210> 81 <211> 123 <212> DNA <213> Artificial Sequence <220> <223> synthesis <400> 81 aggagtaaga ggagcaggct cctgcacagt gactacatga acatgactcc ccgccgcccc 60 gggcccaccc gcaagcatta ccagccctat gccccacccac gcgacttcgc agcctatcgc 120 tcc 123 <210> 82 <211> 41 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 82 Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr 1 5 10 15 Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro 20 25 30 Pro Arg Asp Phe Ala Ala Tyr Arg Ser 35 40 <210> 83 <211> 336 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 83 agagtgaagt tcagcaggag cgcagacgcc cccgcgtaca agcagggcca gaaccagctc 60 tataacgagc tcaatctagg acgaagagag gagtacgatg ttttggacaa gagacgtggc 120 cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat 180 gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc 240 cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc 300 tacgacgccc ttcacatgca ggccctgccc cctcgc 336 <210> 84 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 84 Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly 1 5 10 15 Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr 20 25 30 Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys 35 40 45 Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys 50 55 60 Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg 65 70 75 80 Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala 85 90 95 Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 100 105 110 <210> 85 <211> 477 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 85 atgatcagtc tgattgcggc gttagcggta gatcacgtta tcggcatgga aaccgtcatg 60 ccgtggaacc tgcctgccga tctcgcctgg tttaaacgca acaccttaaa taaacccgtg 120 attatgggcc gccatacctg ggaatcaatc ggtcgtccgt tgccaggacg caaaaatatt 180 atcctcagca gtcaaccgag tacggacgat cgcgtaacgt gggtgaagtc ggtggatgaa 240 gccatcgcgg cgtgtggtga cgtaccagaa atcatggtta ttggcggcgg tcgcgtttat 300 gaacagttct tgccaaaagc gcaaaaactg tatctgacgc atatcgacgc agaagtggaa 360 ggcgacaccc atttcccgga ttacgagccg gatgactggg aatcggtatt cagcgaattc 420 cacgatgctg atgcgcagaa ctctcacagc tattgctttg agattctgga gcggcga 477 <210> 86 <211> 158 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 86 Ile Ser Leu Ile Ala Ala Leu Ala Val Asp Tyr Val Ile Gly Met Glu 1 5 10 15 Asn Ala Met Pro Trp Asn Leu Pro Ala Asp Leu Ala Trp Phe Lys Arg 20 25 30 Asn Thr Leu Asn Lys Pro Val Ile Met Gly Arg His Thr Trp Glu Ser 35 40 45 Ile Gly Arg Pro Leu Pro Gly Arg Lys Asn Ile Ile Leu Ser Ser Gln 50 55 60 Pro Ser Thr Asp Asp Arg Val Thr Trp Val Lys Ser Val Asp Glu Ala 65 70 75 80 Ile Ala Ala Cys Gly Asp Val Pro Glu Ile Met Val Ile Gly Gly Gly 85 90 95 Arg Val Ile Glu Gln Phe Leu Pro Lys Ala Gln Lys Leu Tyr Leu Thr 100 105 110 His Ile Asp Ala Glu Val Glu Gly Asp Thr His Phe Pro Asp Tyr Glu 115 120 125 Pro Asp Asp Trp Glu Ser Val Phe Ser Glu Phe His Asp Ala Asp Ala 130 135 140 Gln Asn Ser His Ser Tyr Cys Phe Glu Ile Leu Glu Arg Arg 145 150 155 <210> 87 <211> 2538 <212> DNA <213> Artificial Sequence <220> <223> Synthesis <400> 87 atggaattcg gcctgagctg gctgtttctg gtggccattc tgaagggcgt gcagtgctcc 60 agagacatcc tgctgacaca gacacctctg agcctgcctg tgtctctggg agatcaggcc 120 agcatcagct gtagaagcag ccagagcctg gtgcacagaa acggcaatac ctacctgcac 180 tggtatctgc agaagcccgg ccagtctcct aagctgctga tccacaaggt gtccaacaga 240 ttcagcggcg tgcccgatag attttctggc tctggcagcg gcaccgactt caccctgaag 300 atctctagag tggaagccga ggacctgggc gtgtacttct gtagccagag cacacatgtg 360 cctccactga cctttggcgc tggcaccaaa ctggaactta aaggcggcgg aggatctggt 420 ggtggtggat ctggcggagg cggttctgaa gtgaaactgc agcagtctgg cccctctctg 480 gttgaacctg gcgcctctgt gatgatctct tgcaaggcca gcggcagcag cttcaccggc 540 tacaacatga actgggtccg acagaacatc ggcaagagcc tggaatggat cggcgccatc 600 gatccttact acggcggcac cagctacaac cagaagttca agggcagagc cacactgacc 660 gtggacaaga ccagcagcac agcctacatg cacctgaagt ccctgacaag cgaggacagc 720 gccgtgtact actgtgtgtc cggcatgaag tattggggcc agggcacaag cgtgaccgtg 780 tctagcgcta agaccacacc tcctagcgtg tacggcagag tgacagtgtc cagcgccgag 840 cctaagagct gcgacaagac acacacctgt cctccatgtc cagctccaga actgctcggc 900 ggaccctccg ttttcctgtt tccacctaag ccaaaggaca ccctcatgat cagcagaacc 960 cctgaagtga cctgcgtggt ggtcgatgtg tcccacgagg atcccgaagt gaagttcaat 1020 tggtacgtgg acggcgtgga agtgcacaac gccaagacca agcctagaga ggaacagtac 1080 aacagcacct acagagtggt gtccgtgctg accgtgctgc atcaggactg gctgaacggc 1140 aaagagtaca agtgcaaagt ctccaacaag gccctgcctg ctcctatcga gaaaccatc 1200 agcaaggcca agggccagcc aagagaaccc caggtttaca cactgcctcc aagcagggac 1260 gagctgacca agaatcaggt gtccctgacc tgcctggtca agggcttcta cccttccgat 1320 atcgccgtgg aatgggagag caatggccag cctgagaaca actacaagac aacccctcct 1380 gtgctggaca gcgacggctc attcttcctg tacagcaagc tgacagtgga taagtcccgg 1440 tggcagcagg gcaatgtgtt cagctgttct gtgatgcacg aggccctgca caaccactac 1500 acccagaaaa gcctgtctct gagccccggc aagaaggacc ctaaagctag cttcgaaatt 1560 gaagttatgt atcctcctcc ttacctagac aatgagaaga gcaatggaac cattatccat 1620 gtgaaaggga aacacctttg tccaagtccc ctatttcccg gaccttctaa gccctttgg 1680 gtgctggtgg tggttggggg agtcctggct tgctatagct tgctagtaac agtggcctt 1740 attattttct gggtgaggag taagaggagc aggctcctgc acagtgacta catgaacatg 1800 actccccgcc gccccgggcc cacccgcaag cattaccagc cctatgcccc accacgcgac 1860 ttcgcagcct atcgctccag agtgaagttc agcaggagcg cagacgcccc cgcgtacaag 1920 cagggccaga accagctcta taacgagctc aatctaggac gaagagagga gtacgatgtt 1980 ttggacaaga gacgtggccg ggaccctgag atggggggaa agccgagaag gaagaaccct 2040 caggaaggcc tgtacaatga actgcagaaa gataagatgg cggaggccta cagtgagatt 2100 gggatgaaag gcgagcgccg gaggggcaag gggcacgatg gcctttacca gggtctcagt 2160 acagccacca aggacaccta cgacgccctt cacatgcagg ccctgccccc tcgcggagtg 2220 caggtggaaa ccatctcccc aggagacggg cgcaccttcc ccaagcgcgg ccagacctgc 2280 gtggtgcact acaccgggat gcttggagat ggaaagaaag ttgactcctc ccgggacaga 2340 aacaagccct ttaagtttat gctaggcaag caggaggtga tccgaggctg ggaagaaggg 2400 gttgcccaga tgagtgtggg tcagggagcc aaactgacta tatctccaga ttatgcctat 2460 ggtgccactg ggcacccagg catcatccca ccacatgcca ctctcgtctt cgatgtggag 2520 cttctagaac tggaatga 2538 <210> 88 <211> 845 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 88 Met Glu Phe Gly Leu Ser Trp Leu Phe Leu Val Ala Ile Leu Lys Gly 1 5 10 15 Val Gln Cys Ser Arg Asp Ile Leu Leu Thr Gln Thr Pro Leu Ser Leu 20 25 30 Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln 35 40 45 Ser Leu Val His Arg Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln 50 55 60 Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile His Lys Val Ser Asn Arg 65 70 75 80 Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp 85 90 95 Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr 100 105 110 Phe Cys Ser Gln Ser Thr His Val Pro Pro Leu Thr Phe Gly Ala Gly 115 120 125 Thr Lys Leu Glu Leu Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 130 135 140 Gly Gly Gly Gly Ser Glu Val Lys Leu Gln Gln Ser Gly Pro Ser Leu 145 150 155 160 Val Glu Pro Gly Ala Ser Val Met Ile Ser Cys Lys Ala Ser Gly Ser 165 170 175 Ser Phe Thr Gly Tyr Asn Met Asn Trp Val Arg Gln Asn Ile Gly Lys 180 185 190 Ser Leu Glu Trp Ile Gly Ala Ile Asp Pro Tyr Tyr Gly Gly Thr Ser 195 200 205 Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser 210 215 220 Ser Ser Thr Ala Tyr Met His Leu Lys Ser Leu Thr Ser Glu Asp Ser 225 230 235 240 Ala Val Tyr Tyr Cys Val Ser Gly Met Lys Tyr Trp Gly Gln Gly Thr 245 250 255 Ser Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr Gly 260 265 270 Arg Val Thr Val Ser Ser Ala Glu Pro Lys Ser Cys Asp Lys Thr His 275 280 285 Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 290 295 300 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 305 310 315 320 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 325 330 335 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 340 345 350 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 355 360 365 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 370 375 380 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 385 390 395 400 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 405 410 415 Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 420 425 430 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 435 440 445 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 450 455 460 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 465 470 475 480 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 485 490 495 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Lys 500 505 510 Asp Pro Lys Ala Ser Phe Glu Ile Glu Val Met Tyr Pro Pro Pro Tyr 515 520 525 Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys 530 535 540 His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp 545 550 555 560 Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val 565 570 575 Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu 580 585 590 Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr 595 600 605 Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr 610 615 620 Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys 625 630 635 640 Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu 645 650 655 Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly 660 665 670 Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu 675 680 685 Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly 690 695 700 Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser 705 710 715 720 Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro 725 730 735 Pro Arg Gly Val Gln Val Glu Thr Ile Ser Pro Gly Asp Gly Arg Thr 740 745 750 Phe Pro Lys Arg Gly Gln Thr Cys Val Val His Tyr Thr Gly Met Leu 755 760 765 Gly Asp Gly Lys Lys Val Asp Ser Ser Arg Asp Arg Asn Lys Pro Phe 770 775 780 Lys Phe Met Leu Gly Lys Gln Glu Val Ile Arg Gly Trp Glu Glu Gly 785 790 795 800 Val Ala Gln Met Ser Val Gly Gln Gly Ala Lys Leu Thr Ile Ser Pro 805 810 815 Asp Tyr Ala Tyr Gly Ala Thr Gly His Pro Gly Ile Ile Pro Pro His 820 825 830 Ala Thr Leu Val Phe Asp Val Glu Leu Leu Glu Leu Glu 835 840 845 <210> 89 <211> 63 <212> DNA <213> Artificial Sequence <220> <223> synthesis <400> 89 atggaattcg gcctgagctg gctgtttctg gtggccattc tgaagggcgt gcagtgctcc 60 aga 63 <210> 90 <211> twenty one <212> PRT <213> Artificial Sequence <220> <223> synthesis <400> 90 Met Glu Phe Gly Leu Ser Trp Leu Phe Leu Val Ala Ile Leu Lys Gly 1 5 10 15 Val Gln Cys Ser Arg 20 <210> 91 <211> 1482 <212> DNA <213> Artificial Sequence <220> <223> synthesis <400> 91 gacatcctgc tgacacagac acctctgagc ctgcctgtgt ctctgggaga tcaggccagc 60 atcagctgta gaagcagcca gagcctggtg cacagaaacg gcaataccta cctgcactgg 120 tatctgcaga agcccggcca gtctcctaag ctgctgatcc acaaggtgtc caacagattc 180 agcggcgtgc ccgatagatt ttctggctct ggcagcggca ccgacttcac cctgaagatc 240 tctagagtgg aagccgagga cctgggcgtg tacttctgta gccagagcac acatgtgcct 300 ccactgacct ttggcgctgg caccaaactg gaacttaaag gcggcggagg atctggtggt 360 ggtggatctg gcggaggcgg ttctgaagtg aaactgcagc agtctggccc ctctctggtt 420 gaacctggcg cctctgtgat gatctcttgc aaggccagcg gcagcagctt caccggctac 480 aacatgaact gggtccgaca gaacatcggc aagagcctgg aatggatcgg cgccatcgat 540 ccttactacg gcggcaccag ctacaaccag aagttcaagg gcagagccac actgaccgtg 600 gacaagagca gcagcacagc ctacatgcac ctgaagtccc tgacaagcga ggacagcgcc 660 gtgtactact gtgtgtccgg catgaagtat tggggccagg gcacaagcgt gaccgtgtct 720 agcgctaaga ccacacctcc tagcgtgtac ggcagagtga cagtgtccag cgccgagcct 780 aagagctgcg acaagacaca cacctgtcct ccatgtccag ctccagaact gctcggcgga 840 ccctccgttt tcctgtttcc acctaagcca aaggacaccc tcatgatcag cagaacccct 900 gaagtgacct gcgtggtggt cgatgtgtcc cacgaggatc ccgaagtgaa gttcaattgg 960 tacgtggacg gcgtggaagt gcacaacgcc aagaccaagc ctagagagga acagtacaac 1020 agcacctaca gagtggtgtc cgtgctgacc gtgctgcatc aggactggct gaacggcaaa 1080 gagtacaagt gcaaagtctc caacaaggcc ctgcctgctc ctatcgagaa aaccatcagc 1140 aaggccaagg gccagccaag agaaccccag gtttacacac tgcctccaag cagggacgag 1200 ctgaccaaga atcaggtgtc cctgacctgc ctggtcaagg gcttctaccc ttccgatatc 1260 gccgtggaat gggagagcaa tggccagcct gagaacaact acaagacaac ccctcctgtg 1320 ctggacagcg acggctcatt cttcctgtac agcaagctga cagtggataa gtcccggtgg 1380 cagcagggca atgtgttcag ctgttctgtg atgcacgagg ccctgcacaa ccactacacc 1440 cagaaaagcc tgtctctgag ccccggcaag aaggacccta aa 1482 <210> 92 <211> 494 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 92 Asp Ile Leu Leu Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Arg 20 25 30 Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile His Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Ser 85 90 95 Thr His Val Pro Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu 100 105 110 Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120 125 Glu Val Lys Leu Gln Gln Ser Gly Pro Ser Leu Val Glu Pro Gly Ala 130 135 140 Ser Val Met Ile Ser Cys Lys Ala Ser Gly Ser Ser Phe Thr Gly Tyr 145 150 155 160 Asn Met Asn Trp Val Arg Gln Asn Ile Gly Lys Ser Leu Glu Trp Ile 165 170 175 Gly Ala Ile Asp Pro Tyr Tyr Gly Gly Thr Ser Tyr Asn Gln Lys Phe 180 185 190 Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 195 200 205 Met His Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 210 215 220 Val Ser Gly Met Lys Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser 225 230 235 240 Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr Gly Arg Val Thr Val Ser 245 250 255 Ser Ala Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 260 265 270 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 275 280 285 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 290 295 300 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 305 310 315 320 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 325 330 335 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 340 345 350 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 355 360 365 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 370 375 380 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 385 390 395 400 Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 405 410 415 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 420 425 430 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 435 440 445 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 450 455 460 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 465 470 475 480 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Lys Asp Pro Lys 485 490 <210> 93 <211> 117 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 93 attgaagtta tgtatcctcc tccttaccta gacaatgaga agagcaatgg aaccattatc 60 catgtgaaag ggaaacacct ttgtccaagt cccctatttc ccggaccttc taagccc 117 <210> 94 <211> 39 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 94 Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn 1 5 10 15 Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu 20 25 30 Phe Pro Gly Pro Ser Lys Pro 35 <210> 95 <211> 81 <212> DNA <213> Artificial Sequence <220> <223> synthesis <400> 95 ttttgggtgc tggtggtggt tgggggagtc ctggcttgct atagcttgct agtaacagtg 60 gcctttatta ttttctgggt g 81 <210> 96 <211> 27 <212> PRT <213> Artificial Sequence <220> <223> synthesis <400> 96 Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu 1 5 10 15 Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val 20 25 <210> 97 <211> 123 <212> DNA <213> Artificial Sequence <220> <223> synthesis <400> 97 aggagtaaga ggagcaggct cctgcacagt gactacatga acatgactcc ccgccgcccc 60 gggcccaccc gcaagcatta ccagccctat gccccaccac gcgacttcgc agcctatcgc 120 tcc 123 <210> 98 <211> 41 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 98 Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr 1 5 10 15 Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro 20 25 30 Pro Arg Asp Phe Ala Ala Tyr Arg Ser 35 40 <210> 99 <211> 336 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 99 agagtgaagt tcagcaggag cgcagacgcc cccgcgtaca agcagggcca gaaccagctc 60 tataacgagc tcaatctagg acgaagagag gagtacgatg ttttggacaa gagacgtggc 120 cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat 180 gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc 240 cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc 300 tacgacgccc ttcacatgca ggccctgccc cctcgc 336 <210> 100 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 100 Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln Gly 1 5 10 15 Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr 20 25 30 Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys 35 40 45 Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys 50 55 60 Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg 65 70 75 80 Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala 85 90 95 Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 100 105 110 <210> 101 <211> 321 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 101 ggagtgcagg tggaaaccat ctccccagga gacgggcgca ccttccccaa gcgcggccag 60 acctgcgtgg tgcactacac cgggatgctt ggagatggaa agaaagttga ctcctcccgg 120 gacagaaaca agccctttaa gtttatgcta ggcaagcagg aggtgatccg aggctgggaa 180 gaaggggttg cccagatgag tgtgggtcag ggagccaaac tgactatatc tccagattat 240 gcctatggtg ccactgggca cccaggcatc atcccaccac atgccactct cgtcttcgat 300 gtggagcttc tagaactgga a 321 <210> 102 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 102 Gly Val Gln Val Glu Thr Ile Ser Pro Gly Asp Gly Arg Thr Phe Pro 1 5 10 15 Lys Arg Gly Gln Thr Cys Val Val His Tyr Thr Gly Met Leu Gly Asp 20 25 30 Gly Lys Lys Val Asp Ser Ser Arg Asp Arg Asn Lys Pro Phe Lys Phe 35 40 45 Met Leu Gly Lys Gln Glu Val Ile Arg Gly Trp Glu Glu Gly Val Ala 50 55 60 Gln Met Ser Val Gly Gln Gly Ala Lys Leu Thr Ile Ser Pro Asp Tyr 65 70 75 80 Ala Tyr Gly Ala Thr Gly His Pro Gly Ile Ile Pro Pro His Ala Thr 85 90 95 Leu Val Phe Asp Val Glu Leu Leu Glu Leu Glu 100 105 <210> 103 <211> 2691 <212> DNA <213> Artificial Sequence <220> <223> Synthetic <400> 103 atggaattcg gcctgagctg gctgtttctg gtggccattc tgaagggcgt gcagtgctcc 60 agagacatcc tgctgacaca gacacctctg agcctgcctg tgtctctggg agatcaggcc 120 agcatcagct gtagaagcag ccagagcctg gtgcacagaa acggcaatac ctacctgcac 180 tggtatctgc agaagcccgg ccagtctcct aagctgctga tccacaaggt gtccaacaga 240 ttcagcggcg tgcccgatag attttctggc tctggcagcg gcaccgactt caccctgaag 300 atctctagag tggaagccga ggacctgggc gtgtacttct gtagccagag cacacatgtg 360 cctccactga cctttggcgc tggcaccaaa ctggaactta aaggcggcgg aggatctggt 420 ggtggtggat ctggcggagg cggttctgaa gtgaaactgc agcagtctgg cccctctctg 480 gttgaacctg gcgcctctgt gatgatctct tgcaaggcca gcggcagcag cttcaccggc 540 tacaacatga actgggtccg acagaacatc ggcaagagcc tggaatggat cggcgccatc 600 gatccttact acggcggcac cagctacaac cagaagttca agggcagagc cacactgacc 660 gtggacaaga gcagcagcac agcctacatg cacctgaagt ccctgacaag cgaggacagc 720 gccgtgtact actgtgtgtc cggcatgaag tattggggcc agggcacaag cgtgaccgtg 780 tctagcgcta agaccacacc tcctagcgtg tacggcagag tgacagtgtc cagcgccgag 840 cctaagagct gcgacaagac acacacctgt cctccatgtc cagctccaga actgctcggc 900 ggaccctccg ttttcctgtt tccacctaag ccaaaggaca ccctcatgat cagcagaacc 960 cctgaagtga cctgcgtggt ggtcgatgtg tcccacgagg atcccgaagt gaagttcaat 1020 tggtacgtgg acggcgtgga agtgcacaac gccaagacca agcctagaga ggaacagtac 1080 aacagcacct acagagtggt gtccgtgctg accgtgctgc atcaggactg gctgaacggc 1140 aaagagtaca agtgcaaagt ctccaacaag gccctgcctg ctcctatcga gaaaaccatc 1200 agcaaggcca agggccagcc aagagaaccc caggtttaca cactgcctcc aagcagggac 1260 gagctgacca agaatcaggt gtccctgacc tgcctggtca agggcttcta cccttccgat 1320 atcgccgtgg aatgggagag caatggccag cctgagaaca actacaagac aacccctcct 1380 gtgctggaca gcgacggctc attcttcctg tacagcaagc tgacagtgga taagtcccgg 1440 tggcagcagg gcaatgtgtt cagctgttct gtgatgcacg aggccctgca caaccactac 1500 acccagaaaa gcctgtctct gagccccggc aagaaggacc ctaaagctag cttcgaaatt 1560 gaagttatgt atcctcctcc ttacctagac aatgagaaga gcaatggaac cattatccat 1620 gtgaaaggga aacacctttg tccaagtccc ctatttcccg gaccttctaa gccctttgg 1680 gtgctggtgg tggttggggg agtcctggct tgctatagct tgctagtaac agtggcctt 1740 attattttct gggtgaggag taagaggagc aggctcctgc acagtgacta catgaacatg 1800 actccccgcc gccccgggcc cacccgcaag cattaccagc cctatgcccc accacgcgac 1860 ttcgcagcct atcgctccag agtgaagttc agcaggagcg cagacgcccc cgcgtacaag 1920 cagggccaga accagctcta taacgagctc aatctaggac gaagagagga gtacgatgtt 1980 ttggacaaga gacgtggccg ggaccctgag atggggggaa agccgagaag gaagaaccct 2040 caggaaggcc tgtacaatga actgcagaaa gataagatgg cggaggccta cagtgagatt 2100 gggatgaaag gcgagcgccg gaggggcaag gggcacgatg gcctttacca gggtctcagt 2160 acagccacca aggacaccta cgacgccctt cacatgcagg ccctgccccc tcgcatcagt 2220 ctgattgcgg cgttagcggt agattacgtt atcggcatgg aaaacgccat gccgtggaac 2280 ctgcctgccg atctcgcctg gtttaaacgc aacaccttaa ataaacccgt gattatgggc 2340 cgccatacct gggaatcaat cggtcgtccg ttgccaggac gcaaaaatat tatcctcagc 2400 agtcaaccga gtacggacga tcgcgtaacg tgggtgaagt cggtggatga agccatcgcg 2460 gcgtgtggtg acgtaccaga aatcatggtg attggcggcg gtcgcgttat tgaacagttc 2520 ttgccaaaag cgcaaaaact gtatctgacg catatcgacg cagaagtgga aggcgacacc 2580 catttcccgg attacgagcc ggatgactgg gaatcggtat tcagcgaatt ccacgatgct 2640 gatgcgcaga actctcacag ctattgcttt gagattctgg agcggcgatg a 2691 <210> 104 <211> 896 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <400> 104 Met Glu Phe Gly Leu Ser Trp Leu Phe Leu Val Ala Ile Leu Lys Gly 1 5 10 15 Val Gln Cys Ser Arg Asp Ile Leu Leu Thr Gln Thr Pro Leu Ser Leu 20 25 30 Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln 35 40 45 Ser Leu Val His Arg Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln 50 55 60 Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile His Lys Val Ser Asn Arg 65 70 75 80 Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp 85 90 95 Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr 100 105 110 Phe Cys Ser Gln Ser Thr His Val Pro Pro Leu Thr Phe Gly Ala Gly 115 120 125 Thr Lys Leu Glu Leu Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 130 135 140 Gly Gly Gly Gly Ser Glu Val Lys Leu Gln Gln Ser Gly Pro Ser Leu 145 150 155 160 Val Glu Pro Gly Ala Ser Val Met Ile Ser Cys Lys Ala Ser Gly Ser 165 170 175 Ser Phe Thr Gly Tyr Asn Met Asn Trp Val Arg Gln Asn Ile Gly Lys 180 185 190 Ser Leu Glu Trp Ile Gly Ala Ile Asp Pro Tyr Tyr Gly Gly Thr Ser 195 200 205 Tyr Asn Gln Lys Phe Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser 210 215 220 Ser Ser Thr Ala Tyr Met His Leu Lys Ser Leu Thr Ser Glu Asp Ser 225 230 235 240 Ala Val Tyr Tyr Cys Val Ser Gly Met Lys Tyr Trp Gly Gln Gly Thr 245 250 255 Ser Val Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr Gly 260 265 270 Arg Val Thr Val Ser Ser Ala Glu Pro Lys Ser Cys Asp Lys Thr His 275 280 285 Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val 290 295 300 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 305 310 315 320 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 325 330 335 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 340 345 350 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 355 360 365 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 370 375 380 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 385 390 395 400 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 405 410 415 Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 420 425 430 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 435 440 445 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 450 455 460 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 465 470 475 480 Trp Gln Gln Gly Asn V...
Claims
1. A chimeric antigen receptor CAR, comprising: a) Extracellular ligand binding domain; b) transmembrane domain; c) a cytoplasmic domain comprising one or more signal transduction domains; and d) a regulatable destabilizing domain RDD, wherein the RDD consists of: Escherichia coli dihydrofolate reductase destabilizing domain ecDHFR DD, wherein the amino acid substitutions consist of R12Y, G67S and Y100I; or FK506 binding protein 12 destabilizing domain FKBP DD, whose amino acid substitutions consist of E31G, F36V, R71G and K105E.
2. The CAR of claim 1, wherein the extracellular ligand binding domain specifically binds to a tumor antigen.
3. The CAR of claim 2, wherein the tumor antigen is disialoganglioside GD2, CD19 or Her2.
4. The CAR of claim 1, wherein the extracellular ligand binding domain comprises a single-chain variable fragment scFv domain.
5. The CAR of claim 4, wherein the scFv comprises the variable regions of the heavy chain VH and light chain VL of an antibody that specifically binds to disialoganglioside GD2.
6. The CAR of claim 5, wherein the antibody that specifically binds to disialoganglioside GD2 is selected from the group consisting of 14G2a, ch14.18, hu14.18K322A, m3F8, hu3F8-IgG1, hu3F8-IgG4, HM3F8, UNITUXIN, and DMAb-20.
7. The CAR of claim 1, wherein the transmembrane domain is a CD28 transmembrane domain.
8. The CAR of claim 1, wherein the cytoplasmic domain comprises a 4-1BB signaling domain.
9. The CAR of claim 1, wherein the cytoplasmic domain comprises a CD28 signaling domain.
10. The CAR of claim 1, wherein the cytoplasmic domain comprises a CD3-ζ signaling domain.
11. The CAR of claim 1, wherein the cytoplasmic domain comprises a 4-1BB signaling domain and a CD3-ζ signaling domain.
12. The CAR of claim 1, wherein the RDD consists of human FKBP DD.
13. The CAR of claim 1, wherein the extracellular ligand binding domain comprises the amino acid sequence of SEQ ID NO:
76.
14. The CAR of claim 1, wherein the transmembrane domain comprises the amino acid sequence of SEQ ID NO:
48.
15. The CAR of claim 1, wherein the signal transduction domain comprises a CD28 domain, and the CD28 domain comprises the amino acid sequence of SEQ ID NO:
50.
16. The CAR of claim 1, wherein one or more signal transduction domains comprise a CD28 domain and a CD3-ζ domain, the CD28 domain comprising the amino acid sequence of SEQ ID NO: 50, and the CD3-ζ domain comprising the amino acid sequence of SEQ ID NO:
52.
17. The CAR of claim 1, wherein the signal transduction domain comprises a CD3-ζ domain, and the CD3-ζ domain comprises the amino acid sequence of SEQ ID NO:
52.
18. The CAR of claim 1, wherein the ecDHFR DD consists of the amino acid sequence of SEQ ID NO:
70.
19. The CAR of claim 1, wherein the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO:
56.
20. The CAR of claim 1, wherein the extracellular ligand binding domain specific for a tumor antigen exhibits antigen-independent trophic signal transduction.
21. A genetically modified T cell comprising a nucleic acid sequence encoding the CAR as described in any one of claims 1-20.
22. The genetically modified T cell of claim 21, wherein the nucleic acid sequence is a human, mouse or humanized mouse nucleic acid sequence.
23. A genetically modified T cell as described in claim 21, wherein the nucleic acid sequence comprises a nucleic acid sequence of SEQ ID NO: 39 for encoding the extracellular ligand binding domain.
24. The genetically modified T cell of claim 21, wherein the nucleic acid sequence comprises a nucleic acid sequence of SEQ ID NO: 47 encoding the transmembrane domain.
25. The genetically modified T cell of claim 21, wherein the nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO:
49.
26. The genetically modified T cell of claim 21, wherein the nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO: 49 and the nucleic acid sequence of SEQ ID NO:
51.
27. The genetically modified T cell of claim 21, wherein the nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO:
51.
28. The genetically modified T cell of claim 21, wherein the nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO: 69 encoding ecDHFRDD.
29. The genetically modified T cell of claim 21, wherein the chimeric antigen receptor comprises the amino acid sequence of SEQ ID NO:
55.
30. Use of the genetically modified T cell according to any one of claims 21 to 29 in the preparation of a medicament for treating cancer in a mammal.
31. The use of claim 30, wherein the cancer is selected from the group consisting of neuroblastoma, glioblastoma, midline glioma, osteosarcoma, sarcoma, B-line acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia, B-cell non-Hodgkin's lymphoma, leukemia and lymphoma, acute lymphoblastic leukemia, Hodgkin's lymphoma and childhood acute lymphoblastic leukemia.
32. The use of claim 30, wherein the treatment reduces the number of cancer cells in the patient.
33. The use of claim 30, wherein the treatment reduces tumor burden and / or eliminates tumors in the patient.
34. A therapeutically effective amount of a composition comprising T cells genetically modified to express the CAR described in any one of claims 1-20, for treating cancer in a subject or delaying its progression.
35. The composition of claim 34, wherein the composition provides one or more of the following effects: - reducing the number of cancer cells in said subject, - reducing tumor burden and / or eliminating tumor in said subject.
